BRCA1 0
is 0
secreted 0
and 0
exhibits 0
properties 0
of 0
a 0
granin 0
. 0

Germline 0
mutations 0
in 0
BRCA1 0
are 0
responsible 0
for 0
most 0
cases 0
of 0
inherited 1
breast 1
and 1
ovarian 1
cancer 1
. 0

However 0
, 0
the 0
function 0
of 0
the 0
BRCA1 0
protein 0
has 0
remained 0
elusive 0
. 0

We 0
now 0
show 0
that 0
BRCA1 0
encodes 0
a 0
190-kD 0
protein 0
with 0
sequence 0
homology 0
and 0
biochemical 0
analogy 0
to 0
the 0
granin 0
protein 0
family 0
. 0

Interestingly 0
, 0
BRCA2 0
also 0
includes 0
a 0
motif 0
similar 0
to 0
the 0
granin 0
consensus 0
at 0
the 0
C 0
terminus 0
of 0
the 0
protein 0
. 0

Both 0
BRCA1 0
and 0
the 0
granins 0
localize 0
to 0
secretory 0
vesicles 0
, 0
are 0
secreted 0
by 0
a 0
regulated 0
pathway 0
, 0
are 0
post-translationally 0
glycosylated 0
and 0
are 0
responsive 0
to 0
hormones 0
. 0

As 0
a 0
regulated 0
secretory 0
protein 0
, 0
BRCA1 0
appears 0
to 0
function 0
by 0
a 0
mechanism 0
not 0
previously 0
described 0
for 0
tumour 3
suppressor 0
gene 0
products 0
. 0

Ovarian 3
cancer 3
risk 0
in 0
BRCA1 0
carriers 0
is 0
modified 0
by 0
the 0
HRAS1 0
variable 0
number 0
of 0
tandem 0
repeat 0
( 0
VNTR 0
) 0
locus 0
. 0

Women 0
who 0
carry 0
a 0
mutation 0
in 0
the 0
BRCA1 0
gene 0
( 0
on 0
chromosome 0
17q21 0
) 0
, 0
have 0
an 0
80 0
% 0
risk 0
of 0
breast 2
cancer 2
and 0
a 0
40 0
% 0
risk 0
of 0
ovarian 2
cancer 2
by 0
the 0
age 0
of 0
70 0
( 0
ref 0
. 0

1 0
) 0
. 0

The 0
variable 0
penetrance 0
of 0
BRCA1 0
suggests 0
that 0
other 0
genetic 0
and 0
non-genetic 0
factors 0
play 0
a 0
role 0
in 0
tumourigenesis 0
in 0
these 0
individuals 0
. 0

The 0
HRAS1 0
variable 0
number 0
of 0
tandem 0
repeats 0
( 0
VNTR 0
) 0
polymorphism 0
, 0
located 0
1 0
kilobase 0
( 0
kb 0
) 0
downstream 0
of 0
the 0
HRAS1 0
proto-oncogene 0
( 0
chromosome 0
11p15 0
. 0

5 0
) 0
is 0
one 0
possible 0
genetic 0
modifier 0
of 0
cancer 3
penetrance 0
. 0

Individuals 0
who 0
have 0
rare 0
alleles 0
of 0
the 0
VNTR 0
have 0
an 0
increased 0
risk 0
of 0
certain 0
types 0
of 0
cancers 4
, 0
including 0
breast 2
cancer 2
( 0
2-4 0
) 0
. 0

To 0
investigate 0
whether 0
the 0
presence 0
of 0
rare 0
HRAS1 0
alleles 0
increases 0
susceptibility 0
to 0
hereditary 1
breast 1
and 1
ovarian 1
cancer 1
, 0
we 0
have 0
typed 0
a 0
panel 0
of 0
307 0
female 0
BRCA1 0
carriers 0
at 0
this 0
locus 0
using 0
a 0
PCR-based 0
technique 0
. 0

The 0
risk 0
for 0
ovarian 2
cancer 2
was 0
2 0
. 0

11 0
times 0
greater 0
for 0
BRCA1 0
carriers 0
harbouring 0
one 0
or 0
two 0
rare 0
HRAS1 0
alleles 0
, 0
compared 0
to 0
carriers 0
with 0
only 0
common 0
alleles 0
( 0
P 0
= 0
0 0
. 0

015 0
) 0
. 0

The 0
magnitude 0
of 0
the 0
relative 0
risk 0
associated 0
with 0
a 0
rare 0
HRAS1 0
allele 0
was 0
not 0
altered 0
by 0
adjusting 0
for 0
the 0
other 0
known 0
risk 0
factors 0
for 0
hereditary 2
ovarian 2
cancer 2
( 0
5 0
) 0
. 0

Susceptibility 0
to 0
breast 2
cancer 2
did 0
not 0
appear 0
to 0
be 0
affected 0
by 0
the 0
presence 0
of 0
rare 0
HRAS1 0
alleles 0
. 0

This 0
study 0
is 0
the 0
first 0
to 0
show 0
the 0
effect 0
of 0
a 0
modifying 0
gene 0
on 0
the 0
penetrance 0
of 0
an 0
inherited 4
cancer 4
syndrome 4
A 0
novel 0
homeodomain-encoding 0
gene 0
is 0
associated 0
with 0
a 0
large 0
CpG 0
island 0
interrupted 0
by 0
the 0
myotonic 3
dystrophy 3
unstable 0
( 0
CTG 0
) 0
n 0
repeat 0
. 0

Myotonic 2
dystrophy 2
( 0
DM 2
) 0
is 0
associated 0
with 0
a 0
( 0
CTG 0
) 0
n 0
trinucleotide 0
repeat 0
expansion 0
in 0
the 0
3-untranslated 0
region 0
of 0
a 0
protein 0
kinase-encoding 0
gene 0
, 0
DMPK 0
, 0
which 0
maps 0
to 0
chromosome 0
19q13 0
. 0

3 0
. 0

Characterisation 0
of 0
the 0
expression 0
of 0
this 0
gene 0
in 0
patient 0
tissues 0
has 0
thus 0
far 0
generated 0
conflicting 0
data 0
on 0
alterations 0
in 0
the 0
steady 0
state 0
levels 0
of 0
DMPK 0
mRNA 0
, 0
and 0
on 0
the 0
final 0
DMPK 0
protein 0
levels 0
in 0
the 0
presence 0
of 0
the 0
expansion 0
. 0

The 0
DM 3
region 0
of 0
chromosome 0
19 0
is 0
gene 0
rich 0
, 0
and 0
it 0
is 0
possible 0
that 0
the 0
repeat 0
expansion 0
may 0
lead 0
to 0
dysfunction 0
of 0
a 0
number 0
of 0
transcription 0
units 0
in 0
the 0
vicinity 0
, 0
perhaps 0
as 0
a 0
consequence 0
of 0
chromatin 0
disruption 0
. 0

We 0
have 0
searched 0
for 0
genes 0
associated 0
with 0
a 0
CpG 0
island 0
at 0
the 0
3 0
end 0
of 0
DMPK 0
. 0

Sequencing 0
of 0
this 0
region 0
shows 0
that 0
the 0
island 0
extends 0
over 0
3 0
. 0

5 0
kb 0
and 0
is 0
interrupted 0
by 0
the 0
( 0
CTG 0
) 0
n 0
repeat 0
. 0

Comparison 0
of 0
genomic 0
sequences 0
downstream 0
( 0
centromeric 0
) 0
of 0
the 0
repeat 0
in 0
human 0
and 0
mouse 0
identified 0
regions 0
of 0
significant 0
homology 0
. 0

These 0
correspond 0
to 0
exons 0
of 0
a 0
gene 0
predicted 0
to 0
encode 0
a 0
homeodomain 0
protein 0
. 0

RT-PCR 0
analysis 0
shows 0
that 0
this 0
gene 0
, 0
which 0
we 0
have 0
called 0
DM 3
locus-associated 0
homeodomain 0
protein 0
( 0
DMAHP 0
) 0
, 0
is 0
expressed 0
in 0
a 0
number 0
of 0
human 0
tissues 0
, 0
including 0
skeletal 0
muscle 0
, 0
heart 0
and 0
brain 0
. 0

Germline 0
mutations 0
in 0
the 0
RB1 0
gene 0
in 0
patients 0
with 0
hereditary 2
retinoblastoma 2
. 0

We 0
have 0
analyzed 0
the 0
27 0
exons 0
and 0
the 0
promoter 0
region 0
of 0
the 0
RB1 0
gene 0
in 0
familial 1
or 1
sporadic 1
bilateral 1
retinoblastoma 1
by 0
using 0
single-strand 0
conformation 0
polymorphism 0
analysis 0
. 0

For 0
improvement 0
over 0
previous 0
studies 0
, 0
a 0
new 0
set 0
of 0
primers 0
has 0
been 0
designed 0
, 0
which 0
allow 0
for 0
amplification 0
of 0
the 0
coding 0
and 0
splicing 0
sequences 0
only 0
. 0

The 0
positioning 0
of 0
the 0
polymerase 0
chain 0
reaction 0
( 0
PCR 0
) 0
primers 0
was 0
such 0
that 0
the 0
resulting 0
PCR 0
products 0
were 0
of 0
different 0
sizes 0
, 0
which 0
enabled 0
us 0
to 0
analyze 0
two 0
different 0
exons 0
simultaneously 0
and 0
still 0
distinguish 0
between 0
the 0
banding 0
profiles 0
for 0
both 0
( 0
biplex 0
analysis 0
) 0
. 0

By 0
using 0
this 0
approach 0
, 0
we 0
were 0
able 0
to 0
identify 0
mutation 0
in 0
22 0
new 0
patients 0
, 0
but 0
the 0
overall 0
efficiency 0
of 0
the 0
procedure 0
when 0
we 0
used 0
a 0
single-pass 0
regimen 0
was 0
only 0
48 0
% 0
. 0

The 0
mutations 0
were 0
small 0
insertions 0
and 0
deletions 0
and 0
point 0
mutations 0
in 0
roughly 0
equal 0
proportions 0
. 0

Type 2
II 2
human 2
complement 2
C2 2
deficiency 2
. 0

Allele-specific 0
amino 0
acid 0
substitutions 0
( 0
Ser189 0
-- 0
Phe 0
; 0
Gly444 0
-- 0
Arg 0
) 0
cause 0
impaired 0
C2 0
secretion 0
. 0

Type 2
II 2
complement 2
protein 2
C2 2
deficiency 2
is 0
characterized 0
by 0
a 0
selective 0
block 0
in 0
C2 0
secretion 0
. 0

The 0
Type 0
II 0
C2 0
null 0
allele 0
( 0
C2Q0 0
) 0
is 0
linked 0
to 0
two 0
major 0
histocompatibility 0
haplotypes 0
( 0
MHC 0
) 0
that 0
differ 0
from 0
the 0
MHC 0
of 0
the 0
more 0
common 0
Type 2
I 2
C2 2
deficiency 2
. 0

To 0
determine 0
the 0
molecular 0
basis 0
of 0
Type 2
II 2
deficiency 2
the 0
two 0
Type 0
II 0
C2Q0 0
genes 0
were 0
isolated 0
and 0
transfected 0
separately 0
into 0
L-cells 0
. 0

Subsequent 0
molecular 0
biology 0
, 0
biosynthetic 0
, 0
and 0
immunofluorescence 0
studies 0
demonstrated 0
that 0
C2 0
secretion 0
is 0
impaired 0
in 0
Type 2
II 2
C2 2
deficiency 2
because 0
of 0
different 0
missense 0
mutations 0
at 0
highly 0
conserved 0
residues 0
in 0
each 0
of 0
the 0
C2Q0 0
alleles 0
. 0

One 0
is 0
in 0
exon 0
5 0
( 0
nucleotide 0
C566 0
-- 0
T 0
; 0
Ser189 0
-- 0
Phe 0
) 0
of 0
the 0
C2Q0 0
gene 0
linked 0
to 0
the 0
MHC 0
haplotype 0
A11 0
, 0
B35 0
, 0
DRw1 0
, 0
BFS 0
, 0
C4A0B1 0
. 0

The 0
other 0
is 0
in 0
exon 0
11 0
( 0
G1930 0
-- 0
A 0
; 0
Gly444 0
-- 0
Arg 0
) 0
of 0
the 0
C2Q0 0
gene 0
linked 0
to 0
the 0
MHC 0
haplotype 0
A2 0
, 0
B5 0
, 0
DRw4 0
, 0
BFS 0
, 0
C4A3B1 0
. 0

Each 0
mutant 0
C2 0
gene 0
product 0
is 0
retained 0
early 0
in 0
the 0
secretory 0
pathway 0
. 0

These 0
mutants 0
provide 0
models 0
for 0
elucidating 0
the 0
C2 0
secretory 0
pathway 0
. 0

Defective 0
dimerization 0
of 0
von 3
Willebrand 3
factor 0
subunits 0
due 0
to 0
a 0
Cys- 0
Arg 0
mutation 0
in 0
type 2
IID 2
von 2
Willebrand 2
disease 2
. 0

The 0
same 0
heterozygous 0
T 0
- 0
C 0
transition 0
at 0
nt 0
8567 0
of 0
the 0
von 3
Willebrand 3
factor 0
( 0
vWF 0
) 0
transcript 0
was 0
found 0
in 0
two 0
unrelated 0
patients 0
with 0
type 2
IID 2
von 2
Willebrand 2
disease 2
, 0
with 0
no 0
other 0
apparent 0
abnormality 0
. 0

In 0
one 0
family 0
, 0
both 0
alleles 0
were 0
normal 0
in 0
the 0
parents 0
and 0
one 0
sister 0
; 0
thus 0
, 0
the 0
mutation 0
originated 0
de 0
novo 0
in 0
the 0
proposita 0
. 0

The 0
second 0
patient 0
also 0
had 0
asymptomatic 0
parents 0
who 0
, 0
however 0
, 0
were 0
not 0
available 0
for 0
study 0
. 0

The 0
structural 0
consequences 0
of 0
the 0
identified 0
mutation 0
, 0
resulting 0
in 0
the 0
CyS2010 0
- 0
Arg 0
substitution 0
, 0
were 0
evaluated 0
by 0
expression 0
of 0
the 0
vWF 0
carboxyl-terminal 0
domain 0
containing 0
residues 0
1366-2050 0
. 0

Insect 0
cells 0
infected 0
with 0
recombinant 0
baculovirus 0
expressing 0
normal 0
vWF 0
sequence 0
secreted 0
a 0
disulfide 0
linked 0
dimeric 0
molecule 0
with 0
an 0
apparent 0
molecular 0
mass 0
of 0
150 0
kDa 0
before 0
reduction 0
, 0
yielding 0
a 0
single 0
band 0
of 0
80 0
kDa 0
after 0
disulfide 0
bond 0
reduction 0
. 0

In 0
contrast 0
, 0
cells 0
expressing 0
the 0
mutant 0
fragment 0
secreted 0
a 0
monomeric 0
molecule 0
of 0
apparent 0
molecular 0
mass 0
of 0
80 0
kDa 0
, 0
which 0
remained 0
unchanged 0
after 0
reduction 0
. 0

We 0
conclude 0
that 0
CyS2010 0
is 0
essential 0
for 0
normal 0
dimerization 0
of 0
vWF 0
subunits 0
through 0
disulfide 0
bonding 0
of 0
carboxyl-terminal 0
domains 0
and 0
that 0
a 0
heterozygous 0
mutation 0
in 0
the 0
corresponding 0
codon 0
is 0
responsible 0
for 0
defective 0
multimer 0
formation 0
in 0
type 2
IID 2
von 2
Willebrand 2
disease 2
. 0

Wiskott-Aldrich 3
syndrome 3
protein 0
, 0
a 0
novel 0
effector 0
for 0
the 0
GTPase 0
CDC42Hs 0
, 0
is 0
implicated 0
in 0
actin 0
polymerization 0
. 0

The 0
Rho 0
family 0
of 0
GTPases 0
control 0
diverse 0
biological 0
processes 0
, 0
including 0
cell 0
morphology 0
and 0
mitogenesis 0
. 0

We 0
have 0
identified 0
WASP 0
, 0
the 0
protein 0
that 0
is 0
defective 0
in 0
Wiskott-Aldrich 2
syndrome 2
( 0
WAS 2
) 0
, 0
as 0
a 0
novel 0
effector 0
for 0
CDC42Hs 0
, 0
but 0
not 0
for 0
the 0
other 0
Rho 0
family 0
members 0
, 0
Rac 0
and 0
Rho 0
. 0

This 0
interaction 0
is 0
dependent 0
on 0
the 0
presence 0
of 0
the 0
G 0
protein-binding 0
domain 0
. 0

Cellular 0
expression 0
of 0
epitope-tagged 0
WASP 0
produces 0
clusters 0
of 0
WASP 0
that 0
are 0
highly 0
enriched 0
in 0
polymerized 0
actin 0
. 0

This 0
clustering 0
is 0
not 0
observed 0
with 0
a 0
C-terminally 0
deleted 0
WASP 0
and 0
is 0
inhibited 0
by 0
coexpression 0
with 0
dominant 0
negative 0
CDC42Hs-N17 0
, 0
but 0
not 0
with 0
dominant 0
negative 0
forms 0
of 0
Rac 0
or 0
Rho 0
. 0

Thus 0
, 0
WASP 0
provides 0
a 0
novel 0
link 0
between 0
CDC42Hs 0
and 0
the 0
actin 0
cytoskeleton 0
, 0
which 0
suggests 0
a 0
molecular 0
mechanism 0
for 0
many 0
of 0
the 0
cellular 4
abnormalities 4
in 0
WAS 2
. 0

The 0
WASP 0
sequence 0
contains 0
two 0
novel 0
domains 0
that 0
are 0
homologous 0
to 0
other 0
proteins 0
involved 0
in 0
action 0
organization 0
. 0

X-linked 2
adrenoleukodystrophy 2
is 0
a 0
frequent 0
cause 0
of 0
idiopathic 0
Addison 2
's 2
disease 2
in 0
young 0
adult 0
male 0
patients 0
. 0

X-Linked 2
adrenoleukodystrophy 2
( 0
ALD 2
) 0
is 0
a 0
genetic 4
disease 4
associated 0
with 0
demyelination 4
of 4
the 4
central 4
nervous 4
system 4
, 0
adrenal 4
insufficiency 4
, 0
and 0
accumulation 0
of 0
very 0
long 0
chain 0
fatty 0
acids 0
in 0
tissue 0
and 0
body 0
fluids 0
. 0

ALD 2
is 0
due 0
to 0
mutation 0
of 0
a 0
gene 0
located 0
in 0
Xq28 0
that 0
encodes 0
a 0
peroxisomal 0
transporter 0
protein 0
of 0
unknown 0
function 0
. 0

The 0
most 0
common 0
phenotype 0
of 0
ALD 2
is 0
the 0
cerebral 0
form 0
( 0
45 0
% 0
) 0
that 0
develops 0
in 0
boys 0
between 0
5-12 0
yr 0
. 0

Adrenomyeloneuropathy 2
( 0
AMN 2
) 0
involves 0
the 0
spinal 0
cord 0
and 0
peripheral 0
nerves 0
in 0
young 0
adults 0
( 0
35 0
% 0
) 0
. 0

Adrenal 4
insufficiency 4
( 0
Addisons 2
disease 2
) 0
is 0
frequently 0
associated 0
with 0
AMN 2
or 0
cerebral 2
ALD 2
and 0
may 0
remain 0
the 0
only 0
clinical 0
expression 0
of 0
ALD 2
( 0
8 0
% 0
of 0
cases 0
) 0
. 0

The 0
prevalence 0
of 0
ALD 2
among 0
adults 0
with 0
Addisons 2
disease 2
remains 0
unknown 0
. 0

To 0
evaluate 0
this 0
prevalence 0
, 0
we 0
performed 0
biochemical 0
analysis 0
of 0
very 0
long 0
chain 0
fatty 0
acids 0
in 0
14 0
male 0
patients 0
( 0
age 0
ranging 0
from 0
12-45 0
yr 0
at 0
diagnosis 0
) 0
previously 0
diagnosed 0
as 0
having 0
primary 0
idiopathic 0
adrenocortical 4
insufficiency 4
. 0

In 0
5 0
of 0
14 0
patients 0
( 0
35 0
% 0
) 0
, 0
elevated 0
plasma 0
concentrations 0
of 0
very 0
long 0
chain 0
fatty 0
acids 0
were 0
detected 0
. 0

None 0
of 0
these 0
patients 0
had 0
adrenocortical 0
antibodies 0
. 0

By 0
electrophysiological 0
tests 0
and 0
magnetic 0
resonance 0
imaging 0
it 0
was 0
determined 0
that 0
two 0
patients 0
had 0
cerebral 2
ALD 2
, 0
one 0
had 0
adrenomyeloneuropathy 2
with 0
cerebral 0
involvement 0
, 0
and 0
two 0
had 0
preclinical 0
AMN 2
. 0

Our 0
data 0
support 0
the 0
hypothesis 0
that 0
ALD 2
is 0
a 0
frequent 0
cause 0
of 0
idiopathic 0
Addisons 2
disease 2
in 0
children 0
and 0
adults 0
. 0

Tumor 3
suppression 0
and 0
apoptosis 0
of 0
human 0
prostate 2
carcinoma 2
mediated 0
by 0
a 0
genetic 0
locus 0
within 0
human 0
chromosome 0
10pter-q11 0
. 0

Prostate 2
cancer 2
is 0
the 0
second 0
leading 0
cause 0
of 0
male 0
cancer 3
deaths 0
in 0
the 0
United 0
States 0
. 0

Yet 0
, 0
despite 0
a 0
large 0
international 0
effort 0
, 0
little 0
is 0
known 0
about 0
the 0
molecular 0
mechanisms 0
that 0
underlie 0
this 0
devastating 0
disease 0
. 0

Prostate 0
secretory 0
epithelial 0
cells 0
and 0
androgen-dependent 0
prostate 2
carcinomas 2
undergo 0
apoptosis 0
in 0
response 0
to 0
androgen 0
deprivation 0
and 0
, 0
furthermore 0
, 0
most 0
prostate 2
carcinomas 2
become 0
androgen 0
independent 0
and 0
refractory 0
to 0
further 0
therapeutic 0
manipulations 0
during 0
disease 0
progression 0
. 0

Definition 0
of 0
the 0
genetic 0
events 0
that 0
trigger 0
apoptosis 0
in 0
the 0
prostate 0
could 0
provide 0
important 0
insights 0
into 0
critical 0
pathways 0
in 0
normal 0
development 0
as 0
well 0
as 0
elucidate 0
the 0
perturbations 0
of 0
those 0
key 0
pathways 0
in 0
neoplastic 0
transformation 0
. 0

We 0
report 0
the 0
functional 0
definition 0
of 0
a 0
novel 0
genetic 0
locus 0
within 0
human 0
chromosome 0
10pter-q11 0
that 0
mediates 0
both 0
in 0
vivo 0
tumor 0
suppression 0
and 0
in 0
vitro 0
apoptosis 0
of 0
prostatic 3
adenocarcinoma 3
cells 0
. 0

A 0
defined 0
fragment 0
of 0
human 0
chromosome 0
10 0
was 0
transferred 0
via 0
microcell 0
fusion 0
into 0
a 0
prostate 3
adenocarcinoma 3
cell 0
line 0
. 0

Microcell 0
hybrids 0
containing 0
only 0
the 0
region 0
10pter-q11 0
were 0
suppressed 0
for 0
tumorigenicity 0
following 0
injection 0
of 0
microcell 0
hybrids 0
into 0
nude 0
mice 0
. 0

Furthermore 0
, 0
the 0
complemented 0
hybrids 0
undergo 0
programmed 0
cell 0
death 0
in 0
vitro 0
via 0
a 0
mechanism 0
that 0
does 0
not 0
require 0
nuclear 0
localization 0
of 0
p53 0
. 0

These 0
data 0
functionally 0
define 0
a 0
novel 0
genetic 0
locus 0
, 0
designated 0
PAC1 0
, 0
for 0
prostate 0
adenocarcinoma 0
1 0
, 0
involved 0
in 0
tumor 0
suppression 0
of 0
human 0
prostate 2
carcinoma 2
and 0
furthermore 0
strongly 0
suggest 0
that 0
the 0
cell 0
death 0
pathway 0
can 0
be 0
functionally 0
restored 0
in 0
prostatic 2
adenocarcinoma 2
. 0

Low 0
incidence 0
of 0
BRCA2 0
mutations 0
in 0
breast 2
carcinoma 2
and 0
other 0
cancers 4
. 0

Inherited 0
mutant 0
alleles 0
of 0
familial 0
tumour 3
suppressor 0
genes 0
predispose 0
individuals 0
to 0
particular 0
types 0
of 0
cancer 4
. 0

In 0
addition 0
to 0
an 0
involvement 0
in 0
inherited 0
susceptibility 0
to 0
cancer 4
, 0
these 0
tumour 3
suppressor 0
genes 0
are 0
targets 0
for 0
somatic 0
mutations 0
in 0
sporadic 4
cancers 4
of 0
the 0
same 0
type 0
found 0
in 0
the 0
familial 0
forms 0
. 0

An 0
exception 0
is 0
BRCA1 0
, 0
which 0
contributes 0
to 0
a 0
significant 0
fraction 0
of 0
familial 1
breast 1
and 1
ovarian 1
cancer 1
, 0
but 0
undergoes 0
mutation 0
at 0
very 0
low 0
rates 0
in 0
sporadic 1
breast 1
and 1
ovarian 1
cancers 1
. 0

This 0
finding 0
suggests 0
that 0
other 0
genes 0
may 0
be 0
the 0
principal 0
targets 0
for 0
somatic 0
mutation 0
in 0
breast 2
carcinoma 2
. 0

A 0
second 0
, 0
recently 0
identified 0
familial 3
breast 3
cancer 3
gene 0
, 0
BRCA2 0
( 0
refs 0
5-8 0
) 0
, 0
accounts 0
for 0
a 0
proportion 0
of 0
breast 2
cancer 2
roughly 0
equal 0
to 0
BRCA1 0
. 0

Like 0
BRCA1 0
, 0
BRCA2 0
behaves 0
as 0
a 0
dominantly 0
inherited 0
tumour 3
suppressor 0
gene 0
. 0

Individuals 0
who 0
inherit 0
one 0
mutant 0
allele 0
are 0
at 0
increased 0
risk 0
for 0
breast 2
cancer 2
, 0
and 0
the 0
tumours 4
they 0
develop 0
lose 0
the 0
wild-type 0
allele 0
by 0
heterozygous 0
deletion 0
. 0

The 0
BRCA2 0
coding 0
sequence 0
is 0
huge 0
, 0
composed 0
of 0
26 0
exons 0
that 0
span 0
10 0
, 0
443 0
bp 0
. 0

Here 0
we 0
investigate 0
the 0
rate 0
of 0
BRCA2 0
mutation 0
in 0
sporadic 2
breast 2
cancers 2
and 0
in 0
a 0
set 0
of 0
cell 0
lines 0
that 0
represent 0
twelve 0
other 0
tumour 3
types 0
. 0

Surprisingly 0
, 0
mutations 0
in 0
BRCA2 0
are 0
infrequent 0
in 0
cancers 4
including 0
breast 2
carcinoma 2
. 0

However 0
, 0
a 0
probable 0
germline 0
mutation 0
in 0
a 0
pancreatic 3
tumour 3
cell 0
line 0
suggests 0
a 0
role 0
for 0
BRCA2 0
in 0
susceptibility 0
to 0
pancreatic 2
cancer 2
. 0

Founding 0
BRCA1 0
mutations 0
in 0
hereditary 1
breast 1
and 1
ovarian 1
cancer 1
in 0
southern 0
Sweden 0
. 0

Nine 0
different 0
germ-line 0
mutations 0
in 0
the 0
BRCA1 0
breast 3
and 3
ovarian 3
cancer 3
susceptibility 0
gene 0
were 0
identified 0
in 0
15 0
of 0
47 0
kindreds 0
from 0
southern 0
Sweden 0
, 0
by 0
use 0
of 0
SSCP 0
and 0
heteroduplex 0
analysis 0
of 0
all 0
exons 0
and 0
flanking 0
intron 0
region 0
and 0
by 0
a 0
protein-truncation 0
test 0
for 0
exon 0
11 0
, 0
followed 0
by 0
direct 0
sequencing 0
. 0

All 0
but 0
one 0
of 0
the 0
mutations 0
are 0
predicted 0
to 0
give 0
rise 0
to 0
premature 0
translation 0
termination 0
and 0
include 0
seven 0
frameshift 0
insertions 0
or 0
deletions 0
, 0
a 0
nonsense 0
mutation 0
, 0
and 0
a 0
splice 0
acceptor 0
site 0
mutation 0
. 0

The 0
remaining 0
mutation 0
is 0
a 0
missense 0
mutation 0
( 0
Cys61Gly 0
) 0
in 0
the 0
zinc-binding 0
motif 0
. 0

Four 0
novel 0
Swedish 0
founding 0
mutations 0
were 0
identified 0
the 0
nucleotide 0
2595 0
deletion 0
A 0
was 0
found 0
in 0
five 0
families 0
, 0
the 0
C 0
1806 0
T 0
nonsense 0
mutation 0
in 0
three 0
families 0
, 0
the 0
3166 0
insertion 0
TGAGA 0
in 0
three 0
families 0
, 0
and 0
the 0
nucleotide 0
1201 0
deletion 0
11 0
in 0
two 0
families 0
. 0

Analysis 0
of 0
the 0
intragenic 0
polymorphism 0
D17S855 0
supports 0
common 0
origins 0
of 0
the 0
mutations 0
. 0

Eleven 0
of 0
the 0
15 0
kindreds 0
manifesting 0
BRCA1 0
mutations 0
were 0
breast-ovarian 3
cancer 3
families 0
, 0
several 0
of 0
them 0
with 0
a 0
predominant 0
ovarian 3
cancer 3
phenotype 0
. 0

The 0
set 0
of 0
32 0
families 0
in 0
which 0
no 0
BRCA1 0
alterations 0
were 0
detected 0
included 0
1 0
breast-ovarian 3
cancer 3
kindred 0
manifesting 0
clear 0
linkage 0
to 0
the 0
BRCA1 0
region 0
and 0
loss 0
of 0
the 0
wild-type 0
chromosome 0
in 0
associated 0
tumors 4
. 0

Other 0
tumor 3
types 0
found 0
in 0
BRCA1 0
mutation 0
/ 0
haplotype 0
carriers 0
included 0
prostatic 1
, 1
pancreas 1
, 1
skin 1
, 1
and 1
lung 1
cancer 1
, 0
a 0
malignant 2
melanoma 2
, 0
an 0
oligodendroglioma 2
, 0
and 0
a 0
carcinosarcoma 2
. 0

In 0
all 0
, 0
12 0
of 0
16 0
kindreds 0
manifesting 0
BRCA1 0
mutation 0
or 0
linkage 0
contained 0
ovarian 2
cancer 2
, 0
as 0
compared 0
with 0
only 0
6 0
of 0
the 0
remaining 0
31 0
families 0
( 0
P 0
. 0

001 0
) 0
. 0

The 0
present 0
study 0
confirms 0
the 0
involvement 0
of 0
BRCA1 0
in 0
disease 0
predisposition 0
for 0
a 0
subset 0
of 0
hereditary 3
breast 3
cancer 3
families 0
often 0
characterized 0
by 0
ovarian 2
cancers 2
. 0

Rapid 0
detection 0
of 0
regionally 0
clustered 0
germ-line 0
BRCA1 0
mutations 0
by 0
multiplex 0
heteroduplex 0
analysis 0
. 0

UKCCCR 0
Familial 0
Ovarian 3
Cancer 3
Study 0
Group 0
. 0

Germ-line 0
mutations 0
of 0
the 0
BRCA1 0
gene 0
are 0
responsible 0
for 0
a 0
substantial 0
proportion 0
of 0
families 0
with 0
multiple 0
cases 0
of 0
early-onset 0
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
. 0

Since 0
the 0
isolation 0
of 0
BRCA1 0
last 0
year 0
, 0
65 0
distinct 0
mutations 0
scattered 0
throughout 0
the 0
coding 0
region 0
have 0
been 0
detected 0
, 0
making 0
analysis 0
of 0
the 0
gene 0
time 0
consuming 0
and 0
technically 0
challenging 0
. 0

We 0
have 0
developed 0
a 0
multiplex 0
heteroduplex 0
analysis 0
that 0
is 0
designed 0
to 0
analyze 0
one-quarter 0
of 0
the 0
coding 0
sequence 0
in 0
a 0
single-step 0
screening 0
procedure 0
and 0
that 0
will 0
detect 0
approximately 0
50 0
% 0
of 0
all 0
BRCA1 0
mutations 0
so 0
far 0
reported 0
in 0
breast 3
/ 3
ovarian 3
cancer 3
families 0
. 0

We 0
have 0
used 0
this 0
technique 0
to 0
analyze 0
BRCA1 0
in 0
162 0
families 0
with 0
a 0
history 0
of 0
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
and 0
identified 0
12 0
distinct 0
mutations 0
in 0
35 0
families 0
. 0

A 0
previously 0
undescribed 0
mutation 0
within 0
the 0
tetramerisation 0
domain 0
of 0
TP53 0
in 0
a 0
family 0
with 0
Li-Fraumeni 2
syndrome 2
. 0

We 0
report 0
details 0
of 0
a 0
family 0
with 0
classic 0
Li-Fraumeni 2
syndrome 2
in 0
which 0
there 0
is 0
a 0
mutation 0
in 0
codon 0
344 0
of 0
the 0
tumour 3
suppressor 0
gene 0
TP53 0
. 0

Codon 0
344 0
is 0
a 0
key 0
residue 0
within 0
the 0
tetramerisation 0
domain 0
, 0
and 0
the 0
amino 0
acid 0
substitution 0
of 0
a 0
proline 0
for 0
a 0
leucine 0
is 0
predicted 0
to 0
have 0
profound 0
implications 0
for 0
tetramerisation 0
and 0
potentially 0
DNA 0
binding 0
. 0

This 0
is 0
the 0
first 0
report 0
of 0
a 0
mutation 0
at 0
this 0
residue 0
in 0
either 0
sporadic 4
tumours 4
or 0
in 0
the 0
germline 0
and 0
the 0
first 0
report 0
of 0
a 0
germline 0
mutation 0
within 0
the 0
tetramerisation 0
domain 0
. 0

The 0
family 0
does 0
not 0
appear 0
to 0
be 0
remarkable 0
in 0
the 0
spectrum 0
of 0
tumours 4
, 0
and 0
there 0
is 0
loss 0
of 0
the 0
wild-type 0
allele 0
in 0
a 0
leiomyosarcoma 2
from 0
the 0
proband 0
. 0

A 0
cell 0
line 0
has 0
been 0
established 0
from 0
the 0
tumour 4
of 0
the 0
proband 0
and 0
cytogenetic 0
and 0
molecular 0
studies 0
carried 0
out 0
, 0
providing 0
an 0
extensive 0
analysis 0
in 0
this 0
family 0
. 0

The 0
spectrum 0
of 0
RB1 0
germ-line 0
mutations 0
in 0
hereditary 2
retinoblastoma 2
. 0

We 0
have 0
searched 0
for 0
germ-line 0
RB1 0
mutations 0
in 0
119 0
patients 0
with 0
hereditary 2
retinoblastoma 2
. 0

Previous 0
investigations 0
by 0
Southern 0
blot 0
hybridization 0
and 0
PCR 0
fragment-length 0
analysis 0
had 0
revealed 0
mutations 0
in 0
48 0
patients 0
. 0

Here 0
we 0
report 0
on 0
the 0
analysis 0
of 0
the 0
remaining 0
71 0
patients 0
. 0

By 0
applying 0
heteroduplex 0
analysis 0
, 0
nonisotopic 0
SSCP 0
, 0
and 0
direct 0
sequencing 0
, 0
we 0
detected 0
germ-line 0
mutations 0
resulting 0
in 0
premature 0
termination 0
codons 0
or 0
disruption 0
of 0
splice 0
signals 0
in 0
51 0
( 0
72 0
% 0
) 0
of 0
the 0
71 0
patients 0
. 0

Four 0
patients 0
also 0
showed 0
rare 0
sequence 0
variants 0
. 0

No 0
region 0
of 0
the 0
RB1 0
gene 0
was 0
preferentially 0
involved 0
in 0
single 0
base 0
substitutions 0
. 0

Recurrent 0
transitions 0
were 0
observed 0
at 0
most 0
of 0
the 0
14 0
codons 0
within 0
the 0
RB1 0
. 0

No 0
mutation 0
was 0
observed 0
in 0
exons 0
25-27 0
, 0
although 0
this 0
region 0
contains 0
two 0
CGA 0
codons 0
. 0

This 0
suggests 0
that 0
mutations 0
within 0
the 0
3-terminal 0
region 0
of 0
the 0
RB1 0
gene 0
may 0
not 0
be 0
oncogenic 0
. 0

When 0
these 0
data 0
were 0
combined 0
with 0
the 0
results 0
of 0
our 0
previous 0
investigations 0
, 0
mutations 0
were 0
identified 0
in 0
a 0
total 0
of 0
99 0
( 0
83 0
% 0
) 0
of 0
119 0
patients 0
. 0

The 0
spectrum 0
comprises 0
15 0
% 0
large 0
deletions 0
, 0
26 0
% 0
small 0
length 0
alterations 0
, 0
and 0
42 0
% 0
base 0
substitutions 0
. 0

No 0
correlation 0
between 0
the 0
location 0
of 0
frameshift 0
or 0
nonsense 0
mutations 0
and 0
phenotypic 0
features 0
, 0
including 0
age 0
at 0
diagnosis 0
, 0
the 0
number 0
of 0
tumor 3
foci 0
, 0
and 0
manifestation 0
of 0
nonocular 4
tumors 4
was 0
observed 0
. 0

Phenotypic 0
characterization 0
of 0
individuals 0
with 0
30-40 0
CAG 0
repeats 0
in 0
the 0
Huntington 3
disease 3
( 0
HD 3
) 0
gene 0
reveals 0
HD 3
cases 0
with 0
36 0
repeats 0
and 0
apparently 0
normal 0
elderly 0
individuals 0
with 0
36-39 0
repeats 0
. 0

Abnormal 0
CAG 0
expansions 0
in 0
the 0
IT-15 0
gene 0
are 0
associated 0
with 0
Huntington 2
disease 2
( 0
HD 2
) 0
. 0

In 0
the 0
diagnostic 0
setting 0
it 0
is 0
necessary 0
to 0
define 0
the 0
limits 0
of 0
the 0
CAG 0
size 0
ranges 0
on 0
normal 0
and 0
HD 3
-associated 0
chromosomes 0
. 0

Most 0
large 0
analyses 0
that 0
defined 0
the 0
limits 0
of 0
the 0
normal 0
and 0
pathological 0
size 0
ranges 0
employed 0
PCR 0
assays 0
, 0
which 0
included 0
the 0
CAG 0
repeats 0
and 0
a 0
CCG 0
repeat 0
tract 0
that 0
was 0
thought 0
to 0
be 0
invariant 0
. 0

Many 0
of 0
these 0
experiments 0
found 0
an 0
overlap 0
between 0
the 0
normal 0
and 0
disease 0
size 0
ranges 0
. 0

Subsequent 0
findings 0
that 0
the 0
CCG 0
repeats 0
vary 0
by 0
8 0
trinucleotide 0
lengths 0
suggested 0
that 0
the 0
limits 0
of 0
the 0
normal 0
and 0
disease 0
size 0
ranges 0
should 0
be 0
reevaluated 0
with 0
assays 0
that 0
exclude 0
the 0
CCG 0
polymorphism 0
. 0

Since 0
patients 0
with 0
between 0
30 0
and 0
40 0
repeats 0
are 0
rare 0
, 0
a 0
consortium 0
was 0
assembled 0
to 0
collect 0
such 0
individuals 0
. 0

All 0
178 0
samples 0
were 0
reanalyzed 0
in 0
Cambridge 0
by 0
using 0
assays 0
specific 0
for 0
the 0
CAG 0
repeats 0
. 0

We 0
have 0
optimized 0
methods 0
for 0
reliable 0
sizing 0
of 0
CAG 0
repeats 0
and 0
show 0
cases 0
that 0
demonstrate 0
the 0
dangers 0
of 0
using 0
PCR 0
assays 0
that 0
include 0
both 0
the 0
CAG 0
and 0
CCG 0
polymorphisms 0
. 0

Seven 0
HD 3
patients 0
had 0
36 0
repeats 0
, 0
which 0
confirms 0
that 0
this 0
allele 0
is 0
associated 0
with 0
disease 0
. 0

Individuals 0
without 0
apparent 0
symptoms 0
or 0
signs 0
of 0
HD 2
were 0
found 0
at 0
36 0
repeats 0
( 0
aged 0
74 0
, 0
78 0
, 0
79 0
, 0
and 0
87 0
years 0
) 0
, 0
37 0
repeats 0
( 0
aged 0
69 0
years 0
) 0
, 0
38 0
repeats 0
( 0
aged 0
69 0
and 0
90 0
years 0
) 0
, 0
and 0
39 0
repeats 0
( 0
aged 0
67 0
, 0
90 0
, 0
and 0
95 0
years 0
) 0
. 0

The 0
detailed 0
case 0
histories 0
of 0
an 0
exceptional 0
case 0
from 0
this 0
series 0
will 0
be 0
presented 0
a 0
95-year-old 0
man 0
with 0
39 0
repeats 0
who 0
did 0
not 0
have 0
classical 0
features 0
of 0
HD 2
. 0

The 0
apparently 0
healthy 0
survival 0
into 0
old 0
age 0
of 0
some 0
individuals 0
with 0
36-39 0
repeats 0
suggests 0
that 0
the 0
HD 3
mutation 0
may 0
not 0
always 0
be 0
fully 0
penetrant 0
. 0

Identification 0
and 0
expression 0
of 0
eight 0
novel 0
mutations 0
among 0
non-Jewish 0
patients 0
with 0
Canavan 2
disease 2
. 0

Canavan 2
disease 2
is 0
inherited 0
as 0
an 0
autosomal 0
recessive 0
trait 0
that 0
is 0
caused 0
by 0
the 0
deficiency 2
of 2
aspartoacylase 2
( 0
ASPA 0
) 0
. 0

The 0
majority 0
of 0
patients 0
with 0
Canavan 2
disease 2
are 0
from 0
an 0
Ashkenazi 0
Jewish 0
background 0
. 0

Mutations 0
in 0
ASPA 0
that 0
lead 0
to 0
loss 0
of 0
enzymatic 0
activity 0
have 0
been 0
identified 0
, 0
and 0
E285A 0
and 0
Y231X 0
are 0
the 0
two 0
predominant 0
mutations 0
that 0
account 0
for 0
97 0
% 0
of 0
the 0
mutant 0
chromosomes 0
in 0
Ashkenazi 0
Jewish 0
patients 0
. 0

The 0
current 0
study 0
was 0
aimed 0
at 0
finding 0
the 0
molecular 0
basis 0
of 0
Canavan 2
disease 2
in 0
25 0
independent 0
patients 0
of 0
non-Jewish 0
background 0
. 0

Eight 0
novel 0
and 0
three 0
previously 0
characterized 0
mutations 0
accounted 0
for 0
80 0
% 0
( 0
40 0
/ 0
50 0
) 0
of 0
mutant 0
chromosomes 0
. 0

The 0
A305E 0
missense 0
mutation 0
accounted 0
for 0
48 0
% 0
( 0
24 0
/ 0
50 0
) 0
of 0
mutant 0
chromosomes 0
in 0
patients 0
of 0
western 0
European 0
descent 0
, 0
while 0
the 0
two 0
predominant 0
Jewish 0
mutations 0
each 0
accounted 0
for 0
a 0
single 0
mutant 0
chromosome 0
. 0

The 0
eight 0
novel 0
mutations 0
identified 0
included 0
1- 0
and 0
4-bp 0
deletions 0
( 0
32 0
deltaT 0
and 0
876 0
deltaAGAA 0
, 0
respectively 0
) 0
and 0
I16T 0
, 0
G27R 0
, 0
D114E 0
, 0
G123E 0
, 0
C152Y 0
, 0
and 0
R168C 0
missense 0
mutations 0
. 0

The 0
homozygous 0
32 0
deltaT 0
deletion 0
was 0
identified 0
in 0
the 0
only 0
known 0
patient 0
of 0
African-American 0
origin 0
with 0
Canavan 2
disease 2
. 0

The 0
heterozygosity 0
for 0
876 0
deltaAGAA 0
mutation 0
was 0
identified 0
in 0
three 0
independent 0
patients 0
from 0
England 0
. 0

Six 0
single-base 0
changes 0
leading 0
to 0
missense 0
mutations 0
were 0
identified 0
in 0
patients 0
from 0
Turkey 0
( 0
D114E 0
, 0
R168C 0
) 0
, 0
The 0
Netherlands 0
( 0
I16T 0
) 0
, 0
Germany 0
( 0
G27R 0
) 0
, 0
Ireland 0
( 0
C152Y 0
) 0
, 0
and 0
Canada 0
( 0
G123E 0
) 0
. 0

A 0
PCR-based 0
protocol 0
is 0
described 0
that 0
was 0
used 0
to 0
introduce 0
mutations 0
in 0
wild-type 0
cDNA 0
. 0

In 0
vitro 0
expression 0
of 0
mutant 0
cDNA 0
clones 0
demonstrated 0
that 0
all 0
of 0
these 0
mutations 0
led 0
to 0
a 0
deficiency 2
of 2
ASPA 2
and 0
should 0
therefore 0
result 0
in 0
Canavan 2
disease 2
. 0

Identification 0
and 0
chromosomal 0
localization 0
of 0
Atm 0
, 0
the 0
mouse 0
homolog 0
of 0
the 0
ataxia-telangiectasia 3
gene 0
. 0

Atm 0
, 0
the 0
mouse 0
homolog 0
of 0
the 0
human 0
ATM 0
gene 0
defective 0
in 0
ataxia-telangiectasia 2
( 0
A-T 2
) 0
, 0
has 0
been 0
identified 0
. 0

The 0
entire 0
coding 0
sequence 0
of 0
the 0
Atm 0
transcript 0
was 0
cloned 0
and 0
found 0
to 0
contain 0
an 0
open 0
reading 0
frame 0
encoding 0
a 0
protein 0
of 0
3066 0
amino 0
acids 0
with 0
84 0
% 0
overall 0
identity 0
and 0
91 0
% 0
similarity 0
to 0
the 0
human 0
ATM 0
protein 0
. 0

Variable 0
levels 0
of 0
expression 0
of 0
Atm 0
were 0
observed 0
in 0
different 0
tissues 0
. 0

Fluorescence 0
in 0
situ 0
hybridization 0
and 0
linkage 0
analysis 0
located 0
the 0
Atm 0
gene 0
on 0
mouse 0
chromosome 0
9 0
, 0
band 0
9C 0
, 0
in 0
a 0
region 0
homologous 0
to 0
the 0
ATM 0
region 0
on 0
human 0
chromosome 0
11q22-q23 0
. 0

The 0
mouse 0
homolog 0
of 0
the 0
Wiskott-Aldrich 3
syndrome 3
protein 0
( 0
WASP 0
) 0
gene 0
is 0
highly 0
conserved 0
and 0
maps 0
near 0
the 0
scurfy 0
( 0
sf 0
) 0
mutation 0
on 0
the 0
X 0
chromosome 0
. 0

The 0
mouse 0
WASP 0
gene 0
, 0
the 0
homolog 0
of 0
the 0
gene 0
mutated 0
in 0
Wiskott-Aldrich 2
syndrome 2
, 0
has 0
been 0
isolated 0
and 0
sequenced 0
. 0

the 0
predicted 0
amino 0
acid 0
sequence 0
is 0
86 0
% 0
identical 0
to 0
the 0
human 0
WASP 0
sequence 0
. 0

A 0
distinct 0
feature 0
of 0
the 0
mouse 0
gene 0
is 0
an 0
expanded 0
polymorphic 0
GGA 0
trinucleotide 0
repeat 0
that 0
codes 0
for 0
polyglycine 0
and 0
varies 0
from 0
15 0
to 0
17 0
triplets 0
in 0
different 0
Mus 0
musculus 0
strains 0
. 0

The 0
genomic 0
structure 0
of 0
the 0
mouse 0
WASP 0
gene 0
is 0
expressed 0
as 0
an 0
approximately 0
2 0
. 0

4-kb 0
mRNA 0
in 0
thymus 0
and 0
spleen 0
. 0

Chromosomal 0
mapping 0
in 0
an 0
interspecific 0
M 0
. 0

Musculus 0
/ 0
M 0
. 0

spretus 0
backcross 0
placed 0
the 0
Wasp 0
locus 0
near 0
the 0
centromere 0
of 0
the 0
mouse 0
X 0
chromosome 0
, 0
inseparable 0
from 0
Gata1 0
, 0
Tcfe3 0
, 0
and 0
scurfy 0
( 0
sf 0
) 0
. 0

This 0
localization 0
makes 0
Wasp 0
a 0
candidate 0
for 0
involvement 0
in 0
scurfy 0
, 0
a 0
T 0
cell-mediated 0
fatal 4
lymphoreticular 4
disease 4
of 0
mice 0
that 0
has 0
previously 0
been 0
proposed 0
as 0
a 0
mouse 0
homolog 0
of 0
Wiskott-Aldrich 2
syndrome 2
. 0

Northern 0
analysis 0
of 0
sf 0
tissue 0
samples 0
indicated 0
the 0
presence 0
of 0
WASP 0
mRNA 0
in 0
liver 0
and 0
skin 0
, 0
presumably 0
as 0
a 0
consequence 0
of 0
lymphocytic 0
infiltration 0
, 0
but 0
non 0
abnormalities 0
in 0
the 0
amount 0
or 0
size 0
of 0
mRNA 0
present 0
. 0

Colchicine 0
in 0
breast 0
milk 0
of 0
patients 0
with 0
familial 2
Mediterranean 2
fever 2
. 0

OBJECTIVE 0
. 0

To 0
clarify 0
whether 0
colchicine 0
is 0
excreted 0
in 0
breast 0
milk 0
, 0
and 0
to 0
compare 0
its 0
concentrations 0
in 0
the 0
serum 0
and 0
breast 0
milk 0
of 0
lactating 0
women 0
who 0
have 0
familial 2
Mediterranean 2
fever 2
( 0
FMF 2
) 0
. 0

METHODS 0
. 0

Using 0
a 0
specific 0
radioimmunoassay 0
, 0
we 0
determined 0
colchicine 0
concentrations 0
in 0
the 0
serum 0
and 0
breast 0
milk 0
of 0
4 0
patients 0
at 0
various 0
time 0
points 0
, 0
following 0
oral 0
administration 0
of 0
the 0
drug 0
. 0

The 0
study 0
evaluated 0
4 0
patients 0
with 0
FMF 2
who 0
had 0
been 0
taking 0
colchicine 0
on 0
a 0
long-term 0
basis 0
. 0

RESULTS 0
. 0

Colchicine 0
was 0
found 0
to 0
be 0
excreted 0
in 0
breast 0
milk 0
. 0

Its 0
levels 0
ranged 0
between 0
1 0
. 0

9 0
and 0
8 0
. 0

6 0
ng 0
/ 0
ml 0
, 0
which 0
were 0
similar 0
to 0
those 0
found 0
in 0
the 0
serum 0
( 0
parallel 0
concentration 0
time 0
curves 0
) 0
. 0

However 0
, 0
there 0
appeared 0
to 0
be 0
a 0
considerable 0
variation 0
in 0
colchicine 0
milk 0
concentration 0
among 0
the 0
different 0
patients 0
, 0
which 0
might 0
be 0
related 0
to 0
individual 0
breast 0
milk 0
composition 0
and 0
, 0
possibly 0
, 0
to 0
other 0
nutritional 0
or 0
metabolic 0
factors 0
. 0

CONCLUSION 0
. 0

The 0
extensive 0
peripheral 0
tissue 0
binding 0
and 0
relatively 0
low 0
concentration 0
of 0
colchicine 0
in 0
breast 0
milk 0
suggests 0
that 0
the 0
amount 0
ingested 0
by 0
the 0
infant 0
is 0
small 0
. 0

Furthermore 0
, 0
based 0
on 0
our 0
clinical 0
experience 0
, 0
nursing 0
appears 0
to 0
be 0
safe 0
for 0
lactating 0
women 0
with 0
FMF 2
who 0
continue 0
to 0
take 0
colchicine 0
. 0

Abnormal 0
myotonic 3
dystrophy 3
protein 0
kinase 0
levels 0
produce 0
only 0
mild 0
myopathy 4
in 0
mice 0
. 0

Myotonic 2
dystrophy 2
( 0
DM 2
) 0
is 0
commonly 0
associated 0
with 0
CTG 0
repeat 0
expansions 0
within 0
the 0
gene 0
for 0
DM-protein 0
kinase 0
( 0
DMPK 0
) 0
. 0

The 0
effect 0
of 0
altered 0
expression 0
levels 0
of 0
DMPK 0
, 0
which 0
is 0
ubiquitously 0
expressed 0
in 0
all 0
muscle 0
cell 0
lineages 0
during 0
development 0
, 0
was 0
examined 0
by 0
disrupting 0
the 0
endogenous 0
Dmpk 0
gene 0
and 0
overexpressing 0
a 0
normal 0
human 0
DMPK 0
transgene 0
in 0
mice 0
. 0

Nullizygous 0
( 0
- 0
/ 0
- 0
) 0
mice 0
showed 0
only 0
inconsistent 0
and 0
minor 0
size 0
changes 0
in 0
head 0
and 0
neck 0
muscle 0
fibres 0
at 0
older 0
age 0
, 0
animals 0
with 0
the 0
highest 0
DMPK 0
transgene 0
expression 0
showed 0
hypertrophic 2
cardiomyopathy 2
and 0
enhanced 0
neonatal 0
mortality 0
. 0

However 0
, 0
both 0
models 0
lack 0
other 0
frequent 0
DM 3
symptoms 0
including 0
the 0
fibre-type 0
dependent 0
atrophy 2
, 0
myotonia 2
, 0
cataract 2
and 0
male-infertility 2
. 0

These 0
results 0
strengthen 0
the 0
contention 0
that 0
simple 0
loss- 0
or 0
gain-of-expression 0
of 0
DMPK 0
is 0
not 0
the 0
only 0
crucial 0
requirement 0
for 0
development 0
of 0
the 0
disease 0
. 0

Mice 0
lacking 0
the 0
myotonic 3
dystrophy 3
protein 0
kinase 0
develop 0
a 0
late 0
onset 0
progressive 0
myopathy 2
. 0

Myotonic 2
dystrophy 2
( 0
DM 2
) 0
is 0
an 0
autosomal 4
dominant 4
disorder 4
resulting 0
from 0
the 0
expansion 0
of 0
a 0
CTG 0
repeat 0
in 0
the 0
3 0
untranslated 0
region 0
of 0
a 0
putative 0
protein 0
kinase 0
( 0
DMPK 0
) 0
. 0

To 0
elucidate 0
the 0
role 0
of 0
DMPK 0
in 0
DM 3
pathogenesis 0
we 0
have 0
developed 0
Dmpk 0
deficient 0
( 0
Dmpk- 0
/ 0
- 0
) 0
mice 0
. 0

Dmpk- 0
/ 0
-mice 0
develop 0
a 0
late-onset 0
, 0
progressive 2
skeletal 2
myopathy 2
that 0
shares 0
some 0
pathological 0
features 0
with 0
DM 2
. 0

Muscles 0
from 0
mature 0
mice 0
show 0
variation 0
in 0
fibre 0
size 0
, 0
increased 0
fibre 2
degeneration 2
and 0
fibrosis 2
. 0

Adult 0
Dmpk- 0
/ 0
-mice 0
show 0
ultrastructural 0
changes 0
in 0
muscle 0
and 0
a 0
50 0
% 0
decrease 0
in 0
force 0
generation 0
compared 0
to 0
young 0
mice 0
. 0

Our 0
results 0
indicate 0
that 0
DMPK 0
may 0
be 0
necessary 0
for 0
the 0
maintenance 0
of 0
skeletal 0
muscle 0
structure 0
and 0
function 0
and 0
suggest 0
that 0
a 0
decrease 0
in 0
DMPK 0
levels 0
may 0
contribute 0
to 0
DM 3
pathology 0
. 0

The 0
tumor 3
suppressor 0
gene 0
Brca1 0
is 0
required 0
for 0
embryonic 0
cellular 0
proliferation 0
in 0
the 0
mouse 0
. 0

Mutations 0
of 0
the 0
BRCA1 0
gone 0
in 0
humans 0
are 0
associated 0
with 0
predisposition 0
to 0
breast 1
and 1
ovarian 1
cancers 1
. 0

We 0
show 0
here 0
that 0
Brca1 0
+ 0
/ 0
- 0
mice 0
are 0
normal 0
and 0
fertile 0
and 0
lack 0
tumors 4
by 0
age 0
eleven 0
months 0
. 0

Homozygous 0
Brca1 0
( 0
5-6 0
) 0
mutant 0
mice 0
die 0
before 0
day 0
7 0
. 0

5 0
of 0
embryogenesis 0
. 0

Mutant 0
embryos 0
are 0
poorly 0
developed 0
, 0
with 0
no 0
evidence 0
of 0
mesoderm 0
formation 0
. 0

The 0
extraembryonic 0
region 0
is 0
abnormal 0
, 0
but 0
aggregation 0
with 0
wild-type 0
tetraploid 0
embryos 0
does 0
not 0
rescue 0
the 0
lethality 0
. 0

In 0
vivo 0
, 0
mutant 0
embryos 0
do 0
not 0
exhibit 0
increased 0
apoptosis 0
but 0
show 0
reduced 0
cell 0
proliferation 0
accompanied 0
by 0
decreased 0
expression 0
of 0
cyclin 0
E 0
and 0
mdm-2 0
, 0
a 0
regulator 0
of 0
p53 0
activity 0
. 0

The 0
expression 0
of 0
cyclin-dependent 0
kinase 0
inhibitor 0
p21 0
is 0
dramatically 0
increased 0
in 0
the 0
mutant 0
embryos 0
. 0

Buttressing 0
these 0
in 0
vivo 0
observations 0
is 0
the 0
fact 0
that 0
mutant 0
blastocyst 0
growth 0
is 0
grossly 0
impaired 0
in 0
vitro 0
. 0

Thus 0
, 0
the 0
death 0
of 0
Brca1 0
( 0
5-6 0
) 0
mutant 0
embryos 0
prior 0
to 0
gastrulation 0
may 0
be 0
due 0
to 0
a 0
failure 0
of 0
the 0
proliferative 0
burst 0
required 0
for 0
the 0
development 0
of 0
the 0
different 0
germ 0
layers 0
. 0

Increased 0
coronary 2
heart 2
disease 2
in 0
Japanese-American 0
men 0
with 0
mutation 0
in 0
the 0
cholesteryl 0
ester 0
transfer 0
protein 0
gene 0
despite 0
increased 0
HDL 0
levels 0
. 0

Plasma 0
high 0
density 0
lipoprotein 0
( 0
HDL 0
) 0
levels 0
are 0
strongly 0
genetically 0
determined 0
and 0
show 0
a 0
general 0
inverse 0
relationship 0
with 0
coronary 2
heart 2
disease 2
( 0
CHD 2
) 0
. 0

The 0
cholesteryl 0
ester 0
transfer 0
protein 0
( 0
CETP 0
) 0
mediates 0
the 0
transfer 0
of 0
cholesteryl 0
esters 0
from 0
HDL 0
to 0
other 0
lipoproteins 0
and 0
is 0
a 0
key 0
participant 0
in 0
the 0
reverse 0
transport 0
of 0
cholesterol 0
from 0
the 0
periphery 0
to 0
the 0
liver 0
. 0

A 0
high 0
prevalence 0
of 0
two 0
different 0
CETP 0
gene 0
mutations 0
( 0
D442G 0
, 0
5 0
. 0

1 0
% 0
; 0
intron 0
14G 0
A 0
, 0
0 0
. 0

5 0
% 0
) 0
, 0
was 0
found 0
in 0
3 0
, 0
469 0
men 0
of 0
Japanese 0
ancestry 0
in 0
the 0
Honolulu 0
Heart 0
Program 0
and 0
mutations 0
were 0
associated 0
with 0
decreased 0
CETP 0
( 0
-35 0
% 0
) 0
and 0
increased 0
HDL 0
chol 0
levels 0
( 0
+ 0
10 0
% 0
for 0
D442G 0
) 0
. 0

However 0
, 0
the 0
overall 0
prevalence 0
of 0
definite 0
CHD 2
was 0
21 0
% 0
in 0
men 0
with 0
mutations 0
and 0
16 0
% 0
in 0
men 0
without 0
mutations 0
. 0

The 0
relative 0
risk 0
( 0
RR 0
) 0
of 0
CHD 2
was 0
1 0
. 0

43 0
in 0
men 0
with 0
mutations 0
( 0
P 0
. 0

05 0
) 0
; 0
after 0
adjustment 0
for 0
CHD 3
risk 0
factors 0
, 0
the 0
RR 0
was 0
1 0
. 0

55 0
( 0
P 0
= 0
. 0

02 0
) 0
; 0
after 0
additional 0
adjustment 0
for 0
HDL 0
levels 0
, 0
the 0
RR 0
was 0
1 0
. 0

68 0
( 0
P 0
= 0
. 0

008 0
) 0
. 0

Similar 0
RR 0
values 0
were 0
obtained 0
for 0
the 0
D442G 0
mutation 0
alone 0
. 0

Increased 0
CHD 2
in 0
men 0
with 0
mutations 0
was 0
primarily 0
observed 0
for 0
HDL 0
chol 0
41-60 0
mg 0
/ 0
dl 0
; 0
for 0
HDL 0
chol 0
60 0
mg 0
/ 0
dl 0
men 0
with 0
and 0
without 0
mutations 0
had 0
low 0
CHD 2
prevalence 0
. 0

Thus 0
, 0
genetic 0
CETP 2
deficiency 2
appears 0
to 0
be 0
an 0
independent 0
risk 0
factor 0
for 0
CHD 2
, 0
primarily 0
due 0
to 0
increased 0
CHD 3
prevalence 0
in 0
men 0
with 0
the 0
D442G 0
mutation 0
and 0
HDL 0
cholesterol 0
between 0
41 0
and 0
60 0
mg 0
/ 0
dl 0
. 0

The 0
findings 0
suggest 0
that 0
both 0
HDL 0
concentration 0
and 0
the 0
dynamics 0
of 0
cholesterol 0
transport 0
through 0
HDL 0
( 0
i 0
. 0

e. 0
, 0
reverse 0
cholesterol 0
transport 0
) 0
determine 0
the 0
anti-atherogenicity 0
of 0
the 0
HDL 0
fraction 0
. 0

Mapping 0
the 0
homolog 0
of 0
the 0
human 0
Rb1 0
gene 0
to 0
chromosome 0
14 0
of 0
higher 0
primates 0
. 0

The 0
Rb1 0
gene 0
has 0
been 0
implicated 0
with 0
retinoblastoma 2
and 0
is 0
located 0
on 0
human 0
Chromosome 0
( 0
Chr 0
) 0
13q14 0
. 0

2 0
2 0
. 0

A 0
unique 0
sequence 0
human 0
Rb1 0
cosmid 0
DNA 0
probe 0
has 0
been 0
used 0
to 0
localize 0
this 0
region 0
on 0
apes 0
Chr 0
14 0
by 0
the 0
FISH 0
technique 0
. 0

The 0
conservation 0
of 0
the 0
Rb1 0
gene 0
in 0
higher 0
primates 0
at 0
the 0
corresponding 0
equivalent 0
chromosome 0
locus 0
( 0
14q14 0
) 0
of 0
the 0
human 0
may 0
serve 0
as 0
a 0
phylogenetic 0
marker 0
to 0
further 0
trace 0
the 0
evolutionary 0
pathway 0
of 0
human 0
descent 0
. 0

Wiskott-Aldrich 2
syndrome 2
: 0
no 0
strict 0
genotype-phenotype 0
correlations 0
but 0
clustering 0
of 0
missense 0
mutations 0
in 0
the 0
amino-terminal 0
part 0
of 0
the 0
WASP 0
gene 0
product 0
. 0

The 0
Wiskott-Aldrich 3
syndrome 3
protein 0
( 0
WASP 0
) 0
gene 0
was 0
found 0
to 0
be 0
mutated 0
in 0
patients 0
presenting 0
with 0
WAS 2
and 0
in 0
patients 0
showing 0
X-linked 2
thrombocytopenia 2
. 0

Mutation 0
analysis 0
in 0
19 0
families 0
of 0
German 0
, 0
Swiss 0
and 0
Turkish 0
descent 0
by 0
single-strand 0
conformation 0
polymorphism 0
and 0
sequencing 0
resulted 0
in 0
the 0
detection 0
of 0
seven 0
novel 0
and 0
10 0
known 0
mutations 0
. 0

A 0
striking 0
clustering 0
of 0
missense 0
mutations 0
in 0
the 0
first 0
four 0
exons 0
contrasted 0
with 0
a 0
random 0
distribution 0
of 0
nonsense 0
mutations 0
. 0

More 0
than 0
85 0
% 0
of 0
all 0
known 0
missense 0
mutations 0
were 0
localized 0
in 0
the 0
amino-terminal 0
stretch 0
of 0
the 0
WASP 0
gene 0
product 0
; 0
this 0
region 0
contained 0
a 0
mutational 0
hot 0
spot 0
at 0
codon 0
86 0
. 0

No 0
genotype-phenotype 0
correlation 0
emerged 0
after 0
a 0
comparison 0
of 0
the 0
identified 0
mutations 0
with 0
the 0
resulting 0
clinical 0
picture 0
for 0
a 0
classical 0
WAS 3
phenotype 0
. 0

A 0
substitution 0
at 0
codon 0
86 0
resulted 0
in 0
an 0
extremely 0
variable 0
expression 0
of 0
the 0
disease 0
in 0
a 0
large 0
Swiss 0
family 0
. 0

An 0
extended 0
homology 0
search 0
revealed 0
a 0
distant 0
relationship 0
of 0
this 0
stretch 0
to 0
the 0
vasodilator-stimulated 0
phosphoprotein 0
( 0
VASP 0
) 0
, 0
which 0
is 0
involved 0
in 0
the 0
maintenance 0
of 0
cyto-architecture 0
by 0
interacting 0
with 0
actin-like 0
filaments 0
. 0

Influence 0
of 0
PAX6 0
gene 0
dosage 0
on 0
development 0
: 0
overexpression 0
causes 0
severe 0
eye 4
abnormalities 4
. 0

Aniridia 2
in 0
man 0
and 0
Small 0
eye 0
in 0
mice 0
are 0
semidominant 4
developmental 4
disorders 4
caused 0
by 0
mutations 0
within 0
the 0
paired 0
box 0
gene 0
PAX6 0
. 0

Whereas 0
heterozygotes 0
suffer 0
from 0
iris 2
hypoplasia 2
, 0
homozygous 0
mice 0
lack 0
eyes 0
and 0
nasal 0
cavities 0
and 0
exhibit 0
brain 4
abnormalities 4
. 0

To 0
investigate 0
the 0
role 0
of 0
gene 0
dosage 0
in 0
more 0
detail 0
, 0
we 0
have 0
generated 0
yeast 0
artificial 0
chromosome 0
transgenic 0
mice 0
carrying 0
the 0
human 0
PAX6 0
locus 0
. 0

When 0
crossed 0
onto 0
the 0
Small 0
eye 0
background 0
, 0
the 0
transgene 0
rescues 0
the 0
mutant 0
phenotype 0
. 0

Strikingly 0
, 0
mice 0
carrying 0
multiple 0
copies 0
on 0
a 0
wild-type 0
background 0
show 0
specific 0
developmental 4
abnormalities 4
of 4
the 4
eye 4
, 0
but 0
not 0
of 0
other 0
tissues 0
expressing 0
the 0
gene 0
. 0

Thus 0
, 0
at 0
least 0
five 0
different 0
eye 0
phenotypes 0
are 0
associated 0
with 0
changes 0
in 0
PAX6 0
expression 0
. 0

We 0
provide 0
evidence 0
that 0
not 0
only 0
reduced 0
, 0
but 0
also 0
increased 0
levels 0
of 0
transcriptional 0
regulators 0
can 0
cause 0
developmental 4
defects 4
. 0

Heterodimer 0
formation 0
and 0
activity 0
in 0
the 0
human 0
enzyme 0
galactose-1-phosphate 0
uridylyltransferase 0
. 0

One 0
of 0
the 0
fundamental 0
questions 0
concerning 0
expression 0
and 0
function 0
of 0
dimeric 0
enzymes 0
involves 0
the 0
impact 0
of 0
naturally 0
occurring 0
mutations 0
on 0
subunit 0
assembly 0
and 0
heterodimer 0
activity 0
. 0

This 0
question 0
is 0
of 0
particular 0
interest 0
for 0
the 0
human 0
enzyme 0
galactose-l-phosphate 0
uridylyl-transferase 0
( 0
GALT 0
) 0
, 0
impairment 0
of 0
which 0
results 0
in 0
the 0
inherited 4
metabolic 4
disorder 4
category= 0
SpecificDisease 0
galactosemia 0
< 0
, 0
because 0
many 0
if 0
not 0
most 0
patients 0
studied 0
to 0
date 0
are 0
compound 0
heterozygotes 0
rather 0
than 0
true 0
molecular 0
homozygotes 0
. 0

Furthermore 0
, 0
the 0
broad 0
range 0
of 0
phenotypic 0
severity 0
observed 0
in 0
these 0
patients 0
raises 0
the 0
possibility 0
that 0
allelic 0
combination 0
, 0
not 0
just 0
allelic 0
constitution 0
, 0
may 0
play 0
some 0
role 0
in 0
determining 0
outcome 0
. 0

In 0
the 0
work 0
described 0
herein 0
, 0
we 0
have 0
selected 0
two 0
distinct 0
naturally 0
occurring 0
null 0
mutations 0
of 0
GALT 0
, 0
Q188R 0
and 0
R333W 0
, 0
and 0
asked 0
the 0
questions 0
( 0
i 0
) 0
what 0
are 0
the 0
impacts 0
of 0
these 0
mutations 0
on 0
subunit 0
assembly 0
, 0
and 0
( 0
ii 0
) 0
if 0
heterodimers 0
do 0
form 0
, 0
are 0
they 0
active 0
? 0

To 0
answer 0
these 0
questions 0
, 0
we 0
have 0
established 0
a 0
yeast 0
system 0
for 0
the 0
coexpression 0
of 0
epitope-tagged 0
alleles 0
of 0
human 0
GALT 0
and 0
investigated 0
both 0
the 0
extent 0
of 0
specific 0
GALT 0
subunit 0
interactions 0
and 0
the 0
activity 0
of 0
defined 0
heterodimer 0
pools 0
. 0

We 0
have 0
found 0
that 0
both 0
homodimers 0
and 0
heterodimers 0
do 0
form 0
involving 0
each 0
of 0
the 0
mutant 0
subunits 0
tested 0
and 0
that 0
both 0
heterodimer 0
pools 0
retain 0
substantial 0
enzymatic 0
activity 0
. 0

These 0
results 0
are 0
significant 0
not 0
only 0
in 0
terms 0
of 0
their 0
implications 0
for 0
furthering 0
our 0
understanding 0
of 0
galactosemia 2
and 0
GALT 0
holoenzyme 0
structure-function 0
relationships 0
but 0
also 0
because 0
the 0
system 0
described 0
may 0
serve 0
as 0
a 0
model 0
for 0
similar 0
studies 0
of 0
other 0
complexes 0
composed 0
of 0
multiple 0
subunits 0
. 0

Cleavage 0
of 0
huntingtin 0
by 0
apopain 0
, 0
a 0
proapoptotic 0
cysteine 0
protease 0
, 0
is 0
modulated 0
by 0
the 0
polyglutamine 0
tract 0
. 0

Apoptosis 0
has 0
recently 0
been 0
recognized 0
as 0
a 0
mode 0
of 0
cell 0
death 0
in 0
Huntington 2
disease 2
( 0
HD 2
) 0
. 0

Apopain 0
, 0
a 0
human 0
counterpart 0
of 0
the 0
nematode 0
cysteine 0
protease 0
death-gene 0
product 0
, 0
CED-3 0
, 0
has 0
a 0
key 0
role 0
in 0
proteolytic 0
events 0
leading 0
to 0
apoptosis 0
. 0

Here 0
we 0
show 0
that 0
apoptotic 0
extracts 0
and 0
apopain 0
itself 0
specifically 0
cleave 0
the 0
HD 3
gene 0
product 0
, 0
huntingtin 0
. 0

The 0
rate 0
of 0
cleavage 0
increases 0
with 0
the 0
length 0
of 0
the 0
huntingtin 0
polyglutamine 0
tract 0
, 0
providing 0
an 0
explanation 0
for 0
the 0
gain-of-function 0
associated 0
with 0
CAG 0
expansion 0
. 0

Our 0
results 0
show 0
that 0
huntingtin 0
is 0
cleaved 0
by 0
cysteine 0
proteases 0
and 0
suggest 0
that 0
HD 2
might 0
be 0
a 0
disorder 4
of 4
inappropriate 4
apoptosis 4
. 0

The 0
5 0
' 0
end 0
of 0
the 0
BRCA1 0
gene 0
lies 0
within 0
a 0
duplicated 0
region 0
of 0
human 0
chromosome 0
17q21 0
. 0

To 0
begin 0
to 0
address 0
the 0
hypothesis 0
that 0
abnormal 0
regulation 0
of 0
the 0
breast 3
/ 3
ovarian 3
cancer 3
susceptibility 0
gene 0
BRCA1 0
is 0
a 0
critical 0
step 0
in 0
sporadic 0
breast 0
/ 0
ovarian 0
tumorigenesis 0
, 0
we 0
have 0
determined 0
the 0
detailed 0
structure 0
of 0
the 0
BRCA1 0
genomic 0
region 0
. 0

We 0
show 0
that 0
this 0
region 0
of 0
the 0
genome 0
contains 0
a 0
tandem 0
duplication 0
of 0
approximately 0
30 0
kilobases 0
, 0
which 0
results 0
in 0
two 0
copies 0
of 0
BRCA1 0
exons 0
1 0
and 0
2 0
, 0
of 0
exons 0
1 0
and 0
3 0
of 0
the 0
adjacent 0
1A1-3B 0
gene 0
and 0
of 0
the 0
previously 0
reported 0
295 0
base 0
pair 0
intergenic 0
region 0
. 0

Sequence 0
analysis 0
of 0
the 0
duplicated 0
exons 0
of 0
BRCA1 0
and 0
1A1-3B 0
and 0
flanking 0
genomic 0
DNA 0
reveals 0
maintenance 0
of 0
the 0
intron-exon 0
structure 0
and 0
a 0
high 0
degree 0
of 0
nucleotide 0
sequence 0
identity 0
, 0
suggesting 0
that 0
these 0
are 0
non-processed 0
pseudogenes 0
and 0
that 0
the 0
duplication 0
is 0
a 0
recent 0
event 0
in 0
evolutionary 0
terms 0
. 0

We 0
also 0
show 0
that 0
a 0
processed 0
pseudogene 0
of 0
the 0
acidic 0
ribosomal 0
phosphoprotein 0
P1 0
( 0
ARPP1 0
) 0
is 0
inserted 0
directly 0
upstream 0
of 0
pseudo-BRCA1 0
exon 0
1A 0
. 0

We 0
believe 0
that 0
these 0
findings 0
could 0
not 0
only 0
confound 0
BRCA1 0
mutation 0
analysis 0
, 0
but 0
could 0
have 0
implications 0
for 0
the 0
normal 0
and 0
abnormal 0
regulation 0
of 0
BRCA1 0
transcription 0
, 0
translation 0
and 0
function 0
. 0

Deletion 0
of 0
small 0
nuclear 0
ribonucleoprotein 0
polypeptide 0
N 0
( 0
SNRPN 0
) 0
in 0
Prader-Willi 2
syndrome 2
detected 0
by 0
fluorescence 0
in 0
situ 0
hybridization 0
: 0
two 0
sibs 0
with 0
the 0
typical 0
phenotype 0
without 0
a 0
cytogenetic 0
deletion 0
in 0
chromosome 0
15q 0
. 0

The 0
small 0
nuclear 0
ribonucleoprotein 0
polypeptide 0
N 0
( 0
SNRPN 0
) 0
gene 0
is 0
regarded 0
as 0
one 0
of 0
the 0
candidates 0
for 0
Prader-Willi 2
syndrome 2
( 0
PWS 2
) 0
. 0

We 0
describe 0
two 0
sibs 0
with 0
typical 0
PWS 2
presenting 0
deletion 0
of 0
SNRPN 0
detected 0
by 0
fluorescence 0
in 0
situ 0
hybridization 0
( 0
FISH 0
) 0
. 0

Neither 0
a 0
cytogenetically 0
detectable 0
15q12 0
deletion 0
nor 0
a 0
deletion 0
for 0
the 0
D15S11 0
, 0
D15S10 0
, 0
and 0
GABRB3 0
cosmid 0
probes 0
were 0
found 0
in 0
either 0
patient 0
. 0

This 0
implies 0
a 0
smaller 0
deletion 0
limited 0
to 0
the 0
PWS 3
critical 0
region 0
. 0

FISH 0
with 0
a 0
SNRPN 0
probe 0
will 0
permit 0
analysis 0
of 0
PWS 3
patients 0
with 0
limited 0
deletions 0
not 0
detectable 0
with 0
other 0
probes 0
. 0

Expression 0
of 0
the 0
von 3
Hippel-Lindau 3
disease 3
tumour 3
suppressor 0
gene 0
during 0
human 0
embryogenesis 0
. 0

The 0
von 3
Hippel-Lindau 3
( 3
VHL 3
) 3
disease 3
product 0
is 0
thought 0
to 0
down-regulate 0
transcription 0
by 0
antagonizing 0
elongin-enhanced 0
transcriptional 0
elongation 0
. 0

Germline 0
VHL 3
gene 0
mutations 0
predispose 0
to 0
the 0
development 0
of 0
retinal 1
, 1
cerebellar 1
and 1
spinal 1
haemangioblastomas 1
, 0
renal 2
cell 2
carcinoma 2
and 0
phaeochromocytoma 2
. 0

In 0
addition 0
, 0
somatic 0
Inactivation 0
of 0
the 0
VHL 3
gene 0
is 0
frequent 0
in 0
sporadic 2
renal 2
cell 2
carcinoma 2
and 0
haemangioblastoma 2
. 0

Regulation 0
of 0
transcript 0
elongation 0
is 0
an 0
important 0
control 0
mechanism 0
for 0
gene 0
expression 0
and 0
the 0
VHL 3
gene 0
might 0
modify 0
the 0
expression 0
of 0
proto-oncogenes 0
and 0
growth 0
suppressor 0
genes 0
during 0
embryogenesis 0
. 0

We 0
therefore 0
investigated 0
the 0
expression 0
of 0
VHL 3
mRNA 0
during 0
human 0
embryogenesis 0
by 0
in 0
situ 0
hybridization 0
studies 0
at 0
4 0
, 0
6 0
and 0
10 0
weeks 0
post 0
conception 0
. 0

Although 0
VHL 3
mRNA 0
was 0
expressed 0
in 0
all 0
three 0
germ 0
layers 0
, 0
strong 0
expression 0
was 0
noted 0
in 0
the 0
central 0
nervous 0
system 0
, 0
kidneys 0
, 0
testis 0
and 0
lung 0
. 0

Within 0
the 0
kidney 0
, 0
VHL 3
mRNA 0
was 0
differentially 0
expressed 0
within 0
renal 0
tubules 0
suggesting 0
that 0
the 0
VHL 3
gene 0
product 0
may 0
have 0
a 0
specific 0
role 0
in 0
kidney 0
development 0
. 0

Two 0
alternatively 0
spliced 0
VHL 3
mRNAs 0
characterized 0
by 0
inclusion 0
( 0
isoform 0
I 0
) 0
or 0
exclusion 0
( 0
isoform 0
II 0
) 0
of 0
exon 0
2 0
are 0
transcribed 0
in 0
adult 0
tissues 0
. 0

To 0
investigate 0
if 0
the 0
two 0
isoforms 0
are 0
differentially 0
expressed 0
during 0
embryogenesis 0
, 0
VHL 3
mRNA 0
was 0
reverse 0
transcribed 0
from 0
13 0
fetal 0
tissues 0
( 0
8-10 0
weeks 0
gestation 0
) 0
. 0

The 0
quantitative 0
distribution 0
of 0
VHL 3
mRNA 0
within 0
fetal 0
tissues 0
reflected 0
that 0
seen 0
by 0
in 0
situ 0
hybridization 0
and 0
the 0
ratio 0
of 0
the 0
two 0
VHL 3
isoforms 0
was 0
similar 0
between 0
tissues 0
. 0

Although 0
the 0
genes 0
regulated 0
by 0
the 0
VHL 3
gene 0
product 0
have 0
not 0
yet 0
been 0
identified 0
, 0
our 0
findings 0
are 0
compatible 0
with 0
the 0
hypothesis 0
that 0
VHL 3
-mediated 0
control 0
of 0
transcriptional 0
elongation 0
may 0
have 0
a 0
role 0
in 0
normal 0
human 0
development 0
. 0

Genetic 0
heterogeneity 0
in 0
hereditary 2
breast 2
cancer 2
: 0
role 0
of 0
BRCA1 0
and 0
BRCA2 0
. 0

The 0
common 0
hereditary 0
forms 0
of 0
breast 2
cancer 2
have 0
been 0
largely 0
attributed 0
to 0
the 0
inheritance 0
of 0
mutations 0
in 0
the 0
BRCA1 0
or 0
BRCA2 0
genes 0
. 0

However 0
, 0
it 0
is 0
not 0
yet 0
clear 0
what 0
proportion 0
of 0
hereditary 2
breast 2
cancer 2
is 0
explained 0
by 0
BRCA1 0
and 0
BRCA2 0
or 0
by 0
some 0
other 0
unidentified 0
susceptibility 0
gene 0
( 0
s 0
) 0
. 0

We 0
describe 0
the 0
proportion 0
of 0
hereditary 2
breast 2
cancer 2
explained 0
by 0
BRCA1 0
or 0
BRCA2 0
in 0
a 0
sample 0
of 0
North 0
American 0
hereditary 2
breast 2
cancers 2
and 0
assess 0
the 0
evidence 0
for 0
additional 0
susceptibility 0
genes 0
that 0
may 0
confer 0
hereditary 3
breast 3
or 3
ovarian 3
cancer 3
risk 0
. 0

Twenty-three 0
families 0
were 0
identified 0
through 0
two 0
high-risk 0
breast 3
cancer 3
research 0
programs 0
. 0

Genetic 0
analysis 0
was 0
undertaken 0
to 0
establish 0
linkage 0
between 0
the 0
breast 3
or 3
ovarian 3
cancer 3
cases 0
and 0
markers 0
on 0
chromosomes 0
17q 0
( 0
BRCA1 0
) 0
and 0
13q 0
( 0
BRCA2 0
) 0
. 0

Mutation 0
analysis 0
in 0
the 0
BRCA1 0
and 0
BRCA2 0
genes 0
was 0
also 0
undertaken 0
in 0
all 0
families 0
. 0

The 0
pattern 0
of 0
hereditary 4
cancer 4
in 0
14 0
( 0
61 0
% 0
) 0
of 0
the 0
23 0
families 0
studied 0
was 0
attributed 0
to 0
BRCA1 0
by 0
a 0
combination 0
of 0
linkage 0
and 0
mutation 0
analyses 0
. 0

No 0
families 0
were 0
attributed 0
to 0
BRCA2 0
. 0

Five 0
families 0
( 0
22 0
% 0
) 0
provided 0
evidence 0
against 0
linkage 0
to 0
both 0
BRCA1 0
and 0
BRCA2 0
. 0

No 0
BRCA1 0
or 0
BRCA2 0
mutations 0
were 0
detected 0
in 0
these 0
five 0
families 0
. 0

The 0
BRCA1 0
or 0
BRCA2 0
status 0
of 0
four 0
families 0
( 0
17 0
% 0
) 0
could 0
not 0
be 0
determined 0
. 0

BRCA1 0
and 0
BRCA2 0
probably 0
explain 0
the 0
majority 0
of 0
hereditary 2
breast 2
cancer 2
that 0
exists 0
in 0
the 0
North 0
American 0
population 0
. 0

However 0
, 0
one 0
or 0
more 0
additional 0
genes 0
may 0
yet 0
be 0
found 0
that 0
explain 0
some 0
proportion 0
of 0
hereditary 2
breast 2
cancer 2
. 0

An 0
intronic 0
mutation 0
in 0
a 0
lariat 0
branchpoint 0
sequence 0
is 0
a 0
direct 0
cause 0
of 0
an 0
inherited 4
human 4
disorder 4
( 0
fish-eye 2
disease 2
) 0
. 0

The 0
first 0
step 0
in 0
the 0
splicing 0
of 0
an 0
intron 0
from 0
nuclear 0
precursors 0
of 0
mRNA 0
results 0
in 0
the 0
formation 0
of 0
a 0
lariat 0
structure 0
. 0

A 0
distinct 0
intronic 0
nucleotide 0
sequence 0
, 0
known 0
as 0
the 0
branchpoint 0
region 0
, 0
plays 0
a 0
central 0
role 0
in 0
this 0
process 0
. 0

We 0
here 0
describe 0
a 0
point 0
mutation 0
in 0
such 0
a 0
sequence 0
. 0

Three 0
sisters 0
were 0
shown 0
to 0
suffer 0
from 0
fish-eye 2
disease 2
( 0
FED 2
) 0
, 0
a 0
disorder 0
which 0
is 0
caused 0
by 0
mutations 0
in 0
the 0
gene 0
coding 0
for 0
lecithin 0
cholesterol 0
acyltransferase 0
( 0
LCAT 0
) 0
. 0

Sequencing 0
of 0
the 0
LCAT 0
gene 0
of 0
all 0
three 0
probands 0
revealed 0
compound 0
heterozygosity 0
for 0
a 0
missense 0
mutation 0
in 0
exon 0
4 0
which 0
is 0
reported 0
to 0
underlie 0
the 0
FED 3
phenotype 0
, 0
and 0
a 0
point 0
mutation 0
located 0
in 0
intron 0
4 0
( 0
IVS4 0
T-22C 0
) 0
. 0

By 0
performing 0
in 0
vitro 0
expression 0
of 0
LCAT 0
minigenes 0
and 0
reverse 0
transcriptase 0
PCR 0
on 0
mRNA 0
isolated 0
from 0
leukocytes 0
of 0
the 0
patient 0
, 0
this 0
gene 0
defect 0
was 0
shown 0
to 0
cause 0
a 0
null 0
allele 0
as 0
the 0
result 0
of 0
complete 0
intron 0
retention 0
. 0

In 0
conclusion 0
, 0
we 0
demonstrated 0
that 0
a 0
point 0
mutation 0
in 0
a 0
lariat 0
branchpoint 0
consensus 0
sequence 0
causes 0
a 0
null 0
allele 0
in 0
a 0
patient 0
with 0
FED 2
. 0

In 0
addition 0
, 0
our 0
finding 0
illustrates 0
the 0
importance 0
of 0
this 0
sequence 0
for 0
normal 0
human 0
mRNA 0
processing 0
. 0

Finally 0
, 0
this 0
report 0
provides 0
a 0
widely 0
applicable 0
strategy 0
which 0
ensures 0
fast 0
and 0
effective 0
screening 0
for 0
intronic 0
defects 0
that 0
underlie 0
differential 0
gene 0
expression 0
. 0

Mutations 0
associated 0
with 0
variant 0
phenotypes 0
in 0
ataxia-telangiectasia 2
. 0

We 0
have 0
identified 0
14 0
families 0
with 0
ataxia-telangiectasia 2
( 0
A-T 2
) 0
in 0
which 0
mutation 0
of 0
the 0
ATM 0
gene 0
is 0
associated 0
with 0
a 0
less 0
severe 0
clinical 0
and 0
cellular 0
phenotype 0
( 0
approximately 0
10 0
% 0
-15 0
% 0
of 0
A-T 3
families 0
identified 0
in 0
the 0
United 0
Kingdom 0
) 0
. 0

In 0
10 0
of 0
these 0
families 0
, 0
all 0
the 0
homozygotes 0
have 0
a 0
137-bp 0
insertion 0
in 0
their 0
cDNA 0
caused 0
by 0
a 0
point 0
mutation 0
in 0
a 0
sequence 0
resembling 0
a 0
splice-donor 0
site 0
. 0

The 0
second 0
A-T 3
allele 0
has 0
a 0
different 0
mutation 0
in 0
each 0
patient 0
. 0

We 0
show 0
that 0
the 0
less 0
severe 0
phenotype 0
in 0
these 0
patients 0
is 0
caused 0
by 0
some 0
degree 0
of 0
normal 0
splicing 0
, 0
which 0
occurs 0
as 0
an 0
alternative 0
product 0
from 0
the 0
insertion-containing 0
allele 0
. 0

The 0
level 0
of 0
the 0
137-bp 0
PCR 0
product 0
containing 0
the 0
insertion 0
was 0
lowest 0
in 0
two 0
patients 0
who 0
showed 0
a 0
later 0
onset 0
of 0
cerebellar 2
ataxia 2
. 0

A 0
further 0
four 0
families 0
who 0
do 0
not 0
have 0
this 0
insertion 0
have 0
been 0
identified 0
. 0

Mutations 0
detected 0
in 0
two 0
of 0
four 0
of 0
these 0
are 0
missense 0
mutations 0
, 0
normally 0
rare 0
in 0
A-T 3
patients 0
. 0

The 0
demonstration 0
of 0
mutations 0
giving 0
rise 0
to 0
a 0
slightly 0
milder 0
phenotype 0
in 0
A-T 2
raises 0
the 0
interesting 0
question 0
of 0
what 0
range 0
of 0
phenotypes 0
might 0
occur 0
in 0
individuals 0
in 0
whom 0
both 0
mutations 0
are 0
milder 0
. 0

One 0
possibility 0
might 0
be 0
that 0
individuals 0
who 0
are 0
compound 0
heterozygotes 0
for 0
ATM 0
mutations 0
are 0
more 0
common 0
than 0
we 0
realize 0
. 0

Mutation 0
of 0
the 0
VHL 0
gene 0
is 0
associated 0
exclusively 0
with 0
the 0
development 0
of 0
non-papillary 2
renal 2
cell 2
carcinomas 2
. 0

To 0
define 0
the 0
possible 0
role 0
of 0
the 0
VHL 3
gene 0
in 0
the 0
development 0
of 0
sporadic 2
renal 2
cell 2
carcinomas 2
, 0
91 0
different 0
parenchymal 4
tumours 4
of 4
the 4
kidney 4
have 0
been 0
investigated 0
for 0
mutation 0
of 0
the 0
VHL 3
gene 0
by 0
single 0
strand 0
conformation 0
polymorphism 0
( 0
SSCP 0
) 0
and 0
/ 0
or 0
heteroduplex 0
( 0
HD 0
) 0
techniques 0
. 0

Chromosome 0
3p 0
deletion 0
was 0
detected 0
in 0
98 0
per 0
cent 0
of 0
non-papillary 2
renal 2
cell 2
carcinomas 2
and 0
in 0
25 0
per 0
cent 0
of 0
chromophobe 0
renal 2
cell 2
carcinomas 2
. 0

In 0
22 0
of 0
the 0
43 0
non-papillary 2
renal 2
cell 2
carcinomas 2
, 0
abnormally 0
migrating 0
DNA 0
bands 0
were 0
detected 0
by 0
SSCP 0
and 0
/ 0
or 0
HD 0
analysis 0
. 0

No 0
mobility 0
shift 0
was 0
seen 0
in 0
any 0
of 0
the 0
23 0
chromophobe 0
renal 2
cell 2
carcinomas 2
. 0

In 0
addition 0
, 0
15 0
papillary 2
renal 2
cell 2
tumours 2
and 0
ten 0
renal 2
oncocytomas 2
, 0
which 0
are 0
characterized 0
by 0
genetic 0
changes 0
other 0
than 0
loss 0
of 0
chromosome 0
3p 0
sequences 0
, 0
were 0
analysed 0
for 0
mutation 0
of 0
the 0
VHL 3
gene 0
. 0

None 0
of 0
these 0
tumours 4
showed 0
abnormal 0
migration 0
patterns 0
. 0

The 0
results 0
indicate 0
that 0
mutation 0
of 0
the 0
VHL 3
gene 0
is 0
associated 0
exclusively 0
with 0
the 0
development 0
of 0
non-papillary 2
renal 2
cell 2
carcinoma 2
. 0

The 0
Emery-Dreifuss 3
muscular 3
dystrophy 3
protein 0
, 0
emerin 0
, 0
is 0
a 0
nuclear 0
membrane 0
protein 0
. 0

A 0
large 0
fragment 0
of 0
emerin 0
cDNA 0
was 0
prepared 0
by 0
PCR 0
and 0
expressed 0
as 0
a 0
recombinant 0
protein 0
in 0
Escherichia 0
coli 0
. 0

Using 0
this 0
as 0
immunogen 0
, 0
we 0
prepared 0
a 0
panel 0
of 0
12 0
monoclonal 0
antibodies 0
which 0
recognise 0
at 0
least 0
four 0
different 0
epitopes 0
on 0
emerin 0
in 0
order 0
to 0
ensure 0
that 0
emerin 0
can 0
be 0
distinguished 0
from 0
non-specific 0
cross-reacting 0
proteins 0
. 0

All 0
the 0
mAbs 0
recognised 0
a 0
34 0
kDa 0
protein 0
in 0
all 0
tissues 0
tested 0
, 0
though 0
minor 0
emerin-related 0
bands 0
were 0
also 0
detected 0
in 0
some 0
tissues 0
. 0

Immunofluorescence 0
microscopy 0
showed 0
that 0
emerin 0
is 0
located 0
at 0
the 0
nuclear 0
rim 0
in 0
all 0
tissues 0
examined 0
. 0

A 0
muscle 0
biopsy 0
from 0
an 0
Emery-Dreifuss 3
muscular 3
dystrophy 3
( 0
EMDM 3
) 0
patient 0
showed 0
complete 0
absence 0
of 0
emerin 0
by 0
both 0
Western 0
blotting 0
and 0
immunohistochemistry 0
, 0
suggesting 0
a 0
simple 0
diagnostic 0
antibody 0
test 0
for 0
EDMD 3
families 0
. 0

Biochemical 0
fractionation 0
of 0
brain 0
and 0
liver 0
tissues 0
showed 0
that 0
emerin 0
was 0
present 0
in 0
nuclei 0
purified 0
by 0
centrifugation 0
through 0
65 0
% 0
sucrose 0
and 0
was 0
absent 0
from 0
soluble 0
fractions 0
( 0
post-100 0
, 0
000 0
g 0
) 0
. 0

From 0
these 0
results 0
, 0
together 0
with 0
sequence 0
and 0
structural 0
homologies 0
between 0
emerin 0
, 0
thymopoietins 0
and 0
the 0
nuclear 0
lamina-associated 0
protein 0
, 0
LAP2 0
, 0
we 0
suggest 0
that 0
emerin 0
will 0
prove 0
to 0
be 0
one 0
member 0
of 0
a 0
family 0
of 0
inner 0
nuclear 0
membrane 0
proteins 0
. 0

Mutation 0
of 0
MSH3 0
in 0
endometrial 2
cancer 2
and 0
evidence 0
for 0
its 0
functional 0
role 0
in 0
heteroduplex 0
repair 0
. 0

Many 0
human 0
tumours 4
have 0
length 0
alterations 0
in 0
repetitive 0
sequence 0
elements 0
. 0

Although 0
this 0
microsatellite 0
instability 0
has 0
been 0
attributed 0
to 0
mutations 0
in 0
four 0
DNA 0
mismatch 0
repair 0
genes 0
in 0
hereditary 3
nonpolyposis 3
colorectal 3
cancer 3
( 0
HNPCC 3
) 0
kindreds 0
, 0
many 0
sporadic 4
tumours 4
exhibit 0
instability 0
but 0
no 0
detectable 0
mutations 0
in 0
these 0
genes 0
. 0

It 0
is 0
therefore 0
of 0
interest 0
to 0
identify 0
other 0
genes 0
that 0
contribute 0
to 0
this 0
instability 0
. 0

In 0
yeast 0
, 0
mutations 0
in 0
several 0
genes 0
, 0
including 0
RTH 0
and 0
MSH3 0
, 0
cause 0
microsatellite 0
instability 0
. 0

Thus 0
, 0
we 0
screened 0
16 0
endometrial 2
carcinomas 2
with 0
microsatellite 0
instability 0
for 0
alterations 0
in 0
FEN1 0
( 0
the 0
human 0
homolog 0
of 0
RTH 0
) 0
and 0
in 0
MSH3 0
( 0
refs 0
12-14 0
) 0
. 0

Although 0
we 0
found 0
no 0
FEN1 0
mutations 0
, 0
a 0
frameshift 0
mutation 0
in 0
MSH3 0
was 0
observed 0
in 0
an 0
endometrial 2
carcinoma 2
and 0
in 0
an 0
endometrial 3
carcinoma 3
cell 0
line 0
. 0

Extracts 0
of 0
the 0
cell 0
line 0
were 0
deficient 0
in 0
repair 0
of 0
DNA 0
substrates 0
containing 0
mismatches 0
or 0
extra 0
nucleotides 0
. 0

Introducing 0
chromosome 0
5 0
, 0
encoding 0
the 0
MSH3 0
gene 0
, 0
into 0
the 0
mutant 0
cell 0
line 0
increased 0
the 0
stability 0
of 0
some 0
but 0
not 0
all 0
microsatellites 0
. 0

Extracts 0
of 0
these 0
cells 0
repaired 0
certain 0
substrates 0
containing 0
extra 0
nucleotides 0
, 0
but 0
were 0
deficient 0
in 0
repair 0
of 0
those 0
containing 0
mismatches 0
or 0
other 0
extra 0
nucleotides 0
. 0

A 0
subsequent 0
search 0
revealed 0
a 0
second 0
gene 0
mutation 0
in 0
HHUA 0
cells 0
, 0
a 0
missense 0
mutation 0
in 0
the 0
MSH6 0
gene 0
. 0

Together 0
the 0
data 0
suggest 0
that 0
the 0
MSH3 0
gene 0
encodes 0
a 0
product 0
that 0
functions 0
in 0
repair 0
of 0
some 0
but 0
not 0
all 0
pre-mutational 0
intermediates 0
, 0
its 0
mutation 0
in 0
tumours 4
can 0
result 0
in 0
genomic 0
instability 0
and 0
, 0
as 0
in 0
yeast 0
, 0
MSH3 0
and 0
MSH6 0
are 0
partially 0
redundant 0
for 0
mismatch 0
repair 0
. 0

Comparative 0
genome 0
mapping 0
of 0
the 0
ataxia-telangiectasia 3
region 0
in 0
mouse 0
, 0
rat 0
, 0
and 0
Syrian 0
hamster 0
. 0

Chromosomal 0
locations 0
of 0
the 0
Atm 0
( 0
ataxia-telangiectasia 3
( 0
AT 3
) 0
-mutated 0
) 0
and 0
Acat1 0
( 0
mitochondrial 0
acetoacetyl-CoA 0
thiolase 0
) 0
genes 0
in 0
mouse 0
, 0
rat 0
, 0
and 0
Syrian 0
hamster 0
were 0
determined 0
by 0
direct 0
R-banding 0
FISH 0
. 0

Both 0
genes 0
were 0
colocalized 0
to 0
the 0
C-D 0
band 0
of 0
mouse 0
chromosome 0
9 0
, 0
the 0
proximal 0
end 0
of 0
q24 0
. 0

1 0
of 0
rat 0
chromosome 0
8 0
, 0
and 0
qa4-qa5 0
of 0
Syrian 0
hamster 0
chromosome 0
12 0
. 0

The 0
regions 0
in 0
the 0
mouse 0
and 0
rat 0
were 0
homologous 0
to 0
human 0
chromosome 0
11q 0
. 0

Fine 0
genetic 0
linkage 0
mapping 0
of 0
the 0
mouse 0
AT 3
region 0
was 0
performed 0
using 0
the 0
interspecific 0
backcross 0
mice 0
. 0

Atm 0
, 0
Acat1 0
, 0
and 0
Npat 0
, 0
which 0
is 0
a 0
new 0
gene 0
isolated 0
from 0
the 0
AT 0
region 0
, 0
and 0
12 0
flanking 0
microsatellite 0
DNA 0
markers 0
were 0
examined 0
. 0

No 0
recombinations 0
were 0
found 0
among 0
the 0
Atm 0
, 0
Npat 0
, 0
Acat1 0
, 0
and 0
D9Mit6 0
loci 0
, 0
and 0
these 0
loci 0
were 0
mapped 0
2 0
. 0

0 0
cM 0
distal 0
to 0
D9Mit99 0
and 0
1 0
. 0

3 0
cM 0
proximal 0
to 0
D9Mit102 0
. 0

Comparison 0
of 0
the 0
linkage 0
map 0
of 0
mouse 0
chromosome 0
9 0
( 0
MMU9 0
) 0
and 0
that 0
of 0
human 0
chromosome 0
11 0
( 0
HSA11 0
) 0
indicates 0
that 0
there 0
is 0
a 0
chromosomal 0
rearrangement 0
due 0
to 0
an 0
inversion 0
between 0
Ets1 0
and 0
Atm-Npat-Acat1 0
and 0
that 0
the 0
inversion 0
of 0
MMU9 0
originated 0
from 0
the 0
chromosomal 0
breakage 0
at 0
the 0
boundary 0
between 0
Gria4 0
and 0
Atm-Npat-Acat1 0
on 0
HSA11 0
. 0

This 0
type 0
of 0
inversion 0
appeared 0
to 0
be 0
conserved 0
in 0
the 0
three 0
rodent 0
species 0
, 0
mouse 0
, 0
rat 0
, 0
and 0
Syrian 0
hamster 0
, 0
using 0
additional 0
comparative 0
mapping 0
data 0
with 0
the 0
Rck 0
gene 0
An 0
animal 0
model 0
for 0
Norrie 2
disease 2
( 0
ND 2
) 0
: 0
gene 0
targeting 0
of 0
the 0
mouse 0
ND 3
gene 0
. 0

In 0
order 0
to 0
elucidate 0
the 0
cellular 0
and 0
molecular 0
processes 0
which 0
are 0
involved 0
in 0
Norrie 2
disease 2
( 0
ND 2
) 0
, 0
we 0
have 0
used 0
gene 0
targeting 0
technology 0
to 0
generate 0
ND 3
mutant 0
mice 0
. 0

The 0
murine 0
homologue 0
of 0
the 0
ND 3
gene 0
was 0
cloned 0
and 0
shown 0
to 0
encode 0
a 0
polypeptide 0
that 0
shares 0
94 0
% 0
of 0
the 0
amino 0
acid 0
sequence 0
with 0
its 0
human 0
counterpart 0
. 0

RNA 0
in 0
situ 0
hybridization 0
revealed 0
expression 0
in 0
retina 0
, 0
brain 0
and 0
the 0
olfactory 0
bulb 0
and 0
epithelium 0
of 0
2 0
week 0
old 0
mice 0
. 0

Hemizygous 0
mice 0
carrying 0
a 0
replacement 0
mutation 0
in 0
exon 0
2 0
of 0
the 0
ND 3
gene 0
developed 0
retrolental 0
structures 0
in 0
the 0
vitreous 0
body 0
and 0
showed 0
an 0
overall 0
disorganization 0
of 0
the 0
retinal 0
ganglion 0
cell 0
layer 0
. 0

The 0
outer 0
plexiform 0
layer 0
disappears 0
occasionally 0
, 0
resulting 0
in 0
a 0
juxtaposed 0
inner 0
and 0
outer 0
nuclear 0
layer 0
. 0

At 0
the 0
same 0
regions 0
, 0
the 0
outer 0
segments 0
of 0
the 0
photoreceptor 0
cell 0
layer 0
are 0
no 0
longer 0
present 0
. 0

These 0
ocular 0
findings 0
are 0
consistent 0
with 0
observations 0
in 0
ND 3
patients 0
and 0
the 0
generated 0
mouse 0
line 0
provides 0
a 0
faithful 0
model 0
for 0
study 0
of 0
early 0
pathogenic 0
events 0
in 0
this 0
severe 0
X-linked 4
recessive 4
neurological 4
disorder 4
. 0

The 0
hybrid 0
PAX3-FKHR 0
fusion 0
protein 0
of 0
alveolar 2
rhabdomyosarcoma 2
transforms 0
fibroblasts 0
in 0
culture 0
. 0

Pediatric 2
alveolar 2
rhabdomyosarcoma 2
is 0
characterized 0
by 0
a 0
chromosomal 0
translocation 0
that 0
fuses 0
parts 0
of 0
the 0
PAX3 0
and 0
FKHR 0
genes 0
. 0

PAX3 0
codes 0
for 0
a 0
transcriptional 0
regulator 0
that 0
controls 0
developmental 0
programs 0
, 0
and 0
FKHR 0
codes 0
for 0
a 0
forkhead-winged 0
helix 0
protein 0
, 0
also 0
a 0
likely 0
transcription 0
factor 0
. 0

The 0
PAX3-FKHR 0
fusion 0
product 0
retains 0
the 0
DNA 0
binding 0
domains 0
of 0
the 0
PAX3 0
protein 0
and 0
the 0
putative 0
activator 0
domain 0
of 0
the 0
FKHR 0
protein 0
. 0

The 0
PAX3-FKHR 0
protein 0
has 0
been 0
shown 0
to 0
function 0
as 0
a 0
transcriptional 0
activator 0
. 0

Using 0
the 0
RCAS 0
retroviral 0
vector 0
, 0
we 0
have 0
introduced 0
the 0
PAX3-FKHR 0
gene 0
into 0
chicken 0
embryo 0
fibroblasts 0
. 0

Expression 0
of 0
the 0
PAX3-FKHR 0
protein 0
in 0
these 0
cells 0
leads 0
to 0
transformation 0
the 0
cells 0
become 0
enlarged 0
, 0
grow 0
tightly 0
packed 0
and 0
in 0
multiple 0
layers 0
, 0
and 0
acquire 0
the 0
ability 0
for 0
anchorage-independent 0
growth 0
. 0

This 0
cellular 0
transformation 0
in 0
vitro 0
will 0
facilitate 0
studies 0
on 0
the 0
mechanism 0
of 0
PAX3-FKHR-induced 0
oncogenesis 0
. 0

Somatic-cell 0
selection 0
is 0
a 0
major 0
determinant 0
of 0
the 0
blood-cell 0
phenotype 0
in 0
heterozygotes 0
for 0
glucose-6-phosphate 0
dehydrogenase 0
mutations 0
causing 0
severe 0
enzyme 4
deficiency 4
. 0

X-chromosome 0
inactivation 0
in 0
mammals 0
is 0
regarded 0
as 0
an 0
essentially 0
random 0
process 0
, 0
but 0
the 0
resulting 0
somatic-cell 0
mosaicism 0
creates 0
the 0
opportunity 0
for 0
cell 0
selection 0
. 0

In 0
most 0
people 0
with 0
red-blood-cell 0
glucose-6-phosphate 2
dehydrogenase 2
( 2
G6PD 2
) 2
deficiency 2
, 0
the 0
enzyme-deficient 0
phenotype 0
is 0
only 0
moderately 0
expressed 0
in 0
nucleated 0
cells 0
. 0

However 0
, 0
in 0
a 0
small 0
subset 0
of 0
hemizygous 0
males 0
who 0
suffer 0
from 0
chronic 2
nonspherocytic 2
hemolytic 2
anemia 2
, 0
the 0
underlying 0
mutations 0
( 0
designated 0
class 0
I 0
) 0
cause 0
more-severe 0
G6PD 2
deficiency 2
, 0
and 0
this 0
might 0
provide 0
an 0
opportunity 0
for 0
selection 0
in 0
heterozygous 0
females 0
during 0
development 0
. 0

In 0
order 0
to 0
test 0
this 0
possibility 0
we 0
have 0
analyzed 0
four 0
heterozygotes 0
for 0
class 0
I 0
G6PD 0
mutations 0
two 0
with 0
G6PD 0
Portici 0
( 0
1178G 0
-- 0
A 0
) 0
and 0
two 0
with 0
G6PD 0
Bari 0
( 0
1187C 0
-- 0
T 0
) 0
. 0

We 0
found 0
that 0
in 0
fractionated 0
blood 0
cell 0
types 0
( 0
including 0
erythroid 0
, 0
myeloid 0
, 0
and 0
lymphoid 0
cell 0
lineages 0
) 0
there 0
was 0
a 0
significant 0
excess 0
of 0
G6PD-normal 0
cells 0
. 0

The 0
significant 0
concordance 0
that 0
we 0
have 0
observed 0
in 0
the 0
degree 0
of 0
imbalance 0
in 0
the 0
different 0
blood-cell 0
lineages 0
indicates 0
that 0
a 0
selective 0
mechanism 0
is 0
likely 0
to 0
operate 0
at 0
the 0
level 0
of 0
pluripotent 0
blood 0
stem 0
cells 0
. 0

Thus 0
, 0
it 0
appears 0
that 0
severe 0
G6PD 2
deficiency 2
affects 0
adversely 0
the 0
proliferation 0
or 0
the 0
survival 0
of 0
nucleated 0
blood 0
cells 0
and 0
that 0
this 0
phenotypic 0
characteristic 0
is 0
critical 0
during 0
hematopoiesis 0
. 0

Analysis 0
of 0
meiotic 0
segregation 0
, 0
using 0
single-sperm 0
typing 0
: 0
meiotic 0
drive 0
at 0
the 0
myotonic 3
dystrophy 3
locus 0
. 0

Meiotic 0
drive 0
at 0
the 0
myotonic 3
dystrophy 3
( 0
DM 3
) 0
locus 0
has 0
recently 0
been 0
suggested 0
as 0
being 0
responsible 0
for 0
maintaining 0
the 0
frequency 0
, 0
in 0
the 0
human 0
population 0
, 0
of 0
DM 3
chromosomes 0
capable 0
of 0
expansion 0
to 0
the 0
disease 0
state 0
. 0

In 0
order 0
to 0
test 0
this 0
hypothesis 0
, 0
we 0
have 0
studied 0
samples 0
of 0
single 0
sperm 0
from 0
three 0
individuals 0
heterozygous 0
at 0
the 0
DM 3
locus 0
, 0
each 0
with 0
one 0
allele 0
larger 0
and 0
one 0
allele 0
smaller 0
than 0
19 0
CTG 0
repeats 0
. 0

To 0
guard 0
against 0
the 0
possible 0
problem 0
of 0
differential 0
PCR 0
amplification 0
rates 0
based 0
on 0
the 0
lengths 0
of 0
the 0
alleles 0
, 0
the 0
sperm 0
were 0
also 0
typed 0
at 0
another 0
closely 0
linked 0
marker 0
whose 0
allele 0
size 0
was 0
unrelated 0
to 0
the 0
allele 0
size 0
at 0
the 0
DM 3
locus 0
. 0

Using 0
statistical 0
models 0
specifically 0
designed 0
to 0
study 0
single-sperm 0
segregation 0
data 0
, 0
we 0
find 0
no 0
evidence 0
of 0
meiotic 0
segregation 0
distortion 0
. 0

The 0
upper 0
limit 0
of 0
the 0
two-sided 0
95 0
% 0
confidence 0
interval 0
for 0
the 0
estimate 0
of 0
the 0
common 0
segregation 0
probability 0
for 0
the 0
three 0
donors 0
is 0
at 0
or 0
below 0
. 0

515 0
for 0
all 0
models 0
considered 0
, 0
and 0
no 0
statistically 0
significant 0
difference 0
from 0
. 0

5 0
is 0
detected 0
in 0
any 0
of 0
the 0
models 0
. 0

This 0
suggests 0
that 0
any 0
greater 0
amount 0
of 0
segregation 0
distortion 0
at 0
the 0
myotonic 3
dystrophy 3
locus 0
must 0
result 0
from 0
events 0
following 0
sperm 0
ejaculation 0
. 0

LPP 0
, 0
the 0
preferred 0
fusion 0
partner 0
gene 0
of 0
HMGIC 0
in 0
lipomas 4
, 0
is 0
a 0
novel 0
member 0
of 0
the 0
LIM 0
protein 0
gene 0
family 0
. 0

A 0
major 0
cytogenetic 0
subgroup 0
of 0
lipomas 4
is 0
characterized 0
by 0
recurrent 0
chromosome 0
aberrations 0
, 0
mainly 0
translocations 0
, 0
that 0
involve 0
chromosome 0
segment 0
12q13-q15 0
. 0

Multiple 0
chromosomes 0
have 0
been 0
found 0
as 0
the 0
translocation 0
partners 0
of 0
chromosome 0
12 0
but 0
3q27-q28 0
is 0
preferentially 0
involved 0
. 0

In 0
previous 0
studies 0
, 0
it 0
has 0
been 0
shown 0
that 0
the 0
high 0
mobility 0
group 0
( 0
HMG 0
) 0
protein 0
gene 0
HMGIC 0
at 0
12q15 0
is 0
consistently 0
rearranged 0
as 0
a 0
consequence 0
of 0
these 0
translocations 0
. 0

Here 0
, 0
we 0
report 0
the 0
identification 0
and 0
characterization 0
of 0
the 0
chromosome 0
3-derived 0
translocation 0
partner 0
gene 0
, 0
which 0
we 0
have 0
designated 0
LPP 0
( 0
lipoma 3
preferred 0
partner 0
gene 0
) 0
. 0

Using 0
3-RACE 0
analysis 0
of 0
HMGIC 0
fusion 0
transcripts 0
in 0
lipoma 3
cell 0
line 0
Li-501 0
/ 0
SV40 0
, 0
ectopic 0
genetic 0
sequences 0
were 0
obtained 0
, 0
which 0
by 0
CASH 0
( 0
chromosome 0
assignment 0
using 0
somatic 0
cell 0
hybrids 0
) 0
and 0
FISH 0
( 0
fluorescence 0
in 0
situ 0
hybridization 0
) 0
analysis 0
were 0
found 0
to 0
originate 0
from 0
chromosome 0
segment 0
3q27-q28 0
. 0

In 0
Northern 0
blot 0
analysis 0
, 0
an 0
mRNA 0
of 0
over 0
10 0
kb 0
was 0
detected 0
by 0
these 0
ectopic 0
sequences 0
in 0
a 0
variety 0
of 0
human 0
tissues 0
but 0
not 0
in 0
brain 0
and 0
peripheral 0
blood 0
leukocytes 0
. 0

Upon 0
partial 0
cDNA 0
cloning 0
, 0
features 0
of 0
the 0
genetic 0
organization 0
of 0
LPP 0
were 0
established 0
. 0

The 0
gene 0
was 0
found 0
to 0
span 0
a 0
genomic 0
region 0
of 0
over 0
400 0
kb 0
. 0

Nucleotide 0
sequence 0
analysis 0
of 0
a 0
composite 0
cDNA 0
of 0
LPP 0
revealed 0
an 0
open 0
reading 0
frame 0
of 0
1836 0
nucleotides 0
encoding 0
a 0
proline-rich 0
protein 0
containing 0
a 0
leucine-zipper 0
motif 0
in 0
its 0
amino-terminal 0
region 0
and 0
three 0
LIM 0
domains 0
in 0
its 0
carboxy-terminal 0
region 0
. 0

The 0
LPP-encoded 0
protein 0
should 0
be 0
classified 0
as 0
a 0
novel 0
member 0
of 0
the 0
group 0
3 0
proteins 0
of 0
the 0
LIM 0
protein 0
gene 0
family 0
. 0

Using 0
reverse 0
transcriptase 0
combined 0
with 0
polymerase 0
chain 0
reactions 0
in 0
the 0
analysis 0
of 0
a 0
number 0
of 0
lipoma 3
cell 0
lines 0
and 0
primary 4
lipomas 4
, 0
it 0
appeared 0
that 0
LPP 0
is 0
frequently 0
rearranged 0
also 0
in 0
cases 0
without 0
a 0
cytogenetically 0
detectable 0
involvement 0
of 0
3q27-q28 0
. 0

Two 0
alternative 0
HMGIC 0
/ 0
LPP 0
hybrid 0
transcripts 0
have 0
been 0
detected 0
; 0
the 0
difference 0
between 0
them 0
is 0
mainly 0
the 0
presence 0
of 0
either 0
two 0
or 0
three 0
LIM 0
domains 0
in 0
the 0
predicted 0
HMGI-C 0
/ 0
LPP 0
fusion 0
proteins 0
. 0

Absence 0
of 0
disease 0
phenotype 0
and 0
intergenerational 0
stability 0
of 0
the 0
CAG 0
repeat 0
in 0
transgenic 0
mice 0
expressing 0
the 0
human 0
Huntington 3
disease 3
transcript 0
. 0

The 0
mutation 0
underlying 0
Huntington 2
disease 2
( 0
HD 2
) 0
is 0
CAG 0
expansion 0
in 0
the 0
first 0
exon 0
of 0
the 0
HD 3
gene 0
. 0

In 0
order 0
to 0
investigate 0
the 0
role 0
of 0
CAG 0
expansion 0
in 0
the 0
pathogenesis 0
of 0
HD 2
, 0
we 0
have 0
produced 0
transgenic 0
mice 0
containing 0
the 0
full 0
length 0
human 0
HD 3
cDNA 0
with 0
44 0
CAG 0
repeats 0
. 0

By 0
1 0
year 0
, 0
these 0
mice 0
have 0
no 0
behavioral 4
abnormalities 4
and 0
morphometric 0
analysis 0
at 0
6 0
( 0
one 0
animal 0
) 0
and 0
9 0
( 0
two 0
animals 0
) 0
months 0
age 0
revealed 0
no 0
changes 0
. 0

Despite 0
high 0
levels 0
of 0
mRNA 0
expression 0
, 0
there 0
was 0
no 0
evidence 0
of 0
the 0
HD 3
gene 0
product 0
in 0
any 0
of 0
these 0
transgenic 0
mice 0
. 0

In 0
vitro 0
transfection 0
studies 0
indicated 0
that 0
the 0
inclusion 0
of 0
120 0
bp 0
of 0
the 0
5 0
UTR 0
in 0
the 0
cDNA 0
construct 0
and 0
the 0
presence 0
of 0
a 0
frameshift 0
mutation 0
at 0
nucleotide 0
2349 0
prevented 0
expression 0
of 0
the 0
HD 3
cDNA 0
. 0

These 0
findings 0
suggest 0
that 0
the 0
pathogenesis 0
of 0
HD 2
is 0
not 0
mediated 0
through 0
DNA-protein 0
interaction 0
and 0
that 0
presence 0
of 0
the 0
RNA 0
transcript 0
with 0
an 0
expanded 0
CAG 0
repeat 0
is 0
insufficient 0
to 0
cause 0
the 0
disease 0
. 0

Rather 0
, 0
translation 0
of 0
the 0
CAG 0
is 0
crucial 0
for 0
the 0
pathogenesis 0
of 0
HD 2
. 0

In 0
contrast 0
to 0
that 0
seen 0
in 0
humans 0
, 0
the 0
CAG 0
repeat 0
in 0
these 0
mice 0
was 0
remarkably 0
stable 0
in 0
97 0
meioses 0
. 0

This 0
suggests 0
that 0
genomic 0
sequences 0
may 0
play 0
a 0
critical 0
role 0
in 0
influencing 0
repeat 0
instability 0
. 0

FISH 0
studies 0
in 0
a 0
patient 0
with 0
sporadic 2
aniridia 2
and 0
t 0
( 0
7 0
; 0
11 0
) 0
( 0
q31.2 0
; 0
p13 0
) 0
. 0

A 0
2 0
year 0
old 0
female 0
presenting 0
with 0
bilateral 2
sporadic 2
aniridia 2
was 0
found 0
to 0
have 0
an 0
apparently 0
balanced 0
reciprocal 0
translocation 0
with 0
a 0
chromosome 0
11 0
breakpoint 0
within 0
band 0
p13 0
. 0

Fluorescence 0
in 0
situ 0
hybridisation 0
( 0
FISH 0
) 0
studies 0
with 0
distal 0
11p13 0
specific 0
cosmids 0
showed 0
that 0
the 0
chromosome 0
11 0
breakpoint 0
lay 0
between 0
the 0
aniridia 2
( 0
PAX6 0
) 0
locus 0
and 0
a 0
region 0
approximately 0
100 0
kb 0
distal 0
to 0
PAX6 0
defined 0
by 0
the 0
cosmid 0
FO2121 0
. 0

Although 0
this 0
patient 0
did 0
not 0
have 0
a 0
detectable 0
deletion 0
within 0
PAX6 0
, 0
her 0
aniridia 2
may 0
have 0
resulted 0
from 0
a 0
disruption 0
of 0
the 0
distal 0
chromatin 0
domain 0
containing 0
either 0
enhancers 0
or 0
regulators 0
for 0
PAX6 0
. 0

This 0
case 0
may 0
therefore 0
be 0
another 0
example 0
of 0
aniridia 2
caused 0
by 0
a 0
position 0
effect 0
as 0
recently 0
described 0
in 0
two 0
familial 3
aniridia 3
patients 0
in 0
which 0
the 0
phenotype 0
cosegregated 0
with 0
chromosome 4
abnormalities 4
with 0
11p13 0
breakpoints 0
. 0

Muscle 0
expression 0
of 0
glucose-6-phosphate 2
dehydrogenase 2
deficiency 2
in 0
different 0
variants 0
. 0

Muscle 0
expression 0
of 0
G6PD 2
deficiency 2
has 0
been 0
investigated 0
in 0
Mediterranean 0
, 0
Seattle-like 0
and 0
A-variants 0
. 0

G6PD 0
activity 0
was 0
detected 0
in 0
samples 0
obtained 0
from 0
biopsies 0
on 0
the 0
quadriceps 0
muscle 0
of 0
seven 0
males 0
and 0
one 0
female 0
. 0

The 0
type 0
of 0
genetic 0
variant 0
was 0
determined 0
by 0
molecular 0
analysis 0
of 0
DNA 0
, 0
extracted 0
from 0
blood 0
samples 0
. 0

All 0
variants 0
showed 0
the 0
enzyme 0
defect 0
in 0
muscle 0
. 0

A 0
statistically 0
significant 0
relationship 0
was 0
found 0
in 0
the 0
activity 0
of 0
G6PD 0
between 0
erythrocytes 0
and 0
muscle 0
of 0
the 0
male 0
subjects 0
( 0
r 0
= 0
0 0
. 0

968 0
; 0
p 0
= 0
0 0
. 0

00008 0
) 0
. 0

The 0
equation 0
for 0
the 0
best 0
fit 0
line 0
was 0
Y 0
= 0
0 0
. 0

390X 0
+ 0
0 0
. 0

198 0
198 0
. 0

The 0
results 0
suggest 0
that 0
, 0
for 0
a 0
given 0
variant 0
, 0
the 0
extent 0
of 0
the 0
enzyme 0
defect 0
in 0
muscle 0
may 0
be 0
determined 0
, 0
using 0
this 0
equation 0
, 0
from 0
the 0
G6PD 0
activity 0
of 0
erythrocytes 0
Gene 0
therapy 0
for 0
phenylketonuria 2
. 0

Classical 0
phenylketonuria 2
( 0
PKU 2
) 0
is 0
an 0
autosomal 4
recessive 4
disorder 4
caused 0
by 0
a 0
deficiency 2
of 2
hepatic 2
phenylalanine 2
hydroxylase 2
( 0
PAH 0
) 0
. 0

Limitations 0
of 0
the 0
current 0
dietary 0
treatment 0
for 0
PKU 2
have 0
led 0
to 0
the 0
development 0
of 0
potential 0
treatments 0
based 0
on 0
somatic 0
gene 0
transfer 0
. 0

Three 0
different 0
vector 0
systems 0
have 0
been 0
examined 0
. 0

Vectors 0
derived 0
from 0
a 0
recombinant 0
retrovirus 0
or 0
a 0
DNA 0
/ 0
protein 0
complex 0
can 0
efficiently 0
transduce 0
the 0
PAH 0
cDNA 0
into 0
PAH-deficient 3
hepatocytes 0
in 0
vitro 0
, 0
but 0
the 0
application 0
of 0
these 0
vector 0
systems 0
is 0
presently 0
limited 0
by 0
their 0
low 0
transduction 0
efficiency 0
in 0
vivo 0
. 0

In 0
contrast 0
, 0
a 0
vector 0
derived 0
from 0
a 0
recombinant 0
adenovirus 0
can 0
restore 0
10 0
% 0
-80 0
% 0
of 0
normal 0
hepatic 0
PAH 0
activity 0
into 0
PAH-deficient 3
mice 0
, 0
which 0
completely 0
normalizes 0
serum 0
phenylalanine 0
levels 0
. 0

This 0
treatment 0
is 0
transient 0
and 0
can 0
not 0
be 0
effectively 0
re-administered 0
due 0
to 0
the 0
presence 0
of 0
neutralizing 0
antibodies 0
directed 0
against 0
the 0
recombinant 0
adenoviral 0
vector 0
. 0

However 0
, 0
these 0
findings 0
suggest 0
that 0
PKU 2
can 0
be 0
completely 0
corrected 0
by 0
somatic 0
gene 0
therapy 0
, 0
and 0
provide 0
some 0
direction 0
for 0
the 0
future 0
development 0
of 0
adenoviral 0
vectors 0
. 0

Exon-intron 0
structure 0
of 0
the 0
human 0
neuronal 0
nicotinic 0
acetylcholine 0
receptor 0
alpha 0
4 0
subunit 0
( 0
CHRNA4 0
) 0
. 0

The 0
human 0
neuronal 0
nicotinic 0
acetylcholine 0
receptor 0
alpha 0
4 0
subunit 0
gene 0
( 0
CHRNA4 0
) 0
is 0
located 0
in 0
the 0
candidate 0
region 0
for 0
three 0
different 0
phenotypes 0
benign 2
familial 2
neonatal 2
convulsions 2
, 0
autosomal 2
dominant 2
nocturnal 2
frontal 2
lobe 2
epilepsy 2
, 0
and 0
low-voltage 0
EEG 0
. 0

Recently 0
, 0
a 0
missense 0
mutation 0
in 0
transmembrane 0
domain 0
2 0
of 0
CHRNA4 0
was 0
found 0
to 0
be 0
associated 0
with 0
autosomal 2
dominant 2
nocturnal 2
frontal 2
lobe 2
epilepsy 2
in 0
one 0
extended 0
pedigree 0
. 0

We 0
have 0
determined 0
the 0
genomic 0
organization 0
of 0
CHRNA4 0
, 0
which 0
consists 0
of 0
six 0
exons 0
distributed 0
over 0
approximately 0
17 0
kb 0
of 0
genomic 0
DNA 0
. 0

The 0
nucleotide 0
sequence 0
obtained 0
from 0
the 0
genomic 0
regions 0
adjacent 0
to 0
the 0
exon 0
boundaries 0
enabled 0
us 0
to 0
develop 0
a 0
set 0
of 0
primer 0
pairs 0
for 0
PCR 0
amplification 0
of 0
the 0
complete 0
coding 0
region 0
. 0

The 0
sequence 0
analysis 0
provides 0
the 0
basis 0
for 0
a 0
comprehensive 0
mutation 0
screening 0
of 0
CHRNA4 0
in 0
the 0
above-mentioned 0
phenotypes 0
and 0
possibly 0
in 0
other 0
types 0
of 0
idiopathic 4
epilepsies 4
. 0

Ashkenazi 0
Jewish 0
population 0
frequencies 0
for 0
common 0
mutations 0
in 0
BRCA1 0
and 0
BRCA2 0
. 0

BRCA1 0
and 0
BRCA2 0
are 0
the 0
two 0
major 0
identified 0
causes 0
of 0
inherited 2
breast 2
cancer 2
, 0
with 0
mutations 0
in 0
either 0
gene 0
conferring 0
up 0
to 0
80-90 0
% 0
lifetime 0
risk 0
of 0
breast 2
cancer 2
in 0
carrier 0
females 0
. 0

Mutations 0
in 0
BRCA1 0
account 0
for 0
approximately 0
45 0
% 0
of 0
familial 2
breast 2
cancer 2
and 0
90 0
% 0
of 0
inherited 1
breast 1
/ 1
ovarian 1
cancer 1
, 0
whereas 0
mutations 0
in 0
BRCA2 0
account 0
for 0
a 0
comparable 0
percentage 0
of 0
inherited 3
breast 3
cancer 3
cases 0
. 0

Over 0
85 0
distinct 0
BRCA1 0
mutations 0
and 0
a 0
growing 0
list 0
of 0
BRCA2 0
mutations 0
have 0
been 0
identified 0
, 0
with 0
the 0
majority 0
resulting 0
in 0
protein 0
truncation 0
. 0

A 0
specific 0
BRCA1 0
mutation 0
, 0
185delAG 0
, 0
has 0
a 0
reported 0
increased 0
carrier 0
frequency 0
of 0
approximately 0
0 0
. 0

9 0
% 0
in 0
the 0
Ashkenazi 0
Jewish 0
population 0
, 0
but 0
is 0
also 0
found 0
in 0
rare 0
non-Jewish 0
patients 0
with 0
a 0
different 0
haplotype 0
. 0

The 0
6174delT 0
mutation 0
in 0
BRCA2 0
was 0
recently 0
identified 0
as 0
a 0
frequent 0
mutation 0
in 0
8 0
out 0
of 0
107 0
Ashkenazi 0
Jewish 0
women 0
diagnosed 0
with 0
breast 2
cancer 2
by 0
age 0
50 0
( 0
ref 0
. 0

8 0
) 0
, 0
as 0
well 0
as 0
in 0
three 0
Ashkenazi 0
male 3
breast 3
cancer 3
patients 0
. 0

We 0
have 0
conducted 0
a 0
large-scale 0
population 0
study 0
to 0
investigate 0
the 0
prevalence 0
of 0
specific 0
BRCA1 0
and 0
BRCA2 0
mutations 0
in 0
Ashkenazi 0
Jewish 0
individuals 0
who 0
were 0
unselected 0
for 0
breast 2
cancer 2
. 0

BRCA1 0
mutation 0
screening 0
on 0
approximately 0
3 0
, 0
000 0
Ashkenazi 0
Jewish 0
samples 0
determined 0
a 0
carrier 0
frequency 0
of 0
1 0
. 0

09 0
% 0
for 0
the 0
185delAG 0
mutation 0
and 0
0 0
. 0

13 0
% 0
for 0
the 0
5382insC 0
mutation 0
. 0

BRCA2 0
analysis 0
on 0
3 0
, 0
085 0
individuals 0
from 0
the 0
same 0
population 0
showed 0
a 0
carrier 0
frequency 0
of 0
1 0
. 0

52 0
% 0
for 0
the 0
6174delT 0
mutation 0
. 0

This 0
expanded 0
population-based 0
study 0
confirms 0
that 0
the 0
BRCA1 0
185delAG 0
mutation 0
and 0
the 0
BRCA2 0
6174delT 0
mutation 0
constitute 0
the 0
two 0
most 0
frequent 0
mutation 0
alleles 0
predisposing 0
to 0
hereditary 2
breast 2
cancer 2
among 0
the 0
Ashkenazim 0
, 0
and 0
suggests 0
a 0
relatively 0
lower 0
penetrance 0
for 0
the 0
6174delT 0
mutation 0
in 0
BRCA2 0
. 0

Dual 0
roles 0
of 0
ATM 0
in 0
the 0
cellular 0
response 0
to 0
radiation 0
and 0
in 0
cell 0
growth 0
control 0
. 0

The 0
gene 0
mutated 0
in 0
ataxia-telangiectasia 3
( 0
AT 3
) 0
patients 0
, 0
denoted 0
ATM 0
, 0
encodes 0
a 0
putative 0
protein 0
or 0
lipid 0
kinase 0
. 0

To 0
elucidate 0
the 0
functions 0
of 0
ATM 0
, 0
we 0
disrupted 0
the 0
mouse 0
ATM 0
gene 0
through 0
homologous 0
recombination 0
in 0
mice 0
. 0

Consistent 0
with 0
cellular 0
defects 0
of 0
AT 3
patients 0
, 0
the 0
ATM- 0
/ 0
- 0
cells 0
are 0
hypersensitive 0
to 0
gamma-irradiation 0
and 0
defective 0
in 0
cell-cycle 0
arrest 0
following 0
radiation 0
, 0
correlating 0
with 0
a 0
defective 0
up-regulation 0
of 0
p53 0
. 0

In 0
addition 0
, 0
ATM- 0
/ 0
- 0
mouse 0
thymocytes 0
are 0
more 0
resistant 0
to 0
apoptosis 0
induced 0
by 0
gamma-irradiation 0
than 0
normal 0
thymocytes 0
. 0

ATM- 0
/ 0
- 0
fibroblasts 0
are 0
inefficient 0
in 0
G1 0
to 0
S-phase 0
progression 0
following 0
serum 0
stimulation 0
and 0
senesce 0
after 0
only 0
a 0
few 0
passages 0
in 0
culture 0
. 0

They 0
have 0
an 0
increased 0
constitutive 0
level 0
of 0
p21CP1 0
/ 0
WAF1 0
. 0

The 0
ATM 0
protein 0
is 0
therefore 0
critical 0
both 0
for 0
cellular 0
responses 0
to 0
ionizing 0
radiation 0
and 0
for 0
normal 0
cell-cycle 0
progression 0
. 0

ATM 0
+ 0
/ 0
- 0
fibroblasts 0
and 0
thymocytes 0
showed 0
intermediately 0
defective 0
responses 0
to 0
irradiation 0
but 0
no 0
growth 0
defect 0
, 0
suggesting 0
that 0
the 0
increased 0
cancer 3
risk 0
of 0
AT 3
heterozygotes 0
could 0
be 0
attributable 0
to 0
poor 0
checkpoint 0
function 0
. 0

Targeted 0
disruption 0
of 0
ATM 0
leads 0
to 0
growth 4
retardation 4
, 0
chromosomal 2
fragmentation 2
during 2
meiosis 2
, 0
immune 4
defects 4
, 0
and 0
thymic 2
lymphoma 2
. 0

ATM 0
, 0
the 0
gene 0
mutated 0
in 0
the 0
inherited 4
human 4
disease 4
category= 0
SpecificDisease 0
ataxia-telangiectasia 0
< 0
, 0
is 0
a 0
member 0
of 0
a 0
family 0
of 0
kinases 0
involved 0
in 0
DNA 0
metabolism 0
and 0
cell-cycle 0
checkpoint 0
control 0
. 0

To 0
help 0
clarify 0
the 0
physiological 0
roles 0
of 0
the 0
ATM 0
protein 0
, 0
we 0
disrupted 0
the 0
ATM 0
gene 0
in 0
mice 0
through 0
homologous 0
recombination 0
. 0

Initial 0
evaluation 0
of 0
the 0
ATM 0
knockout 0
animals 0
indicates 0
that 0
inactivation 0
of 0
the 0
mouse 0
ATM 0
gene 0
recreates 0
much 0
of 0
the 0
phenotype 0
of 0
ataxia-telangiectasia 2
. 0

The 0
homozygous 0
mutant 0
( 0
ATM- 0
/ 0
- 0
) 0
mice 0
are 0
viable 0
, 0
growth-retarded 0
, 0
and 0
infertile 0
. 0

The 0
infertility 2
of 0
ATM- 0
/ 0
- 0
mice 0
results 0
from 0
meiotic 0
failure 0
. 0

Meiosis 0
is 0
arrested 0
at 0
the 0
zygotene 0
/ 0
pachytene 0
stage 0
of 0
prophase 0
I 0
as 0
a 0
result 0
of 0
abnormal 0
chromosomal 0
synapsis 0
and 0
subsequent 0
chromosome 0
fragmentation 0
. 0

Immune 4
defects 4
also 0
are 0
evident 0
in 0
ATM- 0
/ 0
- 0
mice 0
, 0
including 0
reduced 0
numbers 0
of 0
B220 0
+ 0
CD43- 0
pre-B 0
cells 0
, 0
thymocytes 0
, 0
and 0
peripheral 0
T 0
cells 0
, 0
as 0
well 0
as 0
functional 0
impairment 0
of 0
T-cell-dependent 0
immune 0
responses 0
. 0

The 0
cerebella 0
of 0
ATM- 0
/ 0
- 0
mice 0
appear 0
normal 0
by 0
histologic 0
examination 0
at 0
3 0
to 0
4 0
months 0
and 0
the 0
mice 0
have 0
no 0
gross 0
behavioral 4
abnormalities 4
. 0

The 0
majority 0
of 0
mutant 0
mice 0
rapidly 0
develop 0
thymic 2
lymphomas 2
and 0
die 0
before 0
4 0
months 0
of 0
age 0
. 0

These 0
findings 0
indicate 0
that 0
the 0
ATM 0
gene 0
product 0
plays 0
an 0
essential 0
role 0
in 0
a 0
diverse 0
group 0
of 0
cellular 0
processes 0
, 0
including 0
meiosis 0
, 0
the 0
normal 0
growth 0
of 0
somatic 0
tissues 0
, 0
immune 0
development 0
, 0
and 0
tumor 3
suppression 0
. 0

Cloning 0
and 0
characterization 0
of 0
human 0
very-long-chain 0
acyl-CoA 0
dehydrogenase 0
cDNA 0
, 0
chromosomal 0
assignment 0
of 0
the 0
gene 0
and 0
identification 0
in 0
four 0
patients 0
of 0
nine 0
different 0
mutations 0
within 0
the 0
VLCAD 0
gene 0
. 0

Very-long-chain 0
acyl-CoA 0
dehydrogenase 0
( 0
VLCAD 0
) 0
is 0
one 0
of 0
four 0
straight-chain 0
acyl-CoA 0
dehydrogenase 0
( 0
ACD 0
) 0
enzymes 0
, 0
which 0
are 0
all 0
nuclear 0
encoded 0
mitochondrial 0
flavoproteins 0
catalyzing 0
the 0
initial 0
step 0
in 0
fatty 0
acid 0
beta-oxidation 0
. 0

We 0
have 0
used 0
the 0
very 0
fast 0
, 0
Rapid 0
Amplification 0
of 0
cDNA 0
Ends 0
( 0
RACE 0
) 0
based 0
strategy 0
to 0
obtain 0
the 0
sequence 0
of 0
cDNAs 0
encoding 0
human 0
VLCAD 0
from 0
placenta 0
and 0
fibroblasts 0
. 0

Alignment 0
of 0
the 0
predicted 0
amino 0
acid 0
sequence 0
of 0
human 0
VLCAD 0
with 0
those 0
of 0
the 0
other 0
human 0
ACD 0
enzymes 0
revealed 0
extensive 0
sequence 0
homology 0
. 0

Moreover 0
, 0
human 0
VLCAD 0
and 0
human 0
acyl-CoA 0
oxidase 0
showed 0
extensive 0
sequence 0
homology 0
corroborating 0
the 0
notion 0
that 0
these 0
genes 0
are 0
evolutionarily 0
related 0
. 0

Southern 0
blot 0
analysis 0
of 0
genomic 0
DNA 0
from 0
hybrid 0
cell 0
lines 0
was 0
used 0
to 0
localize 0
the 0
VLCAD 0
gene 0
to 0
human 0
chromosome 0
17p11 0
. 0

2-p11 0
2-p11 0
. 0

13105 0
13105 0
. 0

Using 0
Northern 0
and 0
Western 0
blot 0
analysis 0
to 0
investigate 0
the 0
tissue 0
specific 0
distribution 0
of 0
VLCAD 0
mRNA 0
and 0
protein 0
in 0
several 0
human 0
tissues 0
we 0
showed 0
that 0
VLCAD 0
is 0
most 0
abundant 0
in 0
heart 0
and 0
skeletal 0
muscle 0
. 0

This 0
agrees 0
well 0
with 0
the 0
fact 0
that 0
cardiac 0
and 0
muscle 0
symptoms 0
are 0
characteristic 0
for 0
patients 0
with 0
VLCAD 2
deficiency 2
. 0

Northern 0
blot 0
analysis 0
and 0
sequencing 0
of 0
cloned 0
PCR 0
amplified 0
VLCAD 0
cDNA 0
from 0
four 0
unrelated 0
patients 0
with 0
VLCAD 2
deficiency 2
showed 0
that 0
VLCAD 0
mRNA 0
was 0
undetectable 0
in 0
one 0
patient 0
and 0
that 0
the 0
other 0
three 0
have 0
mutations 0
in 0
both 0
VLCAD 0
alleles 0
. 0

Western 0
blot 0
analysis 0
of 0
patient 0
fibroblasts 0
showed 0
that 0
the 0
identified 0
mutations 0
result 0
in 0
severely 0
reduced 0
amounts 0
of 0
VLCAD 0
protein 0
. 0

Molecular 0
bases 0
of 0
combined 2
subtotal 2
deficiencies 2
of 2
C6 2
and 2
C7 2
: 0
their 0
effects 0
in 0
combination 0
with 0
other 0
C6 1
and 1
C7 1
deficiencies 1
. 0

Combined 2
subtotal 2
deficiency 2
of 2
C6 2
and 2
C7 2
, 0
in 0
which 0
both 0
proteins 0
are 0
expressed 0
at 0
very 0
low 0
levels 0
, 0
has 0
been 0
observed 0
in 0
homozygous 0
form 0
in 0
two 0
families 0
. 0

A 0
defect 0
at 0
the 0
5 0
splice 0
donor 0
site 0
of 0
intron 0
15 0
of 0
the 0
C6 0
gene 0
explains 0
the 0
low 0
molecular 0
weight 0
of 0
the 0
C6 0
protein 0
and 0
is 0
probably 0
responsible 0
for 0
its 0
low 0
expressed 0
concentration 0
. 0

The 0
C7 0
defect 0
is 0
more 0
enigmatic 0
the 0
protein 0
is 0
of 0
normal 0
molecular 0
weight 0
, 0
low 0
circulating 0
concentration 0
, 0
and 0
altered 0
isoelectric 0
point 0
. 0

An 0
Arg 0
Ser 0
codon 0
substitution 0
in 0
exon 0
11 0
is 0
the 0
only 0
molecular 0
alteration 0
within 0
the 0
mature 0
C7 0
protein 0
. 0

These 0
defects 0
are 0
associated 0
with 0
a 0
characteristic 0
set 0
of 0
polymorphic 0
DNA 0
markers 0
in 0
the 0
C6 0
/ 0
C7 0
region 0
, 0
forming 0
a 0
distinct 0
haplotype 0
. 0

The 0
haplotype 0
has 0
been 0
found 0
in 0
combination 0
with 0
a 0
number 0
of 0
other 0
haplotypes 0
containing 0
defective 0
genes 0
that 0
lead 0
either 0
to 0
C6 1
or 1
category= 0
CompositeMention 0
C7 0
deficiency 0
< 0
, 0
but 0
with 0
different 0
consequences 0
. 0

Where 0
it 0
is 0
combined 0
with 0
a 0
C6-deficient 3
gene 0
, 0
the 0
serum 0
C7 0
levels 0
can 0
be 0
surprisingly 0
high 0
, 0
possibly 0
because 0
there 0
is 0
no 0
C6 0
generating 0
C56 0
to 0
consume 0
the 0
C7 0
. 0

In 0
contrast 0
, 0
where 0
the 0
C7 0
genes 0
are 0
both 0
defective 0
( 0
but 0
still 0
partially 0
functional 0
) 0
, 0
there 0
may 0
be 0
a 0
profound 0
deficit 0
of 0
circulating 0
C7 0
because 0
there 0
is 0
ample 0
C6 0
to 0
produce 0
C56 0
and 0
consume 0
the 0
already 0
small 0
amount 0
of 0
C7 0
. 0

Each 0
molecular 0
defect 0
has 0
also 0
been 0
found 0
in 0
isolation 0
and 0
has 0
the 0
expected 0
effect 0
. 0

Genetic 0
bases 0
of 0
human 0
complement 2
C7 2
deficiency 2
. 0

Complement 2
C7 2
deficiency 2
( 0
C7D 2
) 0
is 0
associated 0
frequently 0
with 0
recurrent 0
bacterial 4
infections 4
, 0
especially 0
meningitis 4
caused 0
by 0
Neisseria 2
meningitidis 2
. 0

We 0
report 0
in 0
this 0
work 0
the 0
molecular 0
bases 0
of 0
C7D 2
in 0
two 0
unrelated 0
Japanese 0
males 0
. 0

We 0
used 0
exon-specific 0
PCR 0
/ 0
single-strand 0
conformation 0
polymorphism 0
analysis 0
as 0
a 0
screening 0
step 0
for 0
mutations 0
. 0

Subsequent 0
direct 0
sequencing 0
of 0
the 0
target 0
exons 0
identified 0
homozygous 0
mutations 0
in 0
exon 0
16 0
of 0
case 0
1 0
and 0
in 0
exon 0
15 0
of 0
case 0
2 0
. 0

The 0
mutation 0
of 0
case 0
1 0
was 0
a 0
homozygous 0
T 0
to 0
A 0
transversion 0
at 0
nucleotide 0
2250 0
, 0
the 0
third 0
nucleotide 0
of 0
the 0
codon 0
TGT 0
for 0
Cys728 0
, 0
leading 0
to 0
a 0
stop 0
codon 0
TGA 0
( 0
C728X 0
) 0
. 0

In 0
case 0
2 0
, 0
a 0
homozygous 0
2-bp 0
deletion 0
( 0
2137delTG 0
/ 0
2138delGT 0
/ 0
2139delTG 0
) 0
caused 0
a 0
frameshift 0
, 0
generating 0
a 0
premature 0
termination 0
codon 0
4 0
to 0
6 0
nucleotides 0
downstream 0
. 0

Family 0
study 0
in 0
case 0
1 0
confirmed 0
the 0
genetic 0
nature 0
of 0
the 0
defect 0
. 0

Moreover 0
, 0
we 0
detected 0
a 0
novel 0
polymorphism 0
in 0
intron 0
11 0
that 0
presumably 0
is 0
linked 0
to 0
the 0
mutation 0
responsible 0
for 0
C7D 2
in 0
case 0
1 0
. 0

Our 0
results 0
indicate 0
that 0
the 0
pathogenesis 0
of 0
C7D 2
is 0
heterogeneous 0
like 0
most 0
of 0
the 0
other 0
deficiencies 4
of 4
complement 4
components 4
. 0

HPRT-APRT-deficient 3
mice 0
are 0
not 0
a 0
model 0
for 0
lesch-nyhan 2
syndrome 2
. 0

Complete 2
hypoxanthine-guanine 2
phosphoribosyl-transferase 2
( 2
HPRT 2
) 2
deficiency 2
in 0
humans 0
results 0
in 0
the 0
Lesch-Nyhan 2
syndrome 2
which 0
is 0
characterized 0
, 0
among 0
other 0
features 0
, 0
by 0
compulsive 0
self-injurious 0
behavior 0
. 0

HPRT-deficient 3
mice 0
generated 0
using 0
mouse 0
embryonic 0
stem 0
cells 0
exhibit 0
none 0
of 0
the 0
behavioral 0
symptoms 0
associated 0
with 0
the 0
Lesch-Nyhan 2
syndrome 2
. 0

Administration 0
of 0
drugs 0
that 0
inhibit 0
adenine 0
phosphoribosyltransferase 0
( 0
APRT 0
) 0
in 0
HPRT-deficient 3
mice 0
has 0
produced 0
the 0
suggestion 0
that 0
deficiency 2
of 2
APRT 2
in 0
combination 0
with 0
HPRT-deficiency 2
in 0
mice 0
may 0
lead 0
to 0
self-mutilation 0
behavior 0
[ 0
C 0
. 0

L 0
. 0

Wu 0
and 0
D 0
. 0

W 0
. 0

Melton 0
( 0
1993 0
) 0
Nature 0
Genet 0
. 0

3 0
, 0
235-240 0
] 0
. 0

To 0
test 0
this 0
proposition 0
, 0
we 0
bred 0
HPRT-APRT-deficient 3
mice 0
. 0

Although 0
the 0
doubly-deficient 0
mice 0
excrete 0
adenine 0
and 0
its 0
highly 0
insoluble 0
derivative 0
, 0
2 0
, 0
8-dihydroxyadenine 0
, 0
which 0
are 0
also 0
associated 0
with 0
human 0
APRT 2
deficiency 2
, 0
additional 0
abnormalities 0
or 0
any 0
self-injurious 0
behavior 0
were 0
not 0
detected 0
. 0

Thus 0
, 0
APRT-HPRT-deficient 3
mice 0
, 0
which 0
are 0
devoid 0
of 0
any 0
purine 0
salvage 0
pathways 0
, 0
show 0
no 0
novel 0
phenotype 0
and 0
are 0
not 0
a 0
model 0
for 0
the 0
behavioral 4
abnormalities 4
associated 0
with 0
the 0
Lesch-Nyhan 2
syndrome 2
as 0
previously 0
suggested 0
Somatic 0
alterations 0
of 0
the 0
DPC4 0
gene 0
in 0
human 0
colorectal 2
cancers 2
in 0
vivo 0
. 0

BACKGROUND 0
& 0
AIMS 0
The 0
chromosome 0
region 0
18q21 0
has 0
been 0
shown 0
to 0
be 0
frequently 0
deleted 0
in 0
colorectal 2
cancers 2
, 0
and 0
such 0
frequent 0
allelic 0
loss 0
is 0
a 0
hallmark 0
of 0
the 0
presence 0
of 0
a 0
tumor-suppressor 0
gene 0
. 0

The 0
DPC4 0
gene 0
, 0
which 0
is 0
located 0
at 0
18q21 0
, 0
has 0
been 0
identified 0
as 0
a 0
tumor-suppressor 0
gene 0
from 0
examination 0
of 0
pancreatic 2
cancers 2
. 0

The 0
aim 0
of 0
the 0
present 0
study 0
was 0
to 0
determine 0
if 0
it 0
might 0
also 0
be 0
altered 0
in 0
colorectal 2
cancers 2
. 0

METHODS 0
Mutation 0
analyses 0
of 0
the 0
DPC4 0
gene 0
were 0
performed 0
on 0
complementary 0
DNA 0
samples 0
from 0
31 0
primary 0
colorectal 3
cancer 3
specimens 0
using 0
a 0
combination 0
of 0
polymerase 0
chain 0
reaction 0
, 0
single-strand 0
conformation 0
polymorphism 0
, 0
and 0
DNA 0
sequencing 0
. 0

RESULTS 0
Four 0
missense 0
mutations 0
producing 0
amino 0
acid 0
substitutions 0
and 0
a 0
somatic 0
12-base 0
pair 0
deletion 0
in 0
the 0
coding 0
region 0
of 0
the 0
DPC4 0
gene 0
were 0
detected 0
in 0
the 0
31 0
cancers 4
( 0
16 0
% 0
; 0
5 0
of 0
31 0
) 0
. 0

CONCLUSIONS 0
The 0
DPC4 0
gene 0
may 0
play 0
a 0
role 0
as 0
a 0
tumor-suppressor 0
gene 0
in 0
a 0
fraction 0
of 0
colorectal 2
cancers 2
; 0
however 0
, 0
while 0
allelic 0
loss 0
at 0
18q21 0
is 0
very 0
often 0
seen 0
in 0
colorectal 2
cancers 2
, 0
only 0
a 0
minority 0
show 0
DPC4 0
mutations 0
, 0
suggesting 0
that 0
there 0
might 0
be 0
another 0
tumor-suppressor 0
gene 0
in 0
this 0
chromosome 0
region 0
. 0

Pleiotropic 0
defects 0
in 0
ataxia-telangiectasia 3
protein-deficient 0
mice 0
. 0

We 0
have 0
generated 0
a 0
mouse 0
model 0
for 0
ataxia-telangiectasia 2
by 0
using 0
gene 0
targeting 0
to 0
generate 0
mice 0
that 0
do 0
not 0
express 0
the 0
Atm 0
protein 0
. 0

Atm-deficient 3
mice 0
are 0
retarded 0
in 0
growth 0
, 0
do 0
not 0
produce 0
mature 0
sperm 0
, 0
and 0
exhibit 0
severe 0
defects 0
in 0
T 0
cell 0
maturation 0
while 0
going 0
on 0
to 0
develop 0
thymomas 2
. 0

Atm-deficient 3
fibroblasts 0
grow 0
poorly 0
in 0
culture 0
and 0
display 0
a 0
high 0
level 0
of 0
double-stranded 0
chromosome 0
breaks 0
. 0

Atm-deficient 3
thymocytes 0
undergo 0
spontaneous 0
apoptosis 0
in 0
vitro 0
significantly 0
more 0
than 0
controls 0
. 0

Atm-deficient 3
mice 0
then 0
exhibit 0
many 0
of 0
the 0
same 0
symptoms 0
found 0
in 0
ataxia-telangiectasia 3
patients 0
and 0
in 0
cells 0
derived 0
from 0
them 0
. 0

Furthermore 0
, 0
we 0
demonstrate 0
that 0
the 0
Atm 0
protein 0
exists 0
as 0
two 0
discrete 0
molecular 0
species 0
, 0
and 0
that 0
loss 0
of 0
one 0
or 0
of 0
both 0
of 0
these 0
can 0
lead 0
to 0
the 0
development 0
of 0
the 0
disease 0
. 0

The 0
DCC 0
protein 0
and 0
prognosis 0
in 0
colorectal 2
cancer 2
. 0

BACKGROUND 0
Allelic 0
loss 0
of 0
chromosome 0
18q 0
predicts 0
a 0
poor 0
outcome 0
in 0
patients 0
with 0
stage 2
II 2
colorectal 2
cancer 2
. 0

Although 0
the 0
specific 0
gene 0
inactivated 0
by 0
this 0
allelic 0
loss 0
has 0
not 0
been 0
elucidated 0
, 0
the 0
DCC 0
( 0
deleted 0
in 0
colorectal 2
cancer 2
) 0
gene 0
is 0
a 0
candidate 0
. 0

We 0
investigated 0
whether 0
the 0
expression 0
of 0
the 0
DCC 0
protein 0
in 0
tumor 3
cells 0
is 0
a 0
prognostic 0
marker 0
in 0
colorectal 2
carcinoma 2
. 0

METHODS 0
The 0
expression 0
of 0
DCC 0
was 0
evaluated 0
immunohistochemically 0
in 0
132 0
paraffin-embedded 0
samples 0
from 0
patients 0
with 0
curatively 0
resected 0
stage 1
II 1
and 1
III 1
colorectal 1
carcinomas 1
. 0

The 0
Cox 0
proportional-hazards 0
model 0
was 0
used 0
to 0
adjust 0
for 0
covariates 0
including 0
age 0
, 0
sex 0
, 0
tumor 3
site 0
, 0
degree 0
of 0
tumor 3
differentiation 0
, 0
and 0
use 0
of 0
adjuvant 0
therapy 0
. 0

RESULTS 0
The 0
expression 0
of 0
DCC 0
was 0
a 0
strong 0
positive 0
predictive 0
factor 0
for 0
survival 0
in 0
both 0
stage 1
II 1
and 1
stage 1
III 1
colorectal 1
carcinomas 1
. 0

In 0
patients 0
with 0
stage 0
II 0
disease 0
whose 0
tumors 4
expressed 0
DCC 0
, 0
the 0
five-year 0
survival 0
rate 0
was 0
94 0
. 0

3 0
percent 0
, 0
whereas 0
in 0
patients 0
with 0
DCC-negative 2
tumors 2
, 0
the 0
survival 0
rate 0
was 0
61 0
. 0

6 0
percent 0
( 0
P 0
0 0
. 0

001 0
) 0
. 0

In 0
patients 0
with 0
stage 2
III 2
disease 2
, 0
the 0
respective 0
survival 0
rates 0
were 0
59 0
. 0

3 0
percent 0
and 0
33 0
. 0

2 0
percent 0
( 0
P 0
= 0
0 0
. 0

03 0
) 0
. 0

CONCLUSIONS 0
DCC 0
is 0
a 0
prognostic 0
marker 0
in 0
patients 0
with 0
stage 1
II 1
or 1
stage 1
III 1
colorectal 1
cancer 1
. 0

In 0
stage 2
II 2
colorectal 2
carcinomas 2
, 0
the 0
absence 0
of 0
DCC 0
identifies 0
a 0
subgroup 0
of 0
patients 0
with 0
lesions 0
that 0
behave 0
like 0
stage 4
III 4
cancers 4
. 0

These 0
findings 0
may 0
thus 0
have 0
therapeutic 0
implications 0
in 0
this 0
group 0
of 0
patients 0
Association 0
of 0
anxiety-related 4
traits 4
with 0
a 0
polymorphism 0
in 0
the 0
serotonin 0
transporter 0
gene 0
regulatory 0
region 0
. 0

Transporter-facilitated 0
uptake 0
of 0
serotonin 0
( 0
5-hydroxytryptamine 0
or 0
5-HT 0
) 0
has 0
been 0
implicated 0
in 0
anxiety 4
in 0
humans 0
and 0
animal 0
models 0
and 0
is 0
the 0
site 0
of 0
action 0
of 0
widely 0
used 0
uptake-inhibiting 0
antidepressant 0
and 0
antianxiety 0
drugs 0
. 0

Human 0
5-HT 0
transporter 0
( 0
5-HTT 0
) 0
gene 0
transcription 0
is 0
modulated 0
by 0
a 0
common 0
polymorphism 0
in 0
its 0
upstream 0
regulatory 0
region 0
. 0

The 0
short 0
variant 0
of 0
the 0
polymorphism 0
reduces 0
the 0
transcriptional 0
efficiency 0
of 0
the 0
5-HTT 0
gene 0
promoter 0
, 0
resulting 0
in 0
decreased 0
5-HTT 0
expression 0
and 0
5-HT 0
uptake 0
in 0
lymphoblasts 0
. 0

Association 0
studies 0
in 0
two 0
independent 0
samples 0
totaling 0
505 0
individuals 0
revealed 0
that 0
the 0
5-HTT 0
polymorphism 0
accounts 0
for 0
3 0
to 0
4 0
percent 0
of 0
total 0
variation 0
and 0
7 0
to 0
9 0
percent 0
of 0
inherited 0
variance 0
in 0
anxiety-related 4
personality 4
traits 4
in 0
individuals 0
as 0
well 0
as 0
sibships 0
. 0

Phenotypic 0
and 0
genotypic 0
overlap 0
between 0
atelosteogenesis 2
type 2
2 2
and 0
diastrophic 2
dysplasia 2
. 0

Mutations 0
in 0
the 0
diastrophic 3
dysplasia 3
sulfate 0
transporter 0
gene 0
DTDST 0
have 0
been 0
associated 0
with 0
a 0
family 0
of 0
chondrodysplasias 4
that 0
comprises 0
, 0
in 0
order 0
of 0
increasing 0
severity 0
, 0
diastrophic 2
dysplasia 2
( 0
DTD 2
) 0
, 0
atelosteogenesis 2
type 2
2 2
( 0
AO2 2
) 0
, 0
and 0
achondrogenesis 2
type 2
1B 2
( 0
ACG1B 2
) 0
. 0

To 0
learn 0
more 0
about 0
the 0
molecular 0
basis 0
of 0
DTDST 2
chondrodysplasias 2
and 0
about 0
genotype-phenotype 0
correlations 0
, 0
we 0
studied 0
fibroblast 0
cultures 0
of 0
three 0
new 0
patients 0
one 0
with 0
AO-2 2
, 0
one 0
with 0
DTD 2
, 0
and 0
one 0
with 0
an 0
intermediate 0
phenotype 0
( 0
AO2 2
/ 0
DTD 2
) 0
. 0

Reduced 0
incorporation 0
of 0
inorganic 0
sulfate 0
into 0
macromolecules 0
was 0
found 0
in 0
all 0
three 0
. 0

Each 0
of 0
the 0
three 0
patients 0
was 0
found 0
to 0
be 0
heterozygous 0
for 0
a 0
c862t 0
transition 0
predicting 0
a 0
R279W 0
substitution 0
in 0
the 0
third 0
extracellular 0
loop 0
of 0
DTDST 0
. 0

In 0
two 0
patients 0
( 0
DTD 2
and 0
AO2 2
/ 0
DTD 2
) 0
, 0
no 0
other 0
structural 0
mutation 0
was 0
found 0
, 0
but 0
polymerase 0
chain 0
reaction 0
amplification 0
and 0
single-strand 0
conformation 0
polymorphism 0
analysis 0
of 0
fibroblast 0
cDNA 0
showed 0
reduced 0
mRNA 0
levels 0
of 0
the 0
wild-type 0
DTDST 0
allele 0
these 0
two 0
patients 0
may 0
be 0
compound 0
heterozygotes 0
for 0
the 0
`` 0
Finnish 0
`` 0
mutation 0
( 0
as 0
yet 0
uncharacterized 0
at 0
the 0
DNA 0
level 0
) 0
, 0
which 0
causes 0
reduced 0
expression 0
of 0
DTDST 0
. 0

The 0
third 0
patient 0
( 0
with 0
AO2 2
) 0
had 0
the 0
R279W 0
mutation 0
compounded 0
with 0
a 0
novel 0
mutation 0
, 0
the 0
deletion 0
of 0
cytosine 0
418 0
( 0
delta 0
c418 0
) 0
, 0
predicting 0
a 0
frameshift 0
with 0
premature 0
termination 0
. 0

Also 0
the 0
delta 0
c418 0
allele 0
was 0
underrepresented 0
in 0
the 0
cDNA 0
, 0
in 0
accordance 0
with 0
previous 0
observations 0
that 0
premature 0
stop 0
codons 0
reduce 0
mRNA 0
levels 0
. 0

The 0
presence 0
of 0
the 0
DTDST 0
R279W 0
mutation 0
in 0
a 0
total 0
of 0
11 0
patients 0
with 0
AO2 2
or 0
DTD 2
emphasizes 0
the 0
overlap 0
between 0
these 0
conditions 0
. 0

This 0
mutation 0
has 0
not 0
been 0
found 0
so 0
far 0
in 0
8 0
analyzed 0
ACG1B 3
patients 0
, 0
suggesting 0
that 0
it 0
allows 0
some 0
residual 0
activity 0
of 0
the 0
sulfate 0
transporter 0
. 0

Identification 0
of 0
WASP 0
mutations 0
, 0
mutation 0
hotspots 0
and 0
genotype-phenotype 0
disparities 0
in 0
24 0
patients 0
with 0
the 0
Wiskott-Aldrich 2
syndrome 2
. 0

The 0
Wiskott-Aldrich 2
syndrome 2
( 0
WAS 2
) 0
, 0
an 0
X-linked 4
immunodeficiency 4
disease 4
caused 0
by 0
mutation 0
in 0
the 0
recently 0
isolated 0
gene 0
encoding 0
WAS 3
protein 0
( 0
WASP 0
) 0
, 0
is 0
known 0
to 0
be 0
associated 0
with 0
extensive 0
clinical 0
heterogeneity 0
. 0

Cumulative 0
mutation 0
data 0
have 0
revealed 0
that 0
WASP 0
genotypes 0
are 0
also 0
highly 0
variable 0
among 0
WAS 3
patients 0
, 0
but 0
the 0
relationship 0
of 0
phenotype 0
with 0
genotype 0
in 0
this 0
disease 0
remains 0
unclear 0
. 0

To 0
address 0
this 0
issue 0
we 0
characterized 0
WASP 0
mutations 0
in 0
24 0
unrelated 0
WAS 3
patients 0
, 0
including 0
18 0
boys 0
with 0
severe 0
classical 0
WAS 2
and 0
6 0
boys 0
expressing 0
mild 0
forms 0
of 0
the 0
disease 0
, 0
and 0
then 0
examined 0
the 0
degree 0
of 0
correlation 0
of 0
these 0
as 0
well 0
as 0
all 0
previously 0
published 0
WASP 0
mutations 0
with 0
disease 0
severity 0
. 0

By 0
analysis 0
of 0
these 0
compiled 0
mutation 0
data 0
, 0
we 0
demonstrated 0
clustering 0
of 0
WASP 0
mutations 0
within 0
the 0
four 0
most 0
N-terminal 0
exons 0
of 0
the 0
gene 0
and 0
also 0
identified 0
several 0
sites 0
within 0
this 0
region 0
as 0
hotspots 0
for 0
WASP 0
mutation 0
. 0

These 0
characteristics 0
were 0
observed 0
, 0
however 0
, 0
in 0
both 0
severe 0
and 0
mild 0
cases 0
of 0
the 0
disease 0
. 0

Similarly 0
, 0
while 0
the 0
cumulative 0
data 0
revealed 0
a 0
predominance 0
of 0
missense 0
mutations 0
among 0
the 0
WASP 0
gene 0
lesions 0
observed 0
in 0
boys 0
with 0
isolated 2
thrombocytopenia 2
, 0
missense 0
mutations 0
were 0
not 0
exclusively 0
associated 0
with 0
milder 0
WAS 3
phenotypes 0
, 0
but 0
also 0
comprised 0
a 0
substantial 0
portion 0
( 0
38 0
% 0
) 0
of 0
the 0
WASP 0
gene 0
defects 0
found 0
in 0
patients 0
with 0
severe 0
disease 0
. 0

These 0
findings 0
, 0
as 0
well 0
as 0
the 0
detection 0
of 0
identical 0
WASP 0
mutations 0
in 0
patients 0
with 0
disparate 0
phenotypes 0
, 0
reveal 0
a 0
lack 0
of 0
phenotype 0
concordance 0
with 0
genotype 0
in 0
WAS 2
and 0
thus 0
imply 0
that 0
phenotypic 0
outcome 0
in 0
this 0
disease 0
can 0
not 0
be 0
reliably 0
predicted 0
solely 0
on 0
the 0
basis 0
of 0
WASP 0
genotypes 0
. 0

Germline 0
mutations 0
in 0
the 0
3 0
' 0
part 0
of 0
APC 3
exon 0
15 0
do 0
not 0
result 0
in 0
truncated 0
proteins 0
and 0
are 0
associated 0
with 0
attenuated 0
adenomatous 2
polyposis 2
coli 2
. 0

Familial 2
adenomatous 2
polyposis 2
( 0
FAP 2
) 0
is 0
an 0
inherited 0
predisposition 0
to 0
colorectal 2
cancer 2
characterized 0
by 0
the 0
development 0
of 0
numerous 0
adenomatous 4
polyps 4
predominantly 0
in 0
the 0
colorectal 0
region 0
. 0

Germline 0
mutations 0
in 0
the 0
adenomatous 3
polyposis 3
coli 3
( 0
APC 3
) 0
gene 0
are 0
responsible 0
for 0
most 0
cases 0
of 0
FAP 2
. 0

Mutations 0
at 0
the 0
5 0
end 0
of 0
APC 2
are 0
known 0
to 0
be 0
associated 0
with 0
a 0
relatively 0
mild 0
form 0
of 0
the 0
disease 0
, 0
called 0
attenuated 2
adenomatous 2
polyposis 2
coli 2
( 0
AAPC 2
) 0
. 0

We 0
identified 0
a 0
frameshift 0
mutation 0
in 0
the 0
3 0
part 0
of 0
exon 0
15 0
, 0
resulting 0
in 0
a 0
stop 0
codon 0
at 0
1862 0
, 0
in 0
a 0
large 0
Dutch 0
kindred 0
with 0
AAPC 2
. 0

Western 0
blot 0
analysis 0
of 0
lymphoblastoid 0
cell 0
lines 0
derived 0
from 0
affected 0
family 0
members 0
from 0
this 0
kindred 0
, 0
as 0
well 0
as 0
from 0
a 0
previously 0
reported 0
Swiss 0
family 0
carrying 0
a 0
frameshift 0
mutation 0
at 0
codon 0
1987 0
and 0
displaying 0
a 0
similar 0
attenuated 0
phenotype 0
, 0
showed 0
only 0
the 0
wild-type 0
APC 3
protein 0
. 0

Our 0
study 0
indicates 0
that 0
chain-terminating 0
mutations 0
located 0
in 0
the 0
3 0
part 0
of 0
APC 2
do 0
not 0
result 0
in 0
detectable 0
truncated 0
polypeptides 0
and 0
we 0
hypothesize 0
that 0
this 0
is 0
likely 0
to 0
be 0
the 0
basis 0
for 0
the 0
observed 0
AAPC 3
phenotype 0
. 0

Complete 0
genomic 0
sequence 0
and 0
analysis 0
of 0
117 0
kb 0
of 0
human 0
DNA 0
containing 0
the 0
gene 0
BRCA1 0
. 0

Over 0
100 0
distinct 0
disease-associated 0
mutations 0
have 0
been 0
identified 0
in 0
the 0
breast-ovarian 3
cancer 3
susceptibility 0
gene 0
BRCA1 0
. 0

Loss 0
of 0
the 0
wild-type 0
allele 0
in 0
90 0
% 0
of 0
tumors 4
from 0
patients 0
with 0
inherited 0
BRCA1 0
mutations 0
indicates 0
tumor 3
suppressive 0
function 0
. 0

The 0
low 0
incidence 0
of 0
somatic 0
mutations 0
suggests 0
that 0
BRCA1 0
inactivation 0
in 0
sporadic 0
tumors 4
occurs 0
by 0
alternative 0
mechanisms 0
, 0
such 0
as 0
interstitial 0
chromosomal 0
deletion 0
or 0
reduced 0
transcription 0
. 0

To 0
identify 0
possible 0
features 0
of 0
the 0
BRCA1 0
genomic 0
region 0
that 0
may 0
contribute 0
to 0
chromosomal 0
instability 0
as 0
well 0
as 0
potential 0
transcriptional 0
regulatory 0
elements 0
, 0
a 0
117 0
, 0
143-bp 0
DNA 0
sequence 0
encompassing 0
BRCA1 0
was 0
obtained 0
by 0
random 0
sequencing 0
of 0
four 0
cosmids 0
identified 0
from 0
a 0
human 0
chromosome 0
17 0
specific 0
library 0
. 0

The 0
24 0
exons 0
of 0
BRCA1 0
span 0
an 0
81-kb 0
region 0
that 0
has 0
an 0
unusually 0
high 0
density 0
of 0
Alu 0
repetitive 0
DNA 0
( 0
41 0
. 0

5 0
% 0
) 0
, 0
but 0
relatively 0
low 0
density 0
( 0
4 0
. 0

8 0
% 0
) 0
of 0
other 0
repetitive 0
sequences 0
. 0

BRCA1 0
intron 0
lengths 0
range 0
in 0
size 0
from 0
403 0
bp 0
to 0
9 0
. 0

2 0
kb 0
and 0
contain 0
the 0
intragenic 0
microsatellite 0
markers 0
D17S1323 0
, 0
D17S1322 0
, 0
and 0
D17S855 0
, 0
which 0
localize 0
to 0
introns 0
12 0
, 0
19 0
, 0
and 0
20 0
, 0
respectively 0
. 0

In 0
addition 0
to 0
BRCA1 0
, 0
the 0
contig 0
contains 0
two 0
complete 0
genes 0
Rho7 0
, 0
a 0
member 0
of 0
the 0
rho 0
family 0
of 0
GTP 0
binding 0
proteins 0
, 0
and 0
VAT1 0
, 0
an 0
abundant 0
membrane 0
protein 0
of 0
cholinergic 0
synaptic 0
vesicles 0
. 0

Partial 0
sequences 0
of 0
the 0
1A1-3B 0
B-box 0
protein 0
pseudogene 0
and 0
IFP 0
35 0
, 0
an 0
interferon 0
induced 0
leucine 0
zipper 0
protein 0
, 0
reside 0
within 0
the 0
contig 0
. 0

An 0
L21 0
ribosomal 0
protein 0
pseudogene 0
is 0
embedded 0
in 0
BRCA1 0
intron 0
13 0
. 0

The 0
order 0
of 0
genes 0
on 0
the 0
chromosome 0
is 0
centromere-1FP 0
35-VAT1-Rho7-BRCA1-1A1-3B-telomere 0
. 0

Identification 0
of 0
a 0
RING 0
protein 0
that 0
can 0
interact 0
in 0
vivo 0
with 0
the 0
BRCA1 0
gene 0
product 0
. 0

The 0
hereditary 3
breast 3
and 3
ovarian 3
cancer 3
gene 0
, 0
BRCA1 0
, 0
encodes 0
a 0
large 0
polypeptide 0
that 0
contains 0
the 0
cysteine-rich 0
RING 0
motif 0
, 0
a 0
zinc-binding 0
domain 0
found 0
in 0
a 0
variety 0
of 0
regulatory 0
proteins 0
. 0

Here 0
we 0
describe 0
a 0
novel 0
protein 0
that 0
interacts 0
in 0
vivo 0
with 0
the 0
N-terminal 0
region 0
of 0
BRCA1 0
. 0

This 0
BRCA1-associated 0
RING 0
domain 0
( 0
BARD1 0
) 0
protein 0
contains 0
an 0
N-terminal 0
RING 0
motif 0
, 0
three 0
tandem 0
ankyrin 0
repeats 0
, 0
and 0
a 0
C-terminal 0
sequence 0
with 0
significant 0
homology 0
to 0
the 0
phylogenetically 0
conserved 0
BRCT 0
domains 0
that 0
lie 0
near 0
the 0
C 0
terminus 0
of 0
BRCA1 0
. 0

The 0
BARD1 0
/ 0
BRCA1 0
interaction 0
is 0
disrupted 0
by 0
BRCA1 0
missense 0
mutations 0
that 0
segregate 0
with 0
breast 3
cancer 3
susceptibility 0
, 0
indicating 0
that 0
BARD1 0
may 0
be 0
involved 0
in 0
mediating 0
tumour 3
suppression 0
by 0
BRCA1 0
. 0

Detection 0
of 0
heterozygous 0
mutations 0
in 0
BRCA1 0
using 0
high 0
density 0
oligonucleotide 0
arrays 0
and 0
two-colour 0
fluorescence 0
analysis 0
. 0

The 0
ability 0
to 0
scan 0
a 0
large 0
gene 0
rapidly 0
and 0
accurately 0
for 0
all 0
possible 0
heterozygous 0
mutations 0
in 0
large 0
numbers 0
of 0
patient 0
samples 0
will 0
be 0
critical 0
for 0
the 0
future 0
of 0
medicine 0
. 0

We 0
have 0
designed 0
high-density 0
arrays 0
consisting 0
of 0
over 0
96 0
, 0
600 0
oligonucleotides 0
20-nucleotides 0
( 0
nt 0
) 0
in 0
length 0
to 0
screen 0
for 0
a 0
wide 0
range 0
of 0
heterozygous 0
mutations 0
in 0
the 0
3 0
. 0

45-kilobases 0
( 0
kb 0
) 0
exon 0
11 0
of 0
the 0
hereditary 3
breast 3
and 3
ovarian 3
cancer 3
gene 0
BRCA1 0
. 0

Reference 0
and 0
test 0
samples 0
were 0
co-hybridized 0
to 0
these 0
arrays 0
and 0
differences 0
in 0
hybridization 0
patterns 0
quantitated 0
by 0
two-colour 0
analysis 0
. 0

Fourteen 0
of 0
fifteen 0
patient 0
samples 0
with 0
known 0
mutations 0
were 0
accurately 0
diagnosed 0
, 0
and 0
no 0
false 0
positive 0
mutations 0
were 0
identified 0
in 0
20 0
control 0
samples 0
. 0

Eight 0
single 0
nucleotide 0
polymorphisms 0
were 0
also 0
readily 0
detected 0
. 0

DNA 0
chip-based 0
assays 0
may 0
provide 0
a 0
valuable 0
new 0
technology 0
for 0
high-throughput 0
cost-efficient 0
detection 0
of 0
genetic 0
alterations 0
. 0

Autosomal 2
dominant 2
primary 2
hyperparathyroidism 2
and 2
jaw 2
tumor 2
syndrome 2
associated 0
with 0
renal 2
hamartomas 2
and 0
cystic 4
kidney 4
disease 4
: 0
linkage 0
to 0
1q21-q32 0
and 0
loss 0
of 0
the 0
wild 0
type 0
allele 0
in 0
renal 2
hamartomas 2
. 0

Hereditary 2
hyperparathyroidism-jaw 2
tumor 2
syndrome 2
( 0
HPT-JT 2
) 0
is 0
an 0
autosomal 4
dominant 4
disease 4
( 0
OMIM 0
145001 0
) 0
that 0
has 0
recently 0
been 0
mapped 0
to 0
chromosomal 0
region 0
1q21-q32 0
( 0
HRPT2 0
) 0
. 0

Here 0
we 0
report 0
two 0
families 0
with 0
HPT-JT 2
syndrome 2
in 0
which 0
adult 2
renal 2
hamartomas 2
or 0
cystic 4
kidney 4
disease 4
were 0
prominent 0
associated 0
features 0
, 0
possibly 0
representing 0
a 0
new 0
phenotypic 0
variant 0
of 0
the 0
HPT-JT 2
syndrome 2
. 0

In 0
the 0
first 0
family 0
, 0
renal 4
lesions 4
were 0
present 0
in 0
five 0
out 0
of 0
six 0
affected 0
individuals 0
, 0
whereas 0
HPT 2
and 0
JT 2
were 0
seen 0
in 0
four 0
and 0
two 0
cases 0
, 0
respectively 0
. 0

In 0
the 0
second 0
family 0
, 0
JT 2
was 0
found 0
in 0
three 0
of 0
the 0
five 0
affected 0
individuals 0
and 0
two 0
affected 0
members 0
also 0
exhibited 0
polycystic 2
kidney 2
disease 2
. 0

The 0
possibility 0
of 0
the 0
latter 0
cosegregating 0
as 0
a 0
separate 0
autosomal 0
dominant 0
gene 0
can 0
not 0
be 0
ruled 0
out 0
. 0

A 0
sex-dependent 0
penetrance 0
of 0
primary 2
HPT 2
, 0
resulting 0
in 0
predominantly 0
male-affected 0
cases 0
was 0
evident 0
in 0
the 0
two 0
families 0
. 0

Twenty 0
microsatellite 0
markers 0
in 0
the 0
HRPT2 0
region 0
were 0
typed 0
, 0
in 0
addition 0
to 0
markers 0
in 0
the 0
multiple 3
endocrine 3
neoplasia 3
( 3
MEN 3
) 3
types 3
1 3
and 3
2 3
regions 0
at 0
11q13 0
and 0
10q11 0
. 0

The 0
disease 0
in 0
these 0
two 0
kindreds 0
was 0
linked 0
to 0
five 0
markers 0
in 0
the 0
1q21-q32 0
region 0
( 0
logarithm-of-odds 0
scores 0
3 0
. 0

2-4 0
2-4 0
. 0

2 0
) 0
, 0
whereas 0
linkage 0
to 0
the 0
MEN1 3
and 0
MEN2 3
regions 0
was 0
excluded 0
. 0

Meiotic 0
recombinations 0
detected 0
in 0
affected 0
individuals 0
placed 0
the 0
locus 0
telomeric 0
of 0
D1S215 0
, 0
thus 0
narrowing 0
the 0
HRPT2 0
region 0
from 0
60 0
to 0
approximately 0
34 0
centimorgans 0
. 0

Loss 0
of 0
heterozygosity 0
was 0
studied 0
in 0
seven 0
renal 2
hamartomas 2
from 0
two 0
affected 0
individuals 0
in 0
the 0
first 0
family 0
, 0
as 0
well 0
as 0
in 0
a 0
jaw 2
tumor 2
and 0
a 0
parathyroid 2
tumor 2
from 0
the 0
second 0
family 0
. 0

All 0
renal 2
hamartomas 2
showed 0
loss 0
of 0
heterozygosity 0
at 0
the 0
1q21-q32 0
region 0
. 0

The 0
losses 0
invariably 0
involved 0
the 0
wild 0
type 0
allele 0
derived 0
from 0
the 0
unaffected 0
parent 0
, 0
suggesting 0
the 0
inactivation 0
of 0
a 0
tumor 3
suppressor 0
gene 0
in 0
this 0
region 0
. 0

Independent 0
origin 0
of 0
single 0
and 0
double 0
mutations 0
in 0
the 0
human 0
glucose 0
6-phosphate 0
dehydrogenase 0
gene 0
. 0

The 0
vast 0
majority 0
of 0
both 0
polymorphic 0
and 0
sporadic 0
G6PD 0
variants 0
are 0
due 0
to 0
single 0
missense 0
mutations 0
. 0

In 0
the 0
four 0
polymorphic 0
variants 0
that 0
have 0
two 0
point 0
mutations 0
, 0
one 0
of 0
the 0
mutations 0
is 0
always 0
376 0
A 0
-- 0
G 0
( 0
126 0
Asn 0
-- 0
Asp 0
) 0
, 0
which 0
on 0
its 0
own 0
gives 0
rise 0
to 0
the 0
nondeficient 0
polymorphic 0
variant 0
, 0
G6PD 0
A 0
. 0

In 0
a 0
study 0
of 0
G6PD 3
deficient 3
patients 0
who 0
presented 0
with 0
clinical 0
favism 2
in 0
Spain 0
, 0
we 0
have 0
found 0
a 0
new 0
polymorphic 0
variant 0
that 0
we 0
have 0
called 0
G6PD 0
Malaga 0
, 0
whose 0
only 0
abnormality 0
is 0
a 0
542 0
A 0
-- 0
T 0
( 0
181 0
Asp 0
-- 0
Val 0
) 0
mutation 0
. 0

This 0
is 0
the 0
same 0
mutation 0
as 0
previously 0
found 0
in 0
association 0
with 0
the 0
mutation 0
of 0
G6PD 0
A 0
in 0
the 0
double 0
mutant 0
, 0
G6PD 0
Santamaria 0
. 0

G6PD 0
Malaga 0
is 0
associated 0
with 0
enzyme 4
deficiency 4
( 0
class 0
III 0
) 0
, 0
and 0
the 0
enzymic 0
properties 0
of 0
G6PD 0
Malaga 0
and 0
G6PD 0
Santamaria 0
are 0
quite 0
similar 0
, 0
indicating 0
that 0
in 0
this 0
case 0
the 0
effects 0
of 0
the 0
two 0
mutations 0
are 0
additive 0
rather 0
than 0
synergistic 0
. 0

G6PD 0
Santamaria 0
might 0
have 0
been 0
produced 0
by 0
recombination 0
between 0
G6PD 0
A 0
and 0
G6PD 0
Malaga 0
; 0
however 0
haplotype 0
analysis 0
, 0
including 0
the 0
use 0
of 0
a 0
new 0
silent 0
polymorphism 0
, 0
suggests 0
that 0
the 0
same 0
542 0
A 0
-- 0
T 0
mutation 0
has 0
taken 0
place 0
independently 0
in 0
a 0
G6PD 0
B 0
gene 0
to 0
give 0
G6PD 0
Malaga 0
and 0
in 0
a 0
G6PD 0
A 0
gene 0
to 0
give 0
G6PD 0
Santamaria 0
. 0

These 0
findings 0
help 0
to 0
outline 0
the 0
relationship 0
and 0
evolution 0
of 0
mutations 0
in 0
the 0
human 0
G6PD 0
locus 0
. 0

BRCA1 0
R841W 0
: 0
a 0
strong 0
candidate 0
for 0
a 0
common 0
mutation 0
with 0
moderate 0
phenotype 0
. 0

BRCA1 0
mutations 0
cause 0
increased 0
risk 0
for 0
breast 1
and 1
ovarian 1
cancer 1
, 0
frequently 0
of 0
early 0
onset 0
. 0

Many 0
different 0
mutations 0
occur 0
in 0
BRCA1 0
, 0
including 0
several 0
examples 0
of 0
recurrent 0
mutations 0
, 0
each 0
of 0
which 0
accounts 0
for 0
a 0
significant 0
number 0
of 0
families 0
with 0
heritable 0
cancer 3
predisposition 0
. 0

These 0
common 0
mutations 0
have 0
an 0
etiological 0
role 0
in 0
many 0
breast 3
and 3
ovarian 3
cancer 3
cases 0
and 0
provide 0
the 0
opportunity 0
to 0
examine 0
genotype-phenotype 0
correlations 0
and 0
genotype-environment 0
interactions 0
in 0
individuals 0
with 0
the 0
identical 0
BRCA1 0
lesion 0
. 0

We 0
report 0
a 0
novel 0
missense 0
change 0
in 0
BRCA1 0
, 0
2640 0
C 0
-- 0
T 0
( 0
R841W 0
) 0
, 0
found 0
in 0
3 0
cases 0
from 0
a 0
subject 0
group 0
of 0
305 0
breast 3
and 3
79 3
ovarian 3
cancer 3
cases 0
from 0
Orange 0
County 0
, 0
CA 0
. 0

These 0
are 0
consecutive 0
, 0
population-based 0
cases 0
not 0
selected 0
for 0
age 0
or 0
family 0
history 0
. 0

In 0
all 0
three 0
cases 0
, 0
there 0
is 0
a 0
strong 0
family 0
history 0
of 0
breast 1
, 1
ovarian 1
, 1
or 1
other 1
cancers 1
possibly 0
related 0
to 0
a 0
BRCA1 0
defect 0
and 0
family 0
members 0
showed 0
a 0
high 0
concordance 0
of 0
cancer 3
incidence 0
with 0
the 0
presence 0
of 0
R841W 0
. 0

The 0
age 0
of 0
cancer 3
onset 0
was 0
not 0
always 0
distinct 0
from 0
typical 0
sporadic 0
cases 0
. 0

Testing 0
of 0
a 0
sample 0
of 0
413 0
unrelated 0
individuals 0
to 0
examine 0
the 0
hypothesis 0
that 0
R841W 0
might 0
be 0
a 0
rare 0
polymorphism 0
detected 0
one 0
additional 0
instance 0
in 0
a 0
woman 0
with 0
breast 2
cancer 2
diagnosed 0
at 0
age 0
77 0
years 0
, 0
and 0
cancer 4
in 0
one 0
parent 0
. 0

R841W 0
is 0
likely 0
to 0
be 0
an 0
etiologically 0
significant 0
lesion 0
with 0
involvement 0
in 0
close 0
to 0
1 0
% 0
( 0
95 0
% 0
confidence 0
interval 0
of 0
0-1 0
. 0

7 0
% 0
) 0
of 0
all 0
breast 1
and 1
ovarian 1
cancers 1
in 0
this 0
population 0
. 0

Ataxia-telangiectasia 2
: 0
founder 0
effect 0
among 0
north 0
African 0
Jews 0
. 0

The 0
ATM 0
gene 0
is 0
responsible 0
for 0
the 0
autosomal 4
recessive 4
disorder 4
ataxia-telangiectasia 0
( 0
SpecificDisease 0
A-T 0
) 0
, 0
characterized 2
by 0
cerebellar 0
degeneration 0
, 0
immunodeficiency 4
and 4
category= 0
cancer 4
predisposition 0
< 4
. 4

A-T 3
carriers 0
were 0
reported 0
to 0
be 0
moderately 0
cancer-prone 4
. 0

A 0
wide 0
variety 0
of 0
A-T 3
mutations 0
, 0
most 0
of 0
which 0
are 0
unique 0
to 0
single 0
families 0
, 0
were 0
identified 0
in 0
various 0
ethnic 0
groups 0
, 0
precluding 0
carrier 0
screening 0
with 0
mutation-specific 0
assays 0
. 0

However 0
, 0
a 0
single 0
mutation 0
was 0
observed 0
in 0
32 0
/ 0
33 0
defective 0
ATM 0
alleles 0
in 0
Jewish 0
A-T 3
families 0
of 0
North 0
African 0
origin 0
, 0
coming 0
from 0
various 0
regions 0
of 0
Morocco 0
and 0
Tunisia 0
. 0

This 0
mutation 0
, 0
103C 0
-- 0
T 0
, 0
results 0
in 0
a 0
stop 0
codon 0
at 0
position 0
35 0
of 0
the 0
ATM 0
protein 0
. 0

In 0
keeping 0
with 0
the 0
nature 0
of 0
this 0
mutation 0
, 0
various 0
antibodies 0
directed 0
against 0
the 0
ATM 0
protein 0
failed 0
to 0
defect 0
this 0
protein 0
in 0
patient 0
cells 0
. 0

A 0
rapid 0
carrier 0
detection 0
assay 0
detected 0
this 0
mutation 0
in 0
three 0
out 0
of 0
488 0
ATM 0
alleles 0
of 0
Jewish 0
Moroccan 0
or 0
Tunisian 0
origin 0
. 0

This 0
founder 0
effect 0
provides 0
a 0
unique 0
opportunity 0
for 0
population-based 0
screening 0
for 0
A-T 3
carriers 0
in 0
a 0
large 0
Jewish 0
community 0
. 0

Mutation 0
analysis 0
of 0
BRCA1 0
and 0
BRCA2 0
in 0
a 0
male 3
breast 3
cancer 3
population 0
. 0

A 0
population-based 0
series 0
of 0
54 0
male 3
breast 3
cancer 3
cases 0
from 0
Southern 0
California 0
were 0
analyzed 0
for 0
germ-line 0
mutations 0
in 0
the 0
inherited 3
breast 3
/ 3
ovarian 3
cancer 3
genes 0
, 0
BRCA1 0
and 0
BRCA2 0
. 0

Nine 0
( 0
17 0
% 0
) 0
of 0
the 0
patients 0
had 0
a 0
family 0
history 0
of 0
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
in 0
at 0
least 0
one 0
first-degree 0
relative 0
. 0

A 0
further 0
seven 0
( 0
13 0
% 0
) 0
of 0
the 0
patients 0
reported 0
breast 1
/ 1
ovarian 1
cancer 1
in 0
at 0
least 0
one 0
second-degree 0
relative 0
and 0
in 0
no 0
first-degree 0
relatives 0
. 0

No 0
germ-line 0
BRCA1 0
mutations 0
were 0
found 0
. 0

Two 0
male 3
breast 3
cancer 3
patients 0
( 0
4 0
% 0
of 0
the 0
total 0
) 0
were 0
found 0
to 0
carry 0
novel 0
truncating 0
mutations 0
in 0
the 0
BRCA2 0
gene 0
. 0

Only 0
one 0
of 0
the 0
two 0
male 3
breast 3
cancer 3
patients 0
carrying 0
a 0
BRCA2 0
mutation 0
had 0
a 0
family 0
history 0
of 0
cancer 4
, 0
with 0
one 0
case 0
of 0
ovarian 2
cancer 2
in 0
a 0
first-degree 0
relative 0
. 0

The 0
remaining 0
eight 0
cases 0
( 0
89 0
% 0
) 0
of 0
male 2
breast 2
cancer 2
with 0
a 0
family 0
history 0
of 0
breast 1
/ 1
ovarian 1
cancer 1
in 0
first-degree 0
relatives 0
remain 0
unaccounted 0
for 0
by 0
mutations 0
in 0
either 0
the 0
BRCA1 0
gene 0
or 0
the 0
BRCA2 0
gene 0
. 0

Molecular 0
basis 0
for 0
Duarte 1
and 1
Los 1
Angeles 1
variant 1
galactosemia 1
. 0

Human 0
orythrocytes 0
that 0
are 0
homozygous 0
for 0
the 0
Duarte 2
enzyme 2
variant 2
of 2
galactosemia 2
( 0
D 0
/ 0
D 0
) 0
have 0
a 0
characteristic 0
isoform 0
on 0
isoelectric 0
focusing 0
and 0
50 0
% 0
reduction 0
in 0
galactose-1-phosphate 0
uridyltransferase 0
( 0
GALT 0
) 0
enzyme 0
activity 0
. 0

The 0
Duarte 0
biochemical 0
phenotype 0
has 0
a 0
molecular 0
genotype 0
of 0
N314D 0
/ 0
N314D 0
. 0

The 0
characteristic 0
Duarte 0
isoform 0
is 0
also 0
associated 0
with 0
a 0
variant 0
called 0
the 0
`` 0
Los 0
Angeles 0
( 0
LA 0
) 0
phenotype 0
, 0
`` 0
which 0
has 0
increased 0
GALT 0
enzyme 0
activity 0
. 0

We 0
evaluated 0
GALT 0
enzyme 0
activity 0
and 0
screened 0
the 0
GALT 0
genes 0
of 0
145 0
patients 0
with 0
one 0
or 0
more 0
N314D-containing 0
alleles 0
. 0

We 0
found 0
seven 0
with 0
the 0
LA 0
biochemical 0
phenotype 0
, 0
and 0
all 0
had 0
a 0
1721C 0
-- 0
T 0
transition 0
in 0
exon 0
7 0
in 0
cis 0
with 0
the 0
N314D 0
missense 0
mutation 0
. 0

The 0
1721C 0
-- 0
T 0
transition 0
is 0
a 0
neutral 0
polymorphism 0
for 0
leucine 0
at 0
amino 0
acid 0
218 0
( 0
L218L 0
) 0
. 0

In 0
pedigree 0
analyses 0
, 0
this 0
1721C 0
-- 0
T 0
transition 0
segregated 0
with 0
the 0
LA 0
phenotype 0
of 0
increased 0
GALT 0
activity 0
in 0
three 0
different 0
biochemical 0
phenotypes 0
( 0
LA 0
/ 0
N 0
, 0
LA 0
/ 0
G 0
, 0
and 0
LA 0
/ 0
D 0
) 0
. 0

To 0
determine 0
the 0
mechanism 0
for 0
increased 0
activity 0
of 0
the 0
LA 0
variant 0
, 0
we 0
compared 0
GALT 0
mRNA 0
, 0
protein 0
abundance 0
, 0
and 0
enzyme 0
thermal 0
stability 0
in 0
lymphoblast 0
cell 0
lines 0
of 0
D 0
and 0
LA 0
phenotypes 0
with 0
comparable 0
genotypes 0
. 0

GALT 0
protein 0
abundance 0
was 0
increased 0
in 0
LA 0
compared 0
to 0
D 0
alleles 0
, 0
but 0
mRNA 0
was 0
similar 0
among 0
all 0
genotypes 0
. 0

When 0
LA 0
/ 0
D 0
and 0
D 0
/ 0
D 0
GALT 0
biochemical 0
phenotypes 0
were 0
compared 0
to 0
N 0
/ 0
N 0
GALT 0
phenotypes 0
, 0
both 0
had 0
50 0
% 0
, 0
as 0
compared 0
to 0
21 0
% 0
, 0
reduction 0
in 0
GALT 0
activity 0
in 0
the 0
wild 0
type 0
( 0
N 0
/ 0
N 0
) 0
after 0
exposure 0
at 0
identical 0
initial 0
enzyme 0
activity 0
to 0
50 0
degrees 0
C 0
for 0
15 0
min 0
. 0

We 0
conclude 0
that 0
the 0
codon 0
change 0
N314D 0
in 0
cis 0
with 0
the 0
base-pair 0
transition 0
1721C 0
-- 0
T 0
produces 0
the 0
LA 2
variant 2
of 2
galactosemia 2
and 0
that 0
this 0
nucleotide 0
change 0
increases 0
GALT 0
activity 0
by 0
increasing 0
GALT 0
protein 0
abundance 0
without 0
increasing 0
transcription 0
or 0
decreasing 0
thermal 0
lability 0
. 0

A 0
favorable 0
codon 0
bias 0
for 0
the 0
mutated 0
codon 0
with 0
consequently 0
increased 0
translation 0
rates 0
is 0
postulated 0
as 0
the 0
mechanism 0
. 0

The 0
TSG101 0
tumor 3
susceptibility 0
gene 0
is 0
located 0
in 0
chromosome 0
11 0
band 0
p15 0
and 0
is 0
mutated 0
in 0
human 0
breast 2
cancer 2
. 0

Recent 0
work 0
has 0
identified 0
a 0
mouse 0
gene 0
( 0
tsg101 0
) 0
whose 0
inactivation 0
in 0
fibroblasts 0
results 0
in 0
cellular 0
transformation 0
and 0
the 0
ability 0
to 0
produce 0
metastatic 4
tumors 4
in 0
nude 0
mice 0
. 0

Here 0
, 0
we 0
report 0
that 0
the 0
human 0
homolog 0
, 0
TSG101 0
, 0
which 0
we 0
isolated 0
and 0
mapped 0
to 0
chromosome 0
11 0
, 0
bands 0
15 0
. 0

1-15 0
1-15 0
. 0

2 0
, 0
a 0
region 0
proposed 0
to 0
contain 0
tumor 3
suppressor 0
gene 0
( 0
s 0
) 0
, 0
is 0
mutated 0
at 0
high 0
frequency 0
in 0
human 0
breast 2
cancer 2
. 0

In 0
7 0
of 0
15 0
uncultured 0
primary 0
human 0
breast 2
carcinomas 2
, 0
intragenic 0
deletions 0
were 0
shown 0
in 0
TSG101 0
genomic 0
DNA 0
and 0
transcripts 0
by 0
gel 0
and 0
sequence 0
analysis 0
, 0
and 0
mutations 0
affecting 0
two 0
TSG101 0
alleles 0
were 0
identified 0
in 0
four 0
of 0
these 0
cancers 4
. 0

No 0
TSG101 0
defects 0
were 0
found 0
in 0
matched 0
normal 0
breast 0
tissue 0
from 0
the 0
breast 3
cancer 3
patients 0
. 0

These 0
findings 0
strongly 0
implicate 0
TSG101 0
mutations 0
in 0
human 0
breast 2
cancer 2
. 0

Moderate 0
intergenerational 0
and 0
somatic 0
instability 0
of 0
a 0
55-CTG 0
repeat 0
in 0
transgenic 0
mice 0
. 0

Myotonic 2
dystrophy 2
( 0
DM 2
) 0
is 0
associated 0
with 0
the 0
expansion 0
of 0
a 0
( 0
CTG 0
) 0
n 0
trinucleotide 0
repeat 0
in 0
the 0
3 0
untranslated 0
region 0
( 0
UTR 0
) 0
of 0
the 0
DM 3
protein 0
kinase 0
gene 0
( 0
DMPK 0
) 0
. 0

The 0
( 0
CTG 0
) 0
n 0
repeat 0
is 0
polymorphic 0
and 0
varies 0
in 0
size 0
between 0
5 0
and 0
37 0
repeats 0
in 0
unaffected 0
individuals 0
whereas 0
in 0
affected 0
patients 0
there 0
are 0
between 0
50 0
and 0
4 0
, 0
000 0
CTGs 0
. 0

The 0
size 0
of 0
the 0
( 0
CTG 0
) 0
n 0
repeat 0
, 0
which 0
increases 0
through 0
generations 0
, 0
generally 0
correlates 0
with 0
clinical 0
severity 0
and 0
age 0
of 0
onset 0
. 0

The 0
instability 0
of 0
the 0
CTG 0
repeat 0
appears 0
to 0
depend 0
on 0
its 0
size 0
as 0
well 0
as 0
on 0
the 0
sex 0
of 0
the 0
transmitting 0
parent 0
. 0

Moreover 0
, 0
mitotic 0
instability 0
analysis 0
of 0
different 0
human 0
DM 3
tissues 0
shows 0
length 0
mosaicism 0
between 0
different 0
cell 0
lineages 0
. 0

The 0
molecular 0
mechanisms 0
of 0
triplet 0
instability 0
remain 0
elusive 0
. 0

To 0
investigate 0
the 0
role 0
of 0
genomic 0
sequences 0
in 0
instability 0
, 0
we 0
produced 0
transgenic 0
mice 0
containing 0
a 0
45-kb 0
genomic 0
segment 0
with 0
a 0
55-CTG 0
repeat 0
cloned 0
from 0
a 0
mildly 0
affected 0
patient 0
. 0

In 0
contrast 0
to 0
other 0
mouse 0
models 0
containing 0
CAG 0
repeats 0
within 0
cDNAs 0
, 0
these 0
mice 0
showed 0
both 0
intergenerational 0
and 0
somatic 0
repeat 0
instability 0
. 0

Missense 0
mutations 0
in 0
the 0
Fas 0
gene 0
resulting 0
in 0
autoimmune 2
lymphoproliferative 2
syndrome 2
: 0
a 0
molecular 0
and 0
immunological 0
analysis 0
. 0

Programmed 0
cell 0
death 0
( 0
or 0
apoptosis 0
) 0
is 0
a 0
physiological 0
process 0
essential 0
to 0
the 0
normal 0
development 0
and 0
homeostatic 0
maintenance 0
of 0
the 0
immune 0
system 0
. 0

The 0
Fas 0
/ 0
Apo-1 0
receptor 0
plays 0
a 0
crucial 0
role 0
in 0
the 0
regulation 0
of 0
apoptosis 0
, 0
as 0
demonstrated 0
by 0
lymphoproliferation 0
in 0
MRL-lpr 0
/ 0
lpr 0
mice 0
and 0
by 0
the 0
recently 0
described 0
autoimmune 2
lymphoproliferative 2
syndrome 2
( 0
ALPS 2
) 0
in 0
humans 0
, 0
both 0
of 0
which 0
are 0
due 0
to 0
mutations 0
in 0
the 0
Fas 0
gene 0
. 0

We 0
describe 0
a 0
novel 0
family 0
with 0
ALPS 2
in 0
which 0
three 0
affected 0
siblings 0
carry 0
two 0
distinct 0
missense 0
mutations 0
on 0
both 0
the 0
Fas 0
gene 0
alleles 0
and 0
show 0
lack 0
of 0
Fas-induced 0
apoptosis 0
. 0

The 0
children 0
share 0
common 0
clinical 0
features 0
including 0
splenomegaly 4
and 0
lymphadenopathy 4
, 0
but 0
only 0
one 0
developed 0
severe 0
autoimmune 4
manifestations 4
. 0

In 0
all 0
three 0
siblings 0
, 0
we 0
demonstrated 0
the 0
presence 0
of 0
anergic 0
CD3 0
+ 0
CD4-CD8- 0
( 0
double 0
negative 0
, 0
[ 0
DN 0
] 0
) 0
T 0
cells 0
; 0
moreover 0
, 0
a 0
chronic 0
lymphocyte 0
activation 0
was 0
found 0
, 0
as 0
demonstrated 0
by 0
the 0
presence 0
of 0
high 0
levels 0
of 0
HLA-DR 0
expression 0
on 0
peripheral 0
CD3 0
+ 0
cells 0
and 0
by 0
the 0
presence 0
of 0
high 0
levels 0
of 0
serum 0
activation 0
markers 0
such 0
as 0
soluble 0
interleukin-2 0
receptor 0
( 0
slL-2R 0
) 0
and 0
soluble 0
CD30 0
( 0
sCD30 0
) 0
. 0

The 0
ataxia-telangiectasia 3
gene 0
product 0
, 0
a 0
constitutively 0
expressed 0
nuclear 0
protein 0
that 0
is 0
not 0
up-regulated 0
following 0
genome 0
damage 0
. 0

The 0
product 0
of 0
the 0
ataxia-telangiectasia 3
gene 0
( 0
ATM 0
) 0
was 0
identified 0
by 0
using 0
an 0
antiserum 0
developed 0
to 0
a 0
peptide 0
corresponding 0
to 0
the 0
deduced 0
amino 0
acid 0
sequence 0
. 0

The 0
ATM 0
protein 0
is 0
a 0
single 0
, 0
high-molecular 0
weight 0
protein 0
predominantly 0
confined 0
to 0
the 0
nucleus 0
of 0
human 0
fibroblasts 0
, 0
but 0
is 0
present 0
in 0
both 0
nuclear 0
and 0
microsomal 0
fractions 0
from 0
human 0
lymphoblast 0
cells 0
and 0
peripheral 0
blood 0
lymphocytes 0
. 0

ATM 0
protein 0
levels 0
and 0
localization 0
remain 0
constant 0
throughout 0
all 0
stages 0
of 0
the 0
cell 0
cycle 0
. 0

Truncated 0
ATM 0
protein 0
was 0
not 0
detected 0
in 0
lymphoblasts 0
from 0
ataxia-telangiectasia 3
patients 0
homozygous 0
for 0
mutations 0
leading 0
to 0
premature 0
protein 0
termination 0
. 0

Exposure 0
of 0
normal 0
human 0
cells 0
to 0
gamma-irradiation 0
and 0
the 0
radiomimetic 0
drug 0
neocarzinostatin 0
had 0
no 0
effect 0
on 0
ATM 0
protein 0
levels 0
, 0
in 0
contrast 0
to 0
a 0
noted 0
rise 0
in 0
p53 0
levels 0
over 0
the 0
same 0
time 0
interval 0
. 0

These 0
findings 0
are 0
consistent 0
with 0
a 0
role 0
for 0
the 0
ATM 0
protein 0
in 0
ensuring 0
the 0
fidelity 0
of 0
DNA 0
repair 0
and 0
cell 0
cycle 0
regulation 0
following 0
genome 0
damage 0
. 0

Type 0
III 0
collagen 0
is 0
crucial 0
for 0
collagen 0
I 0
fibrillogenesis 0
and 0
for 0
normal 0
cardiovascular 0
development 0
. 0

Type 0
III 0
collagen 0
is 0
a 0
fibrillar 0
forming 0
collagen 0
comprising 0
three 0
alpha1 0
( 0
III 0
) 0
chains 0
and 0
is 0
expressed 0
in 0
early 0
embryos 0
and 0
throughout 0
embryogenesis 0
. 0

In 0
the 0
adult 0
, 0
type 0
III 0
collagen 0
is 0
a 0
major 0
component 0
of 0
the 0
extracellular 0
matrix 0
in 0
a 0
variety 0
of 0
internal 0
organs 0
and 0
skin 0
. 0

Mutations 0
in 0
the 0
COL3A1 0
gene 0
have 0
been 0
implicated 0
as 0
a 0
cause 0
of 0
type 2
IV 2
Ehlers-Danlos 2
syndrome 2
, 0
a 0
disease 0
leading 0
to 0
aortic 0
rupture 0
in 0
early 0
adult 0
life 0
. 0

To 0
directly 0
study 0
the 0
role 0
of 0
Col3a1 0
in 0
development 0
and 0
disease 0
, 0
we 0
have 0
inactivated 0
the 0
Col3a1 0
gene 0
in 0
embryonic 0
stem 0
cells 0
by 0
homologous 0
recombination 0
. 0

The 0
mutated 0
allele 0
was 0
transmitted 0
through 0
the 0
mouse 0
germ 0
line 0
and 0
homozygous 0
mutant 0
animals 0
were 0
derived 0
from 0
heterozygous 0
intercrosses 0
. 0

About 0
10 0
% 0
of 0
the 0
homozygous 0
mutant 0
animals 0
survived 0
to 0
adulthood 0
but 0
have 0
a 0
much 0
shorter 0
life 0
span 0
compared 0
with 0
wild-type 0
mice 0
. 0

The 0
major 0
cause 0
of 0
death 0
of 0
mutant 0
mice 0
was 0
rupture 0
of 0
the 0
major 0
blood 0
vessels 0
, 0
similar 0
to 0
patients 0
with 0
type 2
IV 2
Ehlers-Danlos 2
syndrome 2
. 0

Ultrastructural 0
analysis 0
of 0
tissues 0
from 0
mutant 0
mice 0
revealed 0
that 0
type 0
III 0
collagen 0
is 0
essential 0
for 0
normal 0
collagen 0
I 0
fibrillogenesis 0
in 0
the 0
cardiovascular 0
system 0
and 0
other 0
organs 0
. 0

Nonsense 0
mutation 0
in 0
exon 0
3 0
of 0
the 0
proteolipid 0
protein 0
gene 0
( 0
PLP 0
) 0
in 0
a 0
family 0
with 0
an 0
unusual 0
form 0
of 0
Pelizaeus-Merzbacher 2
disease 2
. 0

We 0
report 0
a 0
G 0
-- 0
A 0
transition 0
at 0
nucleotide 0
431 0
of 0
the 0
proteolipid 0
protein 0
gene 0
( 0
PLP 0
) 0
results 0
in 0
a 0
nonsense 0
codon 0
in 0
a 0
family 0
with 0
an 0
unusual 0
form 0
of 0
Pelizaeus-Merzbacher 2
disease 2
( 0
PMD 2
) 0
. 0

The 0
mutation 0
, 0
which 0
creates 0
a 0
second 0
AluI 0
restriction 0
site 0
, 0
results 0
in 0
a 0
nonsense 0
mutation 0
in 0
PLP 0
. 0

The 0
clinical 0
picture 0
resembles 0
somewhat 0
that 0
of 0
X-linked 2
spastic 2
paraplegia 2
( 0
SPG 2
) 0
. 0

It 0
differs 0
from 0
this 0
and 0
both 0
the 0
classical 0
and 0
connatal 0
forms 0
of 0
PMD 2
in 0
that 0
it 0
is 0
relatively 0
mild 0
in 0
form 0
, 0
onset 0
is 0
delayed 0
beyond 0
age 0
2 0
years 0
, 0
nystagmus 4
is 0
absent 0
, 0
tremors 4
are 0
prominent 0
, 0
mental 4
retardation 4
is 0
not 0
severe 0
, 0
some 0
patients 0
show 0
dementia 4
or 0
personality 4
disorders 4
, 0
the 0
disease 0
is 0
progressive 0
rather 0
than 0
static 0
in 0
some 0
, 0
and 0
several 0
females 0
show 0
signs 0
of 0
disease 0
. 0

The 0
nonsense 0
mutation 0
, 0
which 0
is 0
in 0
exon 0
3B 0
, 0
should 0
block 0
the 0
synthesis 0
of 0
normal 0
PLP 0
but 0
spare 0
DM20 0
, 0
the 0
isoform 0
whose 0
persistence 0
has 0
been 0
associated 0
with 0
mild 0
forms 0
of 0
PLP-associated 4
disease 4
in 0
both 0
humans 0
and 0
mice 0
. 0

Common 0
BRCA1 0
variants 0
and 0
susceptibility 0
to 0
breast 1
and 1
ovarian 1
cancer 1
in 0
the 0
general 0
population 0
. 0

Most 0
multiple 0
case 0
families 0
of 0
young 0
onset 0
breast 2
cancer 2
and 0
ovarian 2
cancer 2
are 0
thought 0
to 0
be 0
due 0
to 0
highly 0
penetrant 0
mutations 0
in 0
the 0
predisposing 0
genes 0
BRCA1 0
and 0
BRCA2 0
. 0

However 0
, 0
these 0
mutations 0
are 0
uncommon 0
in 0
the 0
population 0
and 0
they 0
probably 0
account 0
for 0
only 0
a 0
few 0
percent 0
of 0
all 0
breast 3
cancer 3
incidence 0
. 0

A 0
much 0
larger 0
fraction 0
of 0
breast 2
cancer 2
might 0
, 0
in 0
principle 0
, 0
be 0
due 0
to 0
common 0
variants 0
which 0
confer 0
more 0
modest 0
individual 0
risks 0
. 0

There 0
are 0
several 0
common 0
polymorphisms 0
in 0
the 0
BRCA1 0
gene 0
which 0
generate 0
amino 0
acid 0
substitutions 0
. 0

We 0
have 0
examined 0
the 0
frequency 0
of 0
four 0
of 0
these 0
polymorphisms 0
Gln356Arg 0
, 0
Pro871Leu 0
, 0
Glu1038Gly 0
and 0
Ser1613Gly 0
in 0
large 0
series 0
of 0
breast 1
and 1
ovarian 1
cancer 1
cases 0
and 0
matched 0
controls 0
. 0

Due 0
to 0
strong 0
linkage 0
disequilibrium 0
, 0
these 0
four 0
sites 0
generate 0
only 0
three 0
haplotypes 0
with 0
a 0
frequency 0
1 0
. 0

3 0
% 0
. 0

The 0
most 0
common 0
haplotypes 0
, 0
defined 0
by 0
the 0
alleles 0
Gln356Pro871Glu1038Ser1613 0
and 0
Gln356Leu871Gly1038Gly1613 0
, 0
have 0
frequencies 0
of 0
0 0
. 0

57 0
and 0
0 0
. 0

32 0
respectively 0
, 0
and 0
these 0
frequencies 0
do 0
not 0
differ 0
significantly 0
between 0
patient 0
and 0
control 0
groups 0
. 0

Thus 0
the 0
most 0
common 0
polymorphisms 0
of 0
the 0
BRCA1 0
gene 0
do 0
not 0
make 0
a 0
significant 0
contribution 0
to 0
breast 3
or 3
ovarian 3
cancer 3
risk 0
. 0

However 0
, 0
our 0
data 0
suggest 0
that 0
the 0
Arg356 0
allele 0
may 0
have 0
a 0
different 0
genotype 0
distribution 0
in 0
breast 3
cancer 3
patients 0
from 0
that 0
in 0
controls 0
( 0
Arg356 0
homozygotes 0
are 0
more 0
frequent 0
in 0
the 0
control 0
groups 0
, 0
P 0
= 0
0 0
. 0

01 0
) 0
, 0
indicating 0
that 0
it 0
may 0
be 0
protective 0
against 0
breast 2
cancer 2
. 0

If 0
this 0
finding 0
can 0
be 0
confirmed 0
, 0
it 0
may 0
provide 0
an 0
insight 0
into 0
the 0
structural 0
features 0
of 0
the 0
BRCA1 0
protein 0
that 0
are 0
important 0
for 0
its 0
function 0
. 0

Kniest 2
dysplasia 2
: 0
Dr. 0
W. 0
Kniest 0
, 0
his 0
patient 0
, 0
the 0
molecular 0
defect 0
. 0

Kniest 2
dysplasia 2
is 0
a 0
severe 0
chondrodysplasia 4
caused 0
by 0
the 0
defective 4
formation 4
of 4
type 4
II 4
collagen 4
. 0

We 0
report 0
about 0
Dr 0
. 0

Kniest 0
, 0
who 0
first 0
described 0
the 0
condition 0
in 0
1952 0
, 0
and 0
his 0
patient 0
, 0
who 0
, 0
at 0
the 0
age 0
of 0
50 0
years 0
is 0
severely 4
handicapped 4
with 0
short 4
stature 4
, 0
restricted 4
joint 4
mobility 4
, 0
and 0
blindness 4
but 0
is 0
mentally 0
alert 0
and 0
leads 0
an 0
active 0
life 0
. 0

Molecular 0
analysis 0
of 0
the 0
patients 0
DNA 0
showed 0
a 0
single 0
base 0
( 0
G 0
) 0
deletion 0
involving 0
the 0
GT 0
dinucleotide 0
at 0
the 0
start 0
of 0
intron 0
18 0
destroying 0
a 0
splice 0
site 0
of 0
the 0
COL2A1 0
gene 0
. 0

This 0
is 0
in 0
accordance 0
with 0
molecular 0
findings 0
in 0
other 0
patients 0
with 0
Kniest 2
dysplasia 2
and 0
confirms 0
, 0
in 0
the 0
original 0
patient 0
, 0
that 0
the 0
disorder 0
is 0
caused 0
by 0
small 0
inframe 0
deletions 0
often 0
due 0
to 0
exon 0
skipping 0
as 0
a 0
result 0
of 0
COL2A1 0
splice 0
site 0
mutations 0
. 0

Cloning 0
of 0
the 0
homogentisate 0
1,2-dioxygenase 0
gene 0
, 0
the 0
key 0
enzyme 0
of 0
alkaptonuria 2
in 0
mouse 0
. 0

We 0
determined 0
48 0
amino 0
acid 0
residues 0
from 0
five 0
peptides 0
from 0
the 0
homogeneous 0
monomer 0
of 0
homogentisate 0
1 0
, 0
2-dioxygenase 0
( 0
HGO 0
; 0
E 0
. 0

C 0
. 0

1 0
. 0

13 0
. 0

11 0
. 0

15 0
) 0
of 0
mouse 0
liver 0
. 0

After 0
digestion 0
with 0
trypsin 0
, 0
peptides 0
were 0
separated 0
by 0
reversed 0
phase 0
chromatography 0
and 0
amino 0
acid 0
sequenced 0
. 0

The 0
deduced 0
codon 0
sequence 0
of 0
three 0
peptides 0
was 0
used 0
to 0
derive 0
degenerated 0
oligomeres 0
. 0

By 0
combining 0
these 0
oligos 0
, 0
we 0
were 0
able 0
to 0
amplify 0
fragments 0
from 0
100 0
to 0
300 0
bases 0
( 0
b 0
) 0
from 0
mouse 0
liver 0
cDNA 0
by 0
polymerase 0
chain 0
reaction 0
after 0
reverse 0
transcription 0
( 0
RT-PCR 0
) 0
. 0

A 0
fragment 0
of 0
200 0
b 0
was 0
cloned 0
and 0
used 0
as 0
a 0
probe 0
to 0
screen 0
a 0
mouse 0
liver 0
cDNA 0
library 0
. 0

One 0
clone 0
from 0
this 0
library 0
contained 0
the 0
complete 0
cDNA-insert 0
for 0
HGO 0
as 0
determined 0
by 0
sequencing 0
. 0

The 0
cDNA 0
encodes 0
for 0
a 0
protein 0
of 0
50 0
kDa 0
, 0
as 0
predicted 0
. 0

The 0
cDNA 0
of 0
mouse 0
HGO 0
has 0
an 0
overall 0
identity 0
of 0
41 0
% 0
to 0
the 0
corresponding 0
gene 0
hmgA 0
from 0
Aspergillus 0
. 0

Sequence 0
similarities 0
to 0
human 0
expressed 0
sequence 0
tags 0
( 0
EST 0
) 0
clones 0
ranged 0
from 0
70 0
% 0
to 0
20 0
% 0
. 0

The 0
positions 0
of 0
122 0
conserved 0
amino 0
acids 0
could 0
be 0
determined 0
by 0
multiple 0
sequence 0
alignment 0
. 0

We 0
identified 0
one 0
first 0
intron 0
of 0
928 0
b 0
in 0
the 0
mouse 0
gene 0
. 0

The 0
gene 0
for 0
HGO 0
seems 0
to 0
be 0
expressed 0
in 0
various 0
tissues 0
, 0
as 0
shown 0
by 0
RT-PCR 0
on 0
different 0
cDNAs 0
. 0

FISH 0
experiments 0
with 0
the 0
whole 0
murine 0
cDNA 0
as 0
probe 0
clearly 0
revealed 0
signals 0
at 0
the 0
human 0
chromosomal 0
band 0
3q13 0
. 0

3-q21 0
. 0

This 0
corresponds 0
well 0
to 0
the 0
previous 0
assignment 0
of 0
the 0
locus 0
for 0
the 0
human 0
alkaptonuria 3
gene 0
( 0
AKU 0
) 0
to 0
the 0
same 0
chromosomal 0
region 0
by 0
multipoint 0
linkage 0
analysis 0
. 0

We 0
therefore 0
conclude 0
that 0
the 0
HGO 0
cDNA 0
encodes 0
the 0
gene 0
responsible 0
for 0
alkaptonuria 2
. 0

PTEN 0
, 0
a 0
putative 0
protein 0
tyrosine 0
phosphatase 0
gene 0
mutated 0
in 0
human 0
brain 1
, 1
breast 1
, 1
and 1
prostate 1
cancer 1
. 0

Mapping 0
of 0
homozygous 0
deletions 0
on 0
human 0
chromosome 0
10q23 0
has 0
led 0
to 0
the 0
isolation 0
of 0
a 0
candidate 0
tumor 3
suppressor 0
gene 0
, 0
PTEN 0
, 0
that 0
appears 0
to 0
be 0
mutated 0
at 0
considerable 0
frequency 0
in 0
human 0
cancers 4
. 0

In 0
preliminary 0
screens 0
, 0
mutations 0
of 0
PTEN 0
were 0
detected 0
in 0
31 0
% 0
( 0
13 0
/ 0
42 0
) 0
of 0
glioblastoma 3
cell 0
lines 0
and 0
xenografts 0
, 0
100 0
% 0
( 0
4 0
/ 0
4 0
) 0
of 0
prostate 3
cancer 3
cell 0
lines 0
, 0
6 0
% 0
( 0
4 0
/ 0
65 0
) 0
of 0
breast 3
cancer 3
cell 0
lines 0
and 0
xenografts 0
, 0
and 0
17 0
% 0
( 0
3 0
/ 0
18 0
) 0
of 0
primary 2
glioblastomas 2
. 0

The 0
predicted 0
PTEN 0
product 0
has 0
a 0
protein 0
tyrosine 0
phosphatase 0
domain 0
and 0
extensive 0
homology 0
to 0
tensin 0
, 0
a 0
protein 0
that 0
interacts 0
with 0
actin 0
filaments 0
at 0
focal 0
adhesions 0
. 0

These 0
homologies 0
suggest 0
that 0
PTEN 0
may 0
suppress 0
tumor 3
cell 0
growth 0
by 0
antagonizing 0
protein 0
tyrosine 0
kinases 0
and 0
may 0
regulate 0
tumor 3
cell 0
invasion 0
and 0
metastasis 4
through 0
interactions 0
at 0
focal 0
adhesions 0
. 0

Heterogeneity 0
in 0
Schwartz-Jampel 2
chondrodystrophic 2
myotonia 2
. 0

The 0
Schwartz-Jampel 2
syndrome 2
( 0
SJS 2
; 0
chondrodystrophic 2
myotonia 2
; 0
McK 0
255 0
, 0
800 0
) 0
is 0
a 0
recessively 4
inherited 4
condition 4
defined 0
by 0
myotonia 4
, 0
short 4
stature 4
, 0
and 0
bone 4
dysplasia 4
. 0

Genetic 0
linkage 0
between 0
SJS 2
and 0
chromosomal 0
region 0
1q36-34 0
has 0
been 0
observed 0
in 0
several 0
families 0
, 0
but 0
the 0
gene 0
has 0
not 0
yet 0
been 0
identified 0
. 0

We 0
studied 0
the 0
clinical 0
and 0
radiological 0
features 0
in 0
81 0
patients 0
from 0
the 0
literature 0
and 0
5 0
own 0
patients 0
trying 0
to 0
identify 0
distinct 0
subgroups 0
. 0

In 0
addition 0
, 0
we 0
tested 0
genetic 0
linkage 0
to 0
the 0
SJS 3
locus 0
on 0
chromosome 0
1 0
in 0
one 0
family 0
with 0
two 0
affected 0
sibs 0
. 0

We 0
found 0
that 0
a 0
group 0
of 0
patients 0
have 0
mild 0
skeletal 0
changes 0
which 0
may 0
be 0
secondary 0
consequences 0
of 0
myotonia 4
, 0
while 0
another 0
group 0
of 0
patients 0
appear 0
to 0
have 0
primary 0
bone 4
dysplasia 4
with 0
myotonia 4
. 0

Within 0
this 0
latter 0
group 0
, 0
there 0
are 0
differences 0
in 0
age 0
of 0
manifestation 0
, 0
clinical 0
course 0
and 0
pattern 0
of 0
bone 0
changes 0
. 0

We 0
tentatively 0
isolate 0
three 0
different 0
types 0
of 0
SJS 2
type 2
1A 2
, 0
usually 0
recognized 0
in 0
childhood 0
, 0
with 0
moderate 0
bone 4
dysplasia 4
, 0
corresponding 0
to 0
the 0
original 0
descriptions 0
of 0
Schwartz 0
, 0
Jampel 0
and 0
Aberfeld 0
; 0
type 0
1B 0
, 0
similar 0
to 0
type 0
1A 0
but 0
recognizable 0
at 0
birth 0
, 0
with 0
more 0
pronounced 0
bone 4
dysplasia 4
resembling 0
Kniest 2
dysplasia 2
; 0
and 0
type 0
2 0
, 0
manifest 0
at 0
birth 0
, 0
with 0
increased 0
mortality 0
and 0
bone 4
dysplasia 4
resembling 0
Pyle 2
disease 2
. 0

Genetic 0
analysis 0
of 0
the 0
family 0
with 0
two 0
sibs 0
affected 0
by 0
SJS 2
type 2
2 2
showed 0
evidence 0
against 0
linkage 0
to 0
chromosome 0
1p36-34 0
. 0

CONCLUSIONS 0
SJS 2
is 0
clinically 0
and 0
radiologically 0
heterogeneous 0
. 0

The 0
causes 0
of 0
heterogeneity 0
are 0
not 0
known 0
yet 0
but 0
are 0
likely 0
to 0
include 0
both 0
different 0
mutations 0
at 0
the 0
SJS 3
locus 0
on 0
chromosome 0
1 0
and 0
the 0
presence 0
of 0
a 0
second 0
SJS 3
locus 0
. 0

A 0
tentative 0
clinico-radiological 0
classification 0
can 0
be 0
useful 0
for 0
the 0
characterization 0
of 0
patients 0
and 0
the 0
development 0
of 0
genotype-phenotype 0
correlations 0
. 0

A 0
clinical 0
overview 0
of 0
WT1 0
gene 0
mutations 0
. 0

Mutations 0
in 0
the 0
WT1 0
gene 0
were 0
anticipated 0
to 0
explain 0
the 0
genetic 0
basis 0
of 0
the 0
childhood 0
kidney 2
cancer 2
, 0
Wilms 2
tumour 2
( 0
WT 2
) 0
. 0

Six 0
years 0
on 0
, 0
we 0
review 0
100 0
reports 0
of 0
intragenic 0
WT1 0
mutations 0
and 0
examine 0
the 0
accompanying 0
clinical 0
phenotypes 0
. 0

While 0
only 0
5 0
% 0
of 0
sporadic 2
Wilms 2
tumours 2
have 0
intragenic 0
WT1 0
mutations 0
, 0
90 0
% 0
of 0
patients 0
with 0
the 0
Denys-Drash 2
syndrome 2
( 0
renal 4
nephropathy 4
, 0
gonadal 4
anomaly 4
, 0
predisposition 4
to 4
WT 4
) 0
carry 0
constitutional 0
intragenic 0
WT1 0
mutations 0
. 0

WT1 0
mutations 0
have 0
also 0
been 0
reported 0
in 0
juvenile 2
granulosa 2
cell 2
tumour 2
, 0
non-asbestos 2
related 2
mesothelioma 2
, 0
desmoplastic 2
small 2
round 2
cell 2
tumour 2
and 0
, 0
most 0
recently 0
, 0
acute 2
myeloid 2
leukemia 2
. 0

A 0
mutation 0
in 0
autosomal 2
dominant 2
myotonia 2
congenita 2
affects 0
pore 0
properties 0
of 0
the 0
muscle 0
chloride 0
channel 0
. 0

Autosomal 2
dominant 2
myotonia 2
congenita 2
is 0
an 0
inherited 4
disorder 4
of 4
skeletal 4
muscle 4
caused 0
by 0
mutations 0
in 0
a 0
voltage-gated 0
Cl- 0
channel 0
gene 0
( 0
CLCN1 0
, 0
7q35 0
) 0
. 0

Here 0
, 0
we 0
report 0
that 0
a 0
mutation 0
predicting 0
the 0
substitution 0
of 0
Gly 0
230 0
by 0
glutamic 0
acid 0
( 0
G230E 0
) 0
between 0
segments 0
D3 0
and 0
D4 0
dramatically 0
alters 0
the 0
pore 0
properties 0
of 0
a 0
recombinant 0
human 0
muscle 0
Cl- 0
channel 0
( 0
hCIC-1 0
) 0
expressed 0
in 0
a 0
mammalian 0
cell 0
line 0
( 0
tsA201 0
) 0
. 0

The 0
G230E 0
mutation 0
causes 0
substantial 0
changes 0
in 0
anion 0
and 0
cation 0
selectivity 0
as 0
well 0
as 0
a 0
fundamental 0
change 0
in 0
rectification 0
of 0
the 0
current-voltage 0
relationship 0
. 0

Whereas 0
wild-type 0
channels 0
are 0
characterized 0
by 0
pronounced 0
inward 0
rectification 0
and 0
a 0
Cl 0
thiocyanate 0
Br 0
NO 0
( 0
3 0
) 0
I 0
CH 0
( 0
3 0
) 0
SO 0
( 0
3 0
) 0
selectivity 0
, 0
G230E 0
exhibits 0
outward 0
rectification 0
at 0
positive 0
potentials 0
and 0
a 0
thiocyanate 0
NO 0
( 0
3 0
) 0
I 0
Br 0
Cl 0
CH 0
( 0
3 0
) 0
SO 0
( 0
3 0
) 0
selectivity 0
. 0

Furthermore 0
, 0
the 0
cation-to-anion 0
permeability 0
ratio 0
of 0
the 0
mutant 0
is 0
much 0
greater 0
than 0
that 0
of 0
the 0
wild-type 0
channel 0
. 0

Voltage-dependent 0
blocks 0
by 0
intracellular 0
and 0
extracellular 0
iodide 0
help 0
to 0
distinguish 0
two 0
distinct 0
ion 0
binding 0
sites 0
within 0
the 0
hClC-1 0
conduction 0
pathway 0
. 0

Both 0
binding 0
sites 0
are 0
preserved 0
in 0
the 0
mutant 0
but 0
have 0
decreased 0
affinities 0
for 0
iodide 0
. 0

These 0
findings 0
suggest 0
that 0
Gly 0
230 0
is 0
critical 0
for 0
normal 0
ion 0
conductance 0
in 0
hClC-1 0
and 0
that 0
this 0
residue 0
resides 0
within 0
the 0
channel 0
pore 0
. 0

The 0
incidence 0
of 0
PAX6 0
mutation 0
in 0
patients 0
with 0
simple 0
aniridia 2
: 0
an 0
evaluation 0
of 0
mutation 0
detection 0
in 0
12 0
cases 0
. 0

Twelve 0
aniridia 3
patients 0
, 0
five 0
with 0
a 0
family 0
history 0
and 0
seven 0
presumed 0
to 0
be 0
sporadic 0
, 0
were 0
exhaustively 0
screened 0
in 0
order 0
to 0
test 0
what 0
proportion 0
of 0
people 0
with 0
aniridia 2
, 0
uncomplicated 0
by 0
associated 0
anomalies 0
, 0
carry 0
mutations 0
in 0
the 0
human 0
PAX6 0
gene 0
. 0

Mutations 0
were 0
detected 0
in 0
90 0
% 0
of 0
the 0
cases 0
. 0

Three 0
mutation 0
detection 0
techniques 0
were 0
used 0
to 0
determine 0
if 0
one 0
method 0
was 0
superior 0
for 0
this 0
gene 0
. 0

The 0
protein 0
truncation 0
test 0
( 0
PTT 0
) 0
was 0
used 0
on 0
RT-PCR 0
products 0
, 0
SSCP 0
on 0
genomic 0
PCR 0
amplifications 0
, 0
and 0
chemical 0
cleavage 0
of 0
mismatch 0
on 0
both 0
RT-PCR 0
and 0
genomic 0
amplifications 0
. 0

For 0
RT-PCR 0
products 0
, 0
only 0
the 0
translated 0
portion 0
of 0
the 0
gene 0
was 0
screened 0
. 0

On 0
genomic 0
products 0
exons 0
1 0
to 0
13 0
( 0
including 0
740 0
bp 0
of 0
the 0
3 0
untranslated 0
sequence 0
and 0
all 0
intron 0
/ 0
exon 0
boundaries 0
) 0
were 0
screened 0
, 0
as 0
was 0
a 0
neuroretina 0
specific 0
enhancer 0
in 0
intron 0
4 0
. 0

Ten 0
of 0
the 0
possible 0
12 0
mutations 0
in 0
the 0
five 0
familial 0
cases 0
and 0
five 0
of 0
the 0
sporadic 0
patients 0
were 0
found 0
, 0
all 0
of 0
which 0
conformed 0
to 0
a 0
functional 0
outcome 0
of 0
haploinsufficiency 0
. 0

Five 0
were 0
splice 0
site 0
mutations 0
( 0
one 0
in 0
the 0
donor 0
site 0
of 0
intron 0
4 0
, 0
two 0
in 0
the 0
donor 0
site 0
of 0
intron 0
6 0
, 0
one 0
in 0
each 0
of 0
the 0
acceptor 0
sites 0
of 0
introns 0
8 0
and 0
9 0
) 0
and 0
five 0
were 0
nonsense 0
mutations 0
in 0
exons 0
8 0
, 0
9 0
, 0
10 0
, 0
11 0
, 0
and 0
12 0
. 0

SSCP 0
analysis 0
of 0
individually 0
amplified 0
exons 0
, 0
with 0
which 0
nine 0
of 0
the 0
10 0
mutations 0
were 0
seen 0
, 0
was 0
the 0
most 0
useful 0
detection 0
method 0
for 0
PAX6 0
. 0

Insulin 0
gene 0
region 0
contributes 0
to 0
genetic 0
susceptibility 0
to 0
, 0
but 0
may 0
not 0
to 0
low 0
incidence 0
of 0
, 0
insulin-dependent 2
diabetes 2
mellitus 2
in 0
Japanese 0
. 0

In 0
the 0
Caucasian 0
population 0
, 0
it 0
has 0
been 0
demonstrated 0
that 0
the 0
insulin 0
gene 0
( 0
INS 0
) 0
region 0
contains 0
the 0
insulin-dependent 3
diabetes 3
mellitus 3
locus 0
( 0
IDDM2 0
) 0
. 0

In 0
the 0
Japanese 0
population 0
, 0
however 0
, 0
there 0
has 0
been 0
no 0
report 0
demonstrating 0
the 0
contribution 0
of 0
IDDM2 0
to 0
the 0
pathogenesis 0
of 0
IDDM 2
. 0

We 0
conducted 0
an 0
association 0
study 0
of 0
IDDM 2
in 0
a 0
large 0
number 0
of 0
Japanese 0
subjects 0
with 0
multiple 0
polymorphisms 0
in 0
INS 0
region 0
. 0

We 0
found 0
a 0
significant 0
association 0
of 0
the 0
INS 0
region 0
with 0
IDDM 2
. 0

Alleles 0
positively 0
associated 0
with 0
IDDM 2
in 0
INS 0
region 0
were 0
the 0
same 0
as 0
those 0
positively-associated 0
with 0
IDDM 2
in 0
Caucasian 0
population 0
, 0
although 0
positively-associated 0
alleles 0
are 0
very 0
common 0
( 0
allele 0
frequencies 0
0 0
. 0

9 0
) 0
in 0
the 0
Japanese 0
general 0
population 0
. 0

These 0
data 0
suggest 0
that 0
IDDM2 0
is 0
involved 0
in 0
the 0
genetic 0
susceptibility 0
to 0
IDDM 2
in 0
Japanese 0
. 0

The 0
high 0
frequencies 0
of 0
disease-associated 0
alleles 0
in 0
the 0
general 0
population 0
suggest 0
that 0
IDDM2 0
locus 0
is 0
not 0
responsible 0
for 0
the 0
low 0
incidence 0
of 0
IDDM 2
in 0
Japanese 0
. 0

The 0
human 0
complement 0
C9 0
gene 0
: 0
identification 0
of 0
two 0
mutations 0
causing 0
deficiency 0
and 0
revision 0
of 0
the 0
gene 0
structure 0
. 0

The 0
ninth 0
component 0
of 0
human 0
complement 0
( 0
C9 0
) 0
is 0
the 0
last 0
of 0
the 0
terminal 0
complement 0
components 0
creating 0
the 0
membrane 0
attack 0
complex 0
. 0

C9 0
is 0
a 0
single-chain 0
serum 0
protein 0
that 0
is 0
encoded 0
by 0
a 0
gene 0
located 0
on 0
chromosome 0
5p 0
. 0

Deficiency 2
of 2
terminal 2
complement 2
components 2
is 0
generally 0
associated 0
with 0
recurrent 0
neisseria 2
infections 2
. 0

We 0
studied 0
a 0
previously 0
described 0
Swiss 0
family 0
with 0
inherited 2
C9 2
deficiency 2
. 0

To 0
identify 0
the 0
genetic 0
basis 0
of 0
C9 2
deficiency 2
, 0
we 0
developed 0
an 0
approach 0
using 0
exon-specific 0
PCR 0
and 0
direct 0
DNA 0
sequencing 0
. 0

As 0
a 0
cause 0
of 0
C9 2
deficiency 2
, 0
we 0
found 0
two 0
different 0
point 0
mutations 0
, 0
both 0
generating 0
TGA 0
stop 0
codons 0
in 0
the 0
coding 0
sequence 0
. 0

One 0
mutation 0
, 0
a 0
C 0
to 0
A 0
exchange 0
, 0
was 0
detected 0
in 0
exon 0
2 0
at 0
cDNA 0
position 0
166 0
, 0
the 0
other 0
, 0
a 0
C 0
to 0
T 0
exchange 0
, 0
was 0
located 0
in 0
exon 0
4 0
( 0
cDNA 0
position 0
464 0
) 0
. 0

In 0
family 0
studies 0
of 0
three 0
first-degree 0
relatives 0
with 0
heterozygous 0
C9 2
deficiency 2
, 0
we 0
demonstrated 0
that 0
the 0
two 0
mutations 0
are 0
segregating 0
independently 0
. 0

Therefore 0
, 0
these 0
mutations 0
are 0
sufficient 0
to 0
explain 0
the 0
complete 0
deficiency 0
of 0
both 0
the 0
probands 0
studied 0
. 0

DNA 0
sequencing 0
of 0
the 0
exon-intron 0
junctions 0
revealed 0
a 0
number 0
of 0
revisions 0
regarding 0
the 0
boundaries 0
between 0
exons 0
4 0
, 0
5 0
, 0
and 0
6 0
as 0
well 0
as 0
between 0
exons 0
10 0
and 0
11 0
. 0

No 0
additional 0
introns 0
were 0
detected 0
in 0
exons 0
6 0
and 0
10 0
. 0

Furthermore 0
, 0
DNA 0
marker 0
studies 0
were 0
conducted 0
using 0
known 0
polymorphisms 0
of 0
the 0
C6 0
, 0
C7 0
, 0
and 0
C9 0
genes 0
, 0
confirming 0
the 0
linkage 0
of 0
the 0
observed 0
C9 0
mutations 0
with 0
defined 0
haplotypes 0
. 0

BRCA1 0
mutations 0
in 0
women 0
attending 0
clinics 0
that 0
evaluate 0
the 0
risk 0
of 0
breast 2
cancer 2
. 0

BACKGROUND 0
To 0
define 0
the 0
incidence 0
of 0
BRCA1 0
mutations 0
among 0
patients 0
seen 0
in 0
clinics 0
that 0
evaluate 0
the 0
risk 0
of 0
breast 2
cancer 2
, 0
we 0
analyzed 0
DNA 0
samples 0
from 0
women 0
seen 0
in 0
this 0
setting 0
and 0
constructed 0
probability 0
tables 0
to 0
provide 0
estimates 0
of 0
the 0
likelihood 0
of 0
finding 0
a 0
BRCA1 0
mutation 0
in 0
individual 0
families 0
. 0

METHODS 0
Clinical 0
information 0
, 0
family 0
histories 0
, 0
and 0
blood 0
for 0
DNA 0
analysis 0
were 0
obtained 0
from 0
263 0
women 0
with 0
breast 2
cancer 2
. 0

Conformation-sensitive 0
gel 0
electrophoresis 0
and 0
DNA 0
sequencing 0
were 0
used 0
to 0
identify 0
BRCA1 0
mutations 0
. 0

RESULTS 0
BRCA1 0
mutations 0
were 0
identified 0
in 0
16 0
percent 0
of 0
women 0
with 0
a 0
family 0
history 0
of 0
breast 2
cancer 2
. 0

Only 0
7 0
percent 0
of 0
women 0
from 0
families 0
with 0
a 0
history 0
of 0
breast 2
cancer 2
but 0
not 0
ovarian 2
cancer 2
had 0
BRCA1 0
mutations 0
. 0

The 0
rates 0
were 0
higher 0
among 0
women 0
from 0
families 0
with 0
a 0
history 0
of 0
both 0
breast 1
and 1
ovarian 1
cancer 1
. 0

Among 0
family 0
members 0
, 0
an 0
average 0
age 0
of 0
less 0
than 0
55 0
years 0
at 0
the 0
diagnosis 0
of 0
breast 2
cancer 2
, 0
the 0
presence 0
of 0
ovarian 2
cancer 2
, 0
the 0
presence 0
of 0
breast 1
and 1
ovarian 1
cancer 1
in 0
the 0
same 0
woman 0
, 0
and 0
Ashkenazi 0
Jewish 0
ancestry 0
were 0
all 0
associated 0
with 0
an 0
increased 0
risk 0
of 0
detecting 0
a 0
BRCA1 0
mutation 0
. 0

No 0
association 0
was 0
found 0
between 0
the 0
presence 0
of 0
bilateral 0
breast 2
cancer 2
or 0
the 0
number 0
of 0
breast 2
cancers 2
in 0
a 0
family 0
and 0
the 0
detection 0
of 0
a 0
BRCA1 0
mutation 0
, 0
or 0
between 0
the 0
position 0
of 0
the 0
mutation 0
in 0
the 0
BRCA1 0
gene 0
and 0
the 0
presence 0
of 0
ovarian 2
cancer 2
in 0
a 0
family 0
. 0

CONCLUSIONS 0
Among 0
women 0
with 0
breast 2
cancer 2
and 0
a 0
family 0
history 0
of 0
the 0
disease 0
, 0
the 0
percentage 0
with 0
BRCA1 0
coding-region 0
mutations 0
is 0
less 0
than 0
the 0
45 0
percent 0
predicted 0
by 0
genetic-linkage 0
analysis 0
. 0

These 0
results 0
suggest 0
that 0
even 0
in 0
a 0
referral 0
clinic 0
specializing 0
in 0
screening 0
women 0
from 0
high-risk 0
families 0
, 0
the 0
majority 0
of 0
tests 0
for 0
BRCA1 0
mutations 0
will 0
be 0
negative 0
and 0
therefore 0
uninformative 0
. 0

Mutations 0
in 0
the 0
arginine-rich 0
protein 0
gene 0
( 0
ARP 0
) 0
in 0
pancreatic 2
cancer 2
. 0

The 0
ARP 0
gene 0
encodes 0
a 0
highly 0
conserved 0
arginine-rich 0
protein 0
from 0
chromosomal 0
band 0
3p21 0
. 0

1 0
1 0
. 0

At 0
the 0
cytogenetic 0
level 0
this 0
region 0
is 0
frequently 0
deleted 0
in 0
a 0
variety 0
of 0
different 0
solid 4
tumors 4
, 0
although 0
not 0
in 0
pancreatic 2
cancer 2
. 0

We 0
have 0
reported 0
the 0
presence 0
of 0
a 0
specific 0
mutation 0
( 0
ATG50 0
-- 0
AGG 0
) 0
or 0
deletion 0
of 0
codon 0
50 0
of 0
the 0
ARP 0
gene 0
in 0
different 0
tumor 4
types 4
( 0
Shridhar 0
et 0
al 0
. 0

, 0
1996 0
, 0
1996a 0
) 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
have 0
observed 0
mutations 0
involving 0
codon 0
50 0
in 0
11 0
of 0
37 0
pancreatic 2
tumors 2
. 0

The 0
frequency 0
of 0
codon 0
50 0
mutation 0
is 0
roughly 0
the 0
same 0
in 0
pancreatic 2
tumors 2
as 0
in 0
the 0
other 0
types 0
of 0
tumors 4
previously 0
examined 0
. 0

In 0
addition 0
, 0
we 0
have 0
detected 0
mutations 0
at 0
codon 0
51 0
in 0
multiple 0
PCR 0
subclones 0
in 0
two 0
other 0
pancreatic 2
tumors 2
. 0

Mutations 0
in 0
the 0
ARP 0
gene 0
are 0
thus 0
commonly 0
observed 0
in 0
pancreatic 2
cancer 2
, 0
as 0
well 0
as 0
many 0
other 0
cancers 4
. 0

Difficulties 0
in 0
the 0
ascertainment 0
of 0
C9 2
deficiency 2
: 0
lessons 0
to 0
be 0
drawn 0
from 0
a 0
compound 0
heterozygote 0
C9-deficient 3
subject 0
. 0

A 0
group 0
of 0
patients 0
with 0
long-surviving 0
mismatched 0
kidney 0
allografts 0
were 0
investigated 0
for 0
complement 0
function 0
using 0
haemolytic 0
assays 0
in 0
agarose 0
gels 0
. 0

One 0
patient 0
was 0
found 0
to 0
have 0
no 0
alternative 0
pathway 0
activity 0
but 0
a 0
low 0
normal 0
classical 0
pathway 0
. 0

Surprisingly 0
, 0
investigation 0
revealed 0
that 0
the 0
patients 0
complement 0
was 0
normal 0
for 0
all 0
components 0
except 0
C9 0
, 0
which 0
was 0
functionally 0
absent 0
. 0

The 0
patient 0
was 0
shown 0
to 0
be 0
heterozygous 0
for 0
DNA 0
markers 0
in 0
the 0
C6 0
, 0
C7 0
and 0
C9 0
region 0
of 0
chromosome 0
5 0
and 0
therefore 0
appears 0
to 0
be 0
a 0
compound 0
heterozygote 0
for 0
two 0
uncharacterized 0
C9 3
deficiency 3
genes 0
. 0

Serological 0
analysis 0
by 0
ELISA 0
revealed 0
that 0
he 0
has 0
trace 0
concentrations 0
of 0
a 0
non-functional 0
C9 0
molecule 0
. 0

Western 0
blot 0
analysis 0
was 0
not 0
sufficiently 0
sensitive 0
to 0
permit 0
detection 0
of 0
this 0
molecule 0
. 0

We 0
hypothesize 0
that 0
the 0
patient 0
is 0
heterozygous 0
for 0
a 0
complete 2
deficiency 2
of 2
C9 2
and 0
for 0
a 0
gene 0
directing 0
hyposynthesis 0
of 0
a 0
defective 0
C9 0
. 0

We 0
also 0
suggest 0
that 0
C9 2
deficiency 2
may 0
be 0
more 0
common 0
among 0
Caucasians 0
than 0
has 0
been 0
reported 0
. 0

Screening 0
for 0
ESR 0
mutations 0
in 0
breast 3
and 3
ovarian 3
cancer 3
patients 0
. 0

In 0
the 0
present 0
study 0
, 0
leukocyte 0
DNA 0
from 0
143 0
patients 0
with 0
familial 0
clustering 0
of 0
breast 1
and 1
/ 1
or 1
ovarian 1
cancer 1
and 0
tumour 3
DNA 0
from 0
96 0
breast 2
carcinomas 2
were 0
screened 0
for 0
base 0
mutations 0
in 0
the 0
estrogen 0
receptor 0
gene 0
( 0
ESR 0
) 0
. 0

Three 0
patients 0
with 0
a 0
family 0
history 0
of 0
cancer 4
were 0
carrying 0
a 0
Gly160Cys 0
germline 0
substitution 0
. 0

This 0
alteration 0
was 0
also 0
detected 0
in 0
eight 0
( 0
four 0
females 0
and 0
four 0
males 0
) 0
of 0
729 0
controls 0
( 0
366 0
female 0
, 0
363 0
males 0
) 0
, 0
indicating 0
that 0
the 0
substitution 0
probably 0
represents 0
a 0
polymorphism 0
. 0

However 0
, 0
in 0
the 0
229 0
female 0
controls 0
in 0
whom 0
family 0
history 0
of 0
cancer 4
was 0
known 0
, 0
one 0
of 0
two 0
who 0
had 0
a 0
sister 0
with 0
breast 2
cancer 2
was 0
carrying 0
the 0
variant 0
allele 0
. 0

Hence 0
, 0
a 0
possible 0
clinical 0
significance 0
of 0
the 0
glycine 0
into 0
cysteine 0
can 0
not 0
be 0
completely 0
ruled 0
out 0
and 0
should 0
be 0
further 0
investigated 0
. 0

Somatic 0
mutations 0
were 0
not 0
detected 0
in 0
any 0
of 0
the 0
tumours 4
studied 0
, 0
and 0
the 0
present 0
data 0
do 0
not 0
provide 0
support 0
for 0
somatic 0
ESR 0
base 0
mutations 0
as 0
an 0
important 0
mechanism 0
for 0
hormonal 0
therapy 0
resistance 0
in 0
estrogen 2
receptor-positive 2
breast 2
carcinomas 2
. 0

Molecular 0
bases 0
of 0
C7 2
deficiency 2
: 0
three 0
different 0
defects 0
. 0

The 0
molecular 0
basis 0
of 0
C7 2
deficiency 2
has 0
been 0
investigated 0
in 0
two 0
Irish 0
families 0
and 0
a 0
number 0
of 0
Israeli 0
families 0
of 0
Moroccan 0
Sephardic 0
Jewish 0
origin 0
. 0

Exon 0
PCR 0
and 0
sequencing 0
revealed 0
a 0
heterozygous 0
point 0
mutation 0
at 0
the 0
3 0
splice 0
acceptor 0
site 0
of 0
intron 0
1 0
in 0
one 0
Irish 0
family 0
. 0

In 0
the 0
other 0
Irish 0
family 0
, 0
exons 0
7 0
and 0
8 0
failed 0
to 0
amplify 0
and 0
they 0
were 0
shown 0
to 0
be 0
deleted 0
. 0

Marker 0
haplotype 0
studies 0
of 0
the 0
C6 0
and 0
C7 0
gene 0
region 0
and 0
Southern 0
blots 0
show 0
that 0
the 0
Irish 0
family 0
with 0
the 0
splice 0
defect 0
also 0
segregate 0
for 0
the 0
deletion 0
, 0
which 0
is 0
not 0
easily 0
detected 0
in 0
heterozygotes 0
. 0

The 0
Israeli 0
C7-deficient 3
cases 0
all 0
share 0
a 0
C7 0
haplotype 0
and 0
are 0
homozygous 0
for 0
a 0
mis-sense 0
mutation 0
in 0
exon 0
9 0
. 0

However 0
, 0
one 0
individual 0
is 0
heterozygous 0
for 0
markers 0
at 0
adjacent 0
C6 0
loci 0
, 0
showing 0
that 0
there 0
has 0
been 0
an 0
intergenic 0
recombination 0
and 0
suggesting 0
that 0
the 0
deficiency 0
mutation 0
is 0
of 0
appreciable 0
antiquity 0
. 0

Molecular 0
heterogeneity 0
of 0
classical 1
and 1
Duarte 1
galactosemia 1
: 0
mutation 0
analysis 0
by 0
denaturing 0
gradient 0
gel 0
electrophoresis 0
. 0

Classical 2
galactosemia 2
is 0
caused 0
by 0
one 0
common 0
missense 0
mutation 0
( 0
Q188R 0
) 0
and 0
by 0
several 0
rare 0
mutations 0
in 0
the 0
galactose-1-phosphate 0
uridyltransferase 0
( 0
GALT 0
) 0
gene 0
. 0

The 0
most 0
common 0
variant 0
of 0
GALT 0
, 0
the 0
Duarte 0
variant 0
, 0
occurs 0
as 0
two 0
types 0
, 0
Duarte-1 0
( 0
D-1 0
) 0
and 0
Duarte-2 0
( 0
D-2 0
) 0
, 0
both 0
of 0
which 0
carry 0
the 0
sequence 0
change 0
N314D 0
. 0

D-1 0
increases 0
, 0
whereas 0
D-2 0
decreases 0
GALT 0
activity 0
. 0

To 0
study 0
the 0
molecular 0
genetics 0
of 0
classical 1
and 1
CompositeMention 0
Duarte 0
galactosemia 0
, 0
we 0
analyzed 0
the 0
GALT 0
mutations 0
in 0
30 0
families 0
with 0
category= 0
classical 0
galactosemia 0
< 2
, 2
in 2
10 0
families 0
with 0
the 0
D-2 0
variant 0
and 0
in 0
3 0
individuals 0
carrying 0
the 0
D-1 0
allele 0
by 0
denaturing 0
gradient 0
gel 0
electrophoresis 0
( 0
DGGE 0
) 0
. 0

DGGE 0
detected 0
59 0
of 0
the 0
60 0
classical 0
galactosemia 3
alleles 0
. 0

Q188R 0
accounted 0
for 0
60 0
% 0
, 0
K285N 0
accounted 0
for 0
28 0
% 0
of 0
these 0
alleles 0
. 0

Eight 0
novel 0
candidate 0
galactosemia 3
mutations 0
were 0
found 0
. 0

On 0
all 0
D-2 0
alleles 0
N314D 0
occurred 0
in 0
cis 0
with 0
two 0
intronic 0
sequence 0
changes 0
, 0
on 0
the 0
D-1 0
alleles 0
in 0
cis 0
with 0
a 0
neutral 0
mutation 0
in 0
exon 0
7 0
. 0

We 0
conclude 0
that 0
the 0
mutations 0
causing 0
galactosemia 2
are 0
highly 0
heterogeneous 0
and 0
that 0
K285N 0
is 0
a 0
second 0
common 0
galactosemia 3
mutation 0
in 0
our 0
population 0
. 0

Isolation 0
of 0
full-length 0
ATM 0
cDNA 0
and 0
correction 0
of 0
the 0
ataxia-telangiectasia 3
cellular 0
phenotype 0
. 0

A 0
gene 0
mutated 0
in 0
the 0
human 0
genetic 4
disorder 4
ataxia-telangiectasia 0
( 0
category= 0
SpecificDisease 0
A-T 0
< 0
) 2
, 2
ATM 0
, 0
was 0
recently 0
identified 0
by 0
positional 0
cloning 0
. 0

ATM 0
is 0
a 0
member 0
of 0
the 0
phosphatidylinositol-3-kinase 0
superfamily 0
, 0
some 0
of 0
which 0
are 0
protein 0
kinases 0
and 0
appear 0
to 0
have 0
important 0
roles 0
in 0
cell 0
cycle 0
control 0
and 0
radiation 0
signal 0
transduction 0
. 0

We 0
describe 0
herein 0
, 0
to 0
our 0
knowledge 0
, 0
for 0
the 0
first 0
time 0
, 0
the 0
cloning 0
of 0
a 0
full-length 0
cDNA 0
for 0
ATM 0
and 0
correction 0
of 0
multiple 0
aspects 0
of 0
the 0
radio-sensitive 0
phenotype 0
of 0
A-T 3
cells 0
by 0
transfection 0
with 0
this 0
cDNA 0
. 0

Overexpression 0
of 0
ATM 0
cDNA 0
in 0
A-T 3
cells 0
enhanced 0
the 0
survival 0
of 0
these 0
cells 0
in 0
response 0
to 0
radiation 0
exposure 0
, 0
decreased 0
radiation-induced 0
chromosome 0
aberrations 0
, 0
reduced 0
radio-resistant 0
DNA 0
synthesis 0
, 0
and 0
partially 0
corrected 0
defective 0
cell 0
cycle 0
checkpoints 0
and 0
induction 0
of 0
stress-activated 0
protein 0
kinase 0
. 0

This 0
correction 0
of 0
the 0
defects 0
in 0
A-T 3
cells 0
provides 0
further 0
evidence 0
of 0
the 0
multiplicity 0
of 0
effector 0
functions 0
of 0
the 0
ATM 0
protein 0
and 0
suggests 0
possible 0
approaches 0
to 0
gene 0
therapy 0
. 0

Fusion 0
genes 0
resulting 0
from 0
alternative 0
chromosomal 0
translocations 0
are 0
overexpressed 0
by 0
gene-specific 0
mechanisms 0
in 0
alveolar 2
rhabdomyosarcoma 2
. 0

Chromosomal 0
translocations 0
identified 0
in 0
hematopoietic 1
and 1
solid 1
tumors 1
result 0
in 0
deregulated 0
expression 0
of 0
protooncogenes 0
or 0
creation 0
of 0
chimeric 0
proteins 0
with 0
tumorigenic 0
potential 0
. 0

In 0
the 0
pediatric 0
solid 4
tumor 4
category= 0
SpecificDisease 0
alveolar 0
rhabdomyosarcoma 0
< 0
, 0
a 0
consistent 0
t 0
( 0
2 0
; 0
13 0
) 0
( 0
q35 0
; 0
q14 0
) 0
or 0
variant 0
t 0
( 0
1 0
; 0
13 0
) 0
( 0
p36 0
; 0
q14 0
) 0
translocation 0
generates 0
PAX3-FKHR 0
or 0
PAX7-FKHR 0
fusion 0
proteins 0
, 0
respectively 0
. 0

In 0
this 0
report 0
, 0
we 0
demonstrate 0
that 0
in 0
addition 0
to 0
functional 0
alterations 0
these 0
translocations 0
are 0
associated 0
with 0
fusion 0
product 0
overexpression 0
. 0

Furthermore 0
, 0
PAX3-FKHR 0
and 0
PAX7-FKHR 0
overexpression 0
occurs 0
by 0
distinct 0
mechanisms 0
. 0

Transcription 0
of 0
PAX3-FKHR 0
is 0
increased 0
relative 0
to 0
wild-type 0
PAX3 0
by 0
a 0
copy 0
number-independent 0
process 0
. 0

In 0
contrast 0
, 0
PAX7-FKHR 0
overexpression 0
results 0
from 0
fusion 0
gene 0
amplification 0
. 0

Thus 0
, 0
gene-specific 0
mechanisms 0
were 0
selected 0
to 0
overexpress 0
PAX3-FKHR 0
and 0
PAX7-FKHR 0
in 0
alveolar 2
rhabdomyosarcoma 2
, 0
presumably 0
due 0
to 0
differences 0
in 0
regulation 0
between 0
the 0
wild-type 0
loci 0
. 0

We 0
postulate 0
that 0
these 0
overexpression 0
mechanisms 0
ensure 0
a 0
critical 0
level 0
of 0
gene 0
product 0
for 0
the 0
oncogenic 0
effects 0
of 0
these 0
fusions 0
. 0

atm 0
and 0
p53 0
cooperate 0
in 0
apoptosis 0
and 0
suppression 0
of 0
tumorigenesis 0
, 0
but 0
not 0
in 0
resistance 0
to 0
acute 2
radiation 2
toxicity 2
. 0

Mutations 0
in 0
atm 0
and 0
p53 0
cause 0
the 0
human 0
cancer-associated 4
diseases 4
ataxia-telangiectasia 0
and 0
category= 0
SpecificDisease 0
Li-Fraumeni 0
syndrome 0
< 2
, 2
respectively 2
. 0

The 0
two 0
genes 0
are 0
believed 0
to 0
interact 0
in 0
a 0
number 0
of 0
pathways 0
, 0
including 0
regulation 0
of 0
DNA 0
damage-induced 0
cell-cycle 0
checkpoints 0
, 0
apoptosis 0
and 0
radiation 0
sensitivity 0
, 0
and 0
cellular 0
proliferation 0
. 0

Atm-null 0
mice 0
, 0
as 0
well 0
as 0
those 0
null 0
for 0
p53 0
, 0
develop 0
mainly 0
T-cell 2
lymphomas 2
, 0
supporting 0
the 0
view 0
that 0
these 0
genes 0
have 0
similar 0
roles 0
in 0
thymocyte 0
development 0
. 0

To 0
study 0
the 0
interactions 0
of 0
these 0
two 0
genes 0
on 0
an 0
organismal 0
level 0
, 0
we 0
bred 0
mice 0
heterozygous 0
for 0
null 0
alleles 0
of 0
both 0
atm 0
and 0
p53 0
to 0
produce 0
all 0
genotypic 0
combinations 0
. 0

Mice 0
doubly 0
null 0
for 0
atm 0
and 0
p53 0
exhibited 0
a 0
dramatic 0
acceleration 0
of 0
tumour 3
formation 0
relative 0
to 0
singly 0
null 0
mice 0
, 0
indicating 0
that 0
both 0
genes 0
collaborate 0
in 0
a 0
significant 0
manner 0
to 0
prevent 0
tumorigenesis 0
. 0

With 0
respect 0
to 0
their 0
roles 0
in 0
apoptosis 0
, 0
loss 0
of 0
atm 0
rendered 0
thymocytes 0
only 0
partly 0
resistant 0
to 0
irradiation-induced 0
apoptosis 0
, 0
whereas 0
additional 0
loss 0
of 0
p53 0
engendered 0
complete 0
resistance 0
. 0

This 0
implies 0
that 0
the 0
irradiation-induced 0
atm 0
and 0
p53 0
apoptotic 0
pathways 0
are 0
not 0
completely 0
congruent 0
. 0

Finally-and 0
in 0
contrast 0
to 0
prior 0
predictions-atm 0
and 0
p53 0
do 0
not 0
appear 0
to 0
interact 0
in 0
acute 2
radiation 2
toxicity 2
, 0
suggesting 0
a 0
separate 0
atm 0
effector 0
pathway 0
for 0
this 0
DNA 0
damage 0
response 0
and 0
having 0
implications 0
for 0
the 0
prognosis 0
and 0
treatment 0
of 0
human 0
tumours 4
. 0

Trinucleotide 0
repeat 0
expansion 0
at 0
the 0
myotonic 3
dystrophy 3
locus 0
reduces 0
expression 0
of 0
DMAHP 0
. 0

Myotonic 2
dystrophy 2
, 0
or 0
dystrophia 2
myotonica 2
( 0
DM 2
) 0
, 0
is 0
an 0
autosomal 4
dominant 4
multisystem 4
disorder 4
caused 0
by 0
the 0
expansion 0
of 0
a 0
CTG 0
trinucleotide 0
repeat 0
in 0
the 0
3 0
untranslated 0
region 0
of 0
the 0
DMPK 0
protein 0
kinase 0
gene 0
on 0
chromosome 0
19q13 0
. 0

3 0
( 0
refs 0
1-3 0
) 0
. 0

Although 0
the 0
DM 3
mutation 0
was 0
identified 0
more 0
than 0
five 0
years 0
ago 0
, 0
the 0
pathogenic 0
mechanisms 0
underlying 0
this 0
most 0
prevalent 0
form 0
of 0
hereditary 0
adult 0
neuromuscular 4
disease 4
remain 0
elusive 0
. 0

Previous 0
work 0
from 0
our 0
laboratory 0
demonstrated 0
that 0
a 0
DNase 0
l-hypersensitive 0
site 0
located 0
adjacent 0
to 0
the 0
repeats 0
on 0
the 0
wild-type 0
allele 0
is 0
eliminated 0
by 0
repeat 0
expansion 0
, 0
indicating 0
that 0
large 0
CTG-repeat 0
arrays 0
may 0
be 0
associated 0
with 0
a 0
local 0
chromatin 0
environment 0
that 0
represses 0
gene 0
expression 0
. 0

Here 0
we 0
report 0
that 0
the 0
hypersensitive 0
site 0
contains 0
an 0
enhancer 0
element 0
that 0
regulates 0
transcription 0
of 0
the 0
adjacent 0
DMAHP 0
homeobox 0
gene 0
. 0

Analysis 0
of 0
DMAHP 0
expression 0
in 0
the 0
cells 0
of 0
DM 3
patients 0
with 0
loss 0
of 0
the 0
hypersensitive 0
site 0
revealed 0
a 0
two- 0
to 0
fourfold 0
reduction 0
in 0
steady-state 0
DMAHP 0
transcript 0
levels 0
relative 0
to 0
wild-type 0
controls 0
. 0

Allele-specific 0
analysis 0
of 0
DMAHP 0
expression 0
showed 0
that 0
steady-state 0
transcript 0
levels 0
from 0
the 0
expanded 0
allele 0
were 0
greatly 0
reduced 0
in 0
comparison 0
to 0
those 0
from 0
the 0
wild-type 0
allele 0
. 0

Together 0
, 0
these 0
results 0
demonstrate 0
that 0
CTG-repeat 0
expansions 0
can 0
suppress 0
local 0
gene 0
expression 0
and 0
implicate 0
DMAHP 0
in 0
DM 3
pathogenesis 0
. 0

Constitutively 0
methylated 0
CpG 0
dinucleotides 0
as 0
mutation 0
hot 0
spots 0
in 0
the 0
retinoblastoma 3
gene 0
( 0
RB1 0
) 0
. 0

A 0
wide 0
spectrum 0
of 0
mutations 0
, 0
ranging 0
from 0
point 0
mutations 0
to 0
large 0
deletions 0
, 0
have 0
been 0
described 0
in 0
the 0
retinoblastoma 3
gene 0
( 0
RB1 0
) 0
. 0

Mutations 0
have 0
been 0
found 0
throughout 0
the 0
gene 0
; 0
however 0
, 0
these 0
genetic 0
alterations 0
do 0
not 0
appear 0
to 0
be 0
homogeneously 0
distributed 0
. 0

In 0
particular 0
, 0
a 0
significant 0
proportion 0
of 0
disease-causing 0
mutations 0
results 0
in 0
the 0
premature 0
termination 0
of 0
protein 0
synthesis 0
, 0
and 0
the 0
majority 0
of 0
these 0
mutations 0
occur 0
as 0
C 0
-- 0
T 0
transitions 0
at 0
CpG 0
dinucleotides 0
( 0
CpGs 0
) 0
. 0

Such 0
recurrent 0
CpG 0
mutations 0
, 0
including 0
those 0
found 0
in 0
RB1 0
, 0
are 0
likely 0
the 0
result 0
of 0
the 0
deamination 0
of 0
5-methylcytosine 0
within 0
these 0
CpGs 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
used 0
the 0
sodiumbisulfite 0
conversion 0
method 0
to 0
detect 0
cytosine 0
methylation 0
in 0
representative 0
exons 0
of 0
RB1 0
. 0

We 0
analyzed 0
DNA 0
from 0
a 0
variety 0
of 0
tissues 0
and 0
specifically 0
targeted 0
CGA 0
codons 0
in 0
RB1 0
, 0
where 0
recurrent 0
premature 0
termination 0
mutations 0
have 0
been 0
reported 0
. 0

We 0
found 0
that 0
DNA 0
methylation 0
within 0
RB1 0
exons 0
8 0
, 0
14 0
, 0
25 0
, 0
and 0
27 0
appeared 0
to 0
be 0
restricted 0
to 0
CpGs 0
, 0
including 0
six 0
CGA 0
codons 0
. 0

Other 0
codons 0
containing 0
methylated 0
cytosines 0
have 0
not 0
been 0
reported 0
to 0
be 0
mutated 0
. 0

Therefore 0
, 0
disease-causing 0
mutations 0
at 0
CpGs 0
in 0
RB1 0
appear 0
to 0
be 0
determined 0
by 0
several 0
factors 0
, 0
including 0
the 0
constitutive 0
presence 0
of 0
DNA 0
methylation 0
at 0
cytosines 0
within 0
CpGs 0
, 0
the 0
specific 0
codon 0
within 0
which 0
the 0
methylated 0
cytosine 0
is 0
located 0
, 0
and 0
the 0
particular 0
region 0
of 0
the 0
gene 0
within 0
which 0
that 0
codon 0
resides 0
. 0

The 0
von 3
Hippel-Lindau 3
tumor 3
suppressor 0
gene 0
product 0
interacts 0
with 0
Sp1 0
to 0
repress 0
vascular 0
endothelial 0
growth 0
factor 0
promoter 0
activity 0
. 0

The 0
von 3
Hippel-Lindau 3
tumor 3
suppressor 0
gene 0
( 0
VHL 0
) 0
has 0
a 0
critical 0
role 0
in 0
the 0
pathogenesis 0
of 0
clear-cell 2
renal 2
cell 2
carcinoma 2
( 0
RCC 2
) 0
, 0
as 0
VHL 0
mutations 0
have 0
been 0
found 0
in 0
both 0
von 1
Hippel-Lindau 1
disease-associated 1
and 1
sporadic 1
RCCs 1
. 0

Recent 0
studies 0
suggest 0
that 0
vascular 0
endothelial 0
growth 0
factor 0
( 0
VEGF 0
) 0
mRNA 0
is 0
upregulated 0
in 0
RCC- 1
and 1
von 1
Hippel-Lindau 1
disease-associated 1
tumors 1
. 0

We 0
have 0
therefore 0
assessed 0
the 0
effect 0
of 0
the 0
VHL 0
gene 0
product 0
on 0
VEGF 0
expression 0
. 0

VEGF 0
promoter-luciferase 0
constructs 0
were 0
transiently 0
cotransfected 0
with 0
a 0
wild-type 0
VHL 0
( 0
wt-VHL 0
) 0
vector 0
in 0
several 0
cell 0
lines 0
, 0
including 0
293 0
embryonic 0
kidney 0
and 0
RCC 3
cell 0
lines 0
. 0

wt-VHL 0
protein 0
inhibited 0
VEGF 0
promoter 0
activity 0
in 0
a 0
dose-dependent 0
manner 0
up 0
to 0
5- 0
to 0
10-fold 0
. 0

Deletion 0
analysis 0
defined 0
a 0
144-bp 0
region 0
of 0
the 0
VEGF 0
promoter 0
necessary 0
for 0
VHL 0
repression 0
. 0

This 0
VHL-responsive 0
element 0
is 0
GC 0
rich 0
and 0
specifically 0
binds 0
the 0
transcription 0
factor 0
Sp1 0
in 0
crude 0
nuclear 0
extracts 0
. 0

In 0
Drosophila 0
cells 0
, 0
cotransfected 0
VHL 0
represses 0
Sp1-mediated 0
activation 0
but 0
not 0
basal 0
activity 0
of 0
the 0
VEGF 0
promoter 0
. 0

We 0
next 0
demonstrated 0
in 0
coimmunoprecipitates 0
that 0
VHL 0
and 0
Sp1 0
were 0
part 0
of 0
the 0
same 0
complex 0
and 0
, 0
by 0
using 0
a 0
glutathione-S-transferase-VHL 0
fusion 0
protein 0
and 0
purified 0
Sp1 0
, 0
that 0
VHL 0
and 0
Sp1 0
directly 0
interact 0
. 0

Furthermore 0
, 0
endogenous 0
VEGF 0
mRNA 0
levels 0
were 0
suppressed 0
in 0
permanent 0
RCC 3
cell 0
lines 0
expressing 0
wt-VHL 0
, 0
and 0
nuclear 0
run-on 0
studies 0
indicated 0
that 0
VHL 0
regulation 0
of 0
VEGF 0
occurs 0
at 0
least 0
partly 0
at 0
the 0
transcriptional 0
level 0
. 0

These 0
observations 0
support 0
a 0
new 0
mechanism 0
for 0
VHL-mediated 0
transcriptional 0
repression 0
via 0
a 0
direct 0
inhibitory 0
action 0
on 0
Sp1 0
and 0
suggest 0
that 0
loss 0
of 0
Sp1 0
inhibition 0
may 0
be 0
important 0
in 0
the 0
pathogenesis 0
of 0
von 2
Hippel-Lindau 2
disease 2
and 0
RCC 2
. 0

Adult 2
onset 2
globoid 2
cell 2
leukodystrophy 2
( 0
Krabbe 2
disease 2
) 0
: 0
analysis 0
of 0
galactosylceramidase 0
cDNA 0
from 0
four 0
Japanese 0
patients 0
. 0

We 0
examined 0
galactosylceramidase 0
( 0
GALC 0
) 0
cDNA 0
in 0
four 0
Japanese 0
patients 0
with 0
adult 2
onset 2
globoid 2
cell 2
leukodystrophy 2
( 0
Krabbe 2
disease 2
; 0
AO-GLD 2
) 0
by 0
polymerase 0
chain 0
reaction 0
/ 0
single-strand 0
conformation 0
polymorphism 0
( 0
PCR-SSCP 0
) 0
analysis 0
, 0
subsequent 0
sequence 0
determination 0
, 0
and 0
restriction 0
enzyme 0
digestion 0
of 0
PCR 0
products 0
, 0
initial 0
symptoms 0
were 0
the 0
onset 0
of 0
slowly 0
progressive 0
spastic 4
paraplegia 4
from 0
the 0
middle 0
of 0
the 0
second 0
decade 0
, 0
and 0
all 0
patients 0
had 0
diminished 4
GALC 4
activity 4
in 0
their 0
leukocytes 0
. 0

We 0
identified 0
three 0
missense 0
mutations 0
( 0
I66M 0
, 0
G270D 0
, 0
L618S 0
) 0
and 0
one 0
exon-6 0
skipping 0
( 0
535-573del 0
) 0
. 0

Two 0
of 0
the 0
patients 0
had 0
only 0
the 0
I66M 0
mutant 0
mRNA 0
, 0
and 0
one 0
only 0
the 0
G27OD 0
mutant 0
mRNA 0
. 0

The 0
fourth 0
patient 0
carried 0
a 0
compound 0
heterozygous 0
mutation 0
of 0
535-573del 0
and 0
L618S 0
. 0

To 0
determine 0
the 0
enzymatic 0
activities 0
produced 0
by 0
these 0
mutations 0
, 0
we 0
constructed 0
mutated 0
GALC 0
cDNAs 0
and 0
expressed 0
them 0
in 0
COS-1 0
cells 0
. 0

Three 0
mutations 0
, 0
viz 0
. 0

, 0
G270D 0
, 0
L618S 0
, 0
and 0
exon-6 0
skipping 0
( 0
535-573del 0
) 0
, 0
produced 0
diminished 4
GALC 4
activity 4
as 0
expected 0
. 0

The 0
I66M 0
mutation 0
in 0
the 0
wild-type 0
GALC 0
cDNA 0
( 0
I289 0
) 0
had 0
normal 0
activity 0
, 0
but 0
when 0
this 0
mutation 0
and 0
the 0
V289 0
polymorphism 0
were 0
introduced 0
into 0
the 0
same 0
allele 0
, 0
it 0
had 0
decreased 0
activity 0
. 0

Thus 0
, 0
the 0
combination 0
of 0
a 0
unique 0
mutation 0
and 0
polymorphism 0
causes 0
conformational 0
change 0
in 0
the 0
GALC 0
enzyme 0
, 0
resulting 0
in 0
low 0
enzymatic 0
activity 0
. 0

AO-GLD 3
mutations 0
, 0
including 0
those 0
found 0
here 0
, 0
are 0
located 0
in 0
the 0
N-terminus 0
( 0
I66M 0
, 0
G270D 0
, 0
535-573del 0
) 0
or 0
C-terminus 0
( 0
L618S 0
) 0
of 0
the 0
GALC 0
enzyme 0
, 0
whereas 0
the 0
reported 0
mutations 0
in 0
the 0
infantile 0
form 0
( 0
IF-GLD 2
) 0
are 0
in 0
the 0
central 0
domain 0
. 0

This 0
difference 0
in 0
mutation 0
sites 0
may 0
affect 0
the 0
clinical 0
features 0
of 0
GLD 2
. 0

